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1 Summary  
 
Background 
Vaccines against infectious diseases are given worldwide and provide one of the most 
effective and cost-effective interventions available in public health. The goal of any 
preventive vaccination is to attain effective protection by deliberate means against a 
potentially disabling or lethal disease, using an acceptable intervention causing mini-
mal adverse events. As with any medicinal product, no vaccine is completely effective 
or completely safe. 
 
Many vaccines are provided routinely to the general population, particularly those 
given in childhood. In certain subpopulations, the vaccination or the natural disease 
may pose a higher risk. It is essential to identify vaccine effects in subpopulations in 
order to maximise both vaccine safety and effectiveness in public health programs. 
Gathering and summarising the evidence from pre- and post-licensing surveillance, 
pharmacovigilance systems and epidemiological studies become essential tasks in de-
termining the specific risk-benefit profile of a vaccine in subpopulations, and in recog-
nising more fully the spectrum of vaccine-related adverse events. 
 
This dissertation synthesises evidence for safety and effectiveness of vaccines against 
influenza and tuberculosis in pregnant women and in HIV-infected children, respec-
tively, through reviews of the available published and unpublished literature, and an 
analysis of immunisation policies.  
 
Objectives  
1. Describe and analyse the risk-benefit of inactivated influenza vaccination in 
pregnant women, and to compare different national policies. 
2. Assess systematically the risk of live attenuated BCG vaccines in HIV-infected 
infants and perform a meta-analysis on the risk of disseminated BCG disease. 
3. Combine and synthesise the available evidence on the management of BCG-
related adverse events, towards establishing therapeutic guidelines. 
4. Based on these findings, to provide insights on the implications for influenza and 
BCG vaccine policies in pregnant women and HIV-infected children, 
respectively. 
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Findings 
In Chapters 7 and 11, the issue of inactivated influenza vaccines in pregnancy is exa-
mined. Historical reports and epidemiological evidence following two pandemics dur-
ing the 20th century documented high influenza-related mortality (about 50%) and se-
vere sequelae in pregnant women. During annual influenza seasons, the largest cohort 
studies have shown excess influenza-attributed hospitalisations in pregnant women, 
with an excess admission rate similar to that of non-pregnant women with chronic 
medical conditions, a higher-risk subgroup for whom influenza vaccination is com-
monly recommended. The risk of influenza-related hospital admissions during the in-
fluenza season increased in the presence of comorbidities and advancing gestational 
weeks, with the excess rates highest in the third trimester. A small randomised clinical 
trial with women receiving influenza vaccine in the third trimester showed a reduction 
in influenza-like illness and laboratory-confirmed febrile influenza illness in their in-
fants. There are few available studies on influenza vaccine safety in pregnancy, but 
those available have not indicated any serious adverse effects. Several countries have 
moved to provide national immunisation recommendations identifying pregnant 
women as a high-risk group targeted for inactivated influenza vaccination. Robust sur-
veillance mechanisms are warranted, with long term follow up of outcomes in settings 
where vaccination in pregnancy is recommended.  
 
The issue of safety and effectiveness of live attenuated BCG vaccine in the paediatric 
HIV-infected subpopulation was addressed through review, meta-analysis and 
commentary in Chapter 8a/8b. BCG vaccine’s main benefit of effectiveness against 
disseminated forms of tuberculosis in HIV-uninfected children has not been 
determined or adequately studied in the HIV-infected subpopulation. Based on inter-
national studies, the pooled risk estimate of the incidence of disseminated BCG disease 
in the HIV-infected sub-population was 979 per 100,000 (95% CI: 564 to 1506) HIV-
infected vaccinees, or about 1%. This risk is more than one thousand-fold higher than 
in HIV-negative children. WHO changed recommendations in 2007 and made BCG 
vaccine a contraindication in HIV-infected individuals, if the HIV-infected status is 
known. There are several operational challenges in the implementation of a selective 
BCG vaccination program based on HIV status for resource-poor, high-risk countries. 
Efforts to reduce BCG vaccination in HIV-infected children should be made feasible in 
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settings where early infant HIV testing and HIV prevention and treatment programs 
are scaled up. 
 
With over 80 years of experience with BCG vaccination, a spectrum of related adverse 
events is described. Chapter 9 addresses the issue further by reviewing the evidence 
for clinical management of iatrogenic BCG disease in children. An early and pivotal 
decision point for management is the assessment of the affected individual’s immune 
status, as immunosuppressed individuals have a higher likelihood of severe and serious 
BCG disease although often presenting with non-specific signs. In general, local and 
regional BCG disease in immunocompetent individuals can be managed conservative-
ly. 
 
Conclusions 
The findings from this dissertation contribute towards a fuller understanding of the 
risk-benefit profiles of two major vaccines given worldwide. The first review summa-
rised the available body of evidence and determined that in previous years, certain in-
fluenza viral strains have posed a higher risk of morbidity and mortality in pregnancy. 
Available data are limited, but have not pointed to any serious adverse effects from 
inactivated influenza vaccination in pregnancy. Larger studies with laboratory-con-
firmed influenza outcomes and long-term data in specialised vaccination registries are 
warranted. The second review calculated the first pooled risk estimate of disseminated 
BCG disease in HIV-infected infants, through a systematic review and meta-analysis 
of hospital-based studies, and outlined the challenges in implementing safer, selective 
BCG vaccination programs for settings with low resources and high HIV endemicity. 
Operational research needs to be conducted to evaluate such major vaccine policy tran-
sitions. The third major review in this dissertation provided a synthesis of evidence-
based management of BCG-related adverse events, towards establishing standard 
guidelines that improve case management. 
 
Ongoing assessments of the current evidence for a vaccine’s risk-benefit in subpopula-
tions, as contained in these reviews, are clearly essential for updating vaccine indica-
tions and contraindications, and in identifying gaps in research. These assessments al-
low for re-examining of vaccine policy which, in the end, strengthen the rationale and 
responsibilities of immunisation programmes that are well understood and acceptable 
to the public. 
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2 Résumé 
 
Contexte 
Les vaccins contre les maladies infectieuses sont distribués à l’échelle mondiale et 
constituent une des interventions les plus efficaces et rentables disponible en santé pu-
blique. L’objectif de toute vaccination préventive est d’atteindre une protection 
efficace par des moyens spécifiques contre une maladie potentiellement invalidante ou 
mortelle, en ayant recours à une intervention acceptable causant le minimum d’effets 
indésirables. Comme pour tout produit médical, aucun vaccin n’est complètement 
efficace ni complètement sûr.  
 
De nombreux vaccins sont couramment distribués à la population, en particulier ceux 
administrés durant l’enfance. Dans certaines sous-populations, la vaccination ou la ma-
ladie survenant naturellement peut présenter un plus grand risque. Il est essentiel 
d’identifier les effets des vaccins dans les différentes sous-populations afin de maximi-
ser la sécurité des vaccins et leur efficacité dans les programmes de santé publique. Le 
regroupement et la synthèse des observations obtenues durant les suivis qui précèdent 
et suivent l’obtention de la licence de commercialisation, ainsi que les observations 
issues des systèmes de pharmacovigilance et des études épidémiologiques, sont des 
tâches essentielles pour déterminer le rapport spécifique risque-bénéfice d’un vaccin 
dans différentes sous-populations, et pour connaître de manière plus complète le 
spectre des effets indésirables liés au vaccin. 
 
Cette thèse synthétise les observations sur la sécurité et l’efficacité des vaccins contre 
la grippe chez les femmes enceintes et contre la tuberculose chez les enfants infectés 
par le VIH grâce à une étude systématique de la littérature disponible, publiée ou non, 
et à une analyse des politiques d’immunisation. 
 
 Objectifs 
1. Décrire et analyser le rapport risque-bénéfice des vaccins inactivés contre la 
grippe chez les femmes enceintes et comparer les différentes directives natio-
nales.  
2. Résumé 
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2. Evaluer systématiquement le risque des vaccins BCG vivants atténués chez des 
nourrissons infectés par le VIH et effectuer une méta-analyse du risque de ma-
ladie BCG systémique. 
3. Combiner et faire une évaluation synthétique des informations disponibles sur 
la gestion des effets indésirables liés au BCG, en vue d’établir des directives 
thérapeutiques. 
4. Sur la base de ces résultats, fournir un aperçu et un commentaire critique sur les 
implications des politiques contre la grippe et le vaccin BCG, respectivement 
chez les femmes enceintes et les enfants infectés par le VIH. 
 
Résultats 
Les chapitres 7 et 11 traitent la problématique des vaccins inactivés contre la grippe 
durant la grossesse. Des rapports historiques et des observations épidémiologiques qui 
ont suivi deux pandémies du 20e siècle révèlent une haute mortalité liée à la grippe 
(jusqu’à 50%) et de graves séquelles chez les femmes enceintes. Durant les périodes 
saisonnières de grippe, les plus grandes études de cohorte montrent un excédent de cas 
d’hospitalisation attribués à la grippe chez les femmes enceintes. L’excédent de ce 
taux d’admission est similaire à celui des femmes qui ne sont pas enceintes mais 
souffrant de maladies chroniques, sous-groupe qui présente un risque plus élevé et 
pour lequel la vaccination est couramment recommandée. Le risque d’hospitalisation, 
lié à la grippe saisonnière, augmente en présence de comorbidités et lors d’un stade de 
grossesse avancée, le taux d’excès le plus élevé se situant au troisième trimestre. Un 
essai clinique réalisé sur un échantillon restreint de femmes, prises au hasard et 
recevant un vaccin contre la grippe durant le troisième trimestre, montre une réduction 
des cas de maladies ressemblant à la grippe et des cas de grippe fébrile confirmés par 
laboratoire chez leurs nourrissons. Il y a peu d’études disponibles sur la sécurité de la 
vaccination contre la grippe durant la grossesse, mais celles disponibles n’indiquent 
aucun effet indésirable grave. Plusieurs pays fournissent actuellement des 
recommandations nationales concernant l’immunisation et considèrent les femmes 
enceintes comme un groupe à haut risque devant recevoir un vaccin inactivé contre la 
grippe. De sérieux systèmes de surveillance, avec un suivi des résultats sur le long 
terme, sont justifiés dans les contextes où la vaccination contre la grippe durant la 
grossesse est recommandée. 
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La problématique de la sécurité et de l’efficacité du vaccin BCG vivant atténué parmi 
la sous-population pédiatrique infectée par le VIH est traitée dans les chapitres 8a et 
8b sous la forme d’une analyse systématique de la littérature, d’une méta-analyse et 
d’un commentaire critique. L’utilité du vaccin BCG en relation avec son efficacité 
contre les formes systémiques de tuberculoses a été étudiée parmi les enfants non-
infectés par le VIH, mais n’a pas été déterminée ou étudiée convenablement dans la 
sous-population pédiatrique infectée par le VIH.  Sur la base d’études internationales, 
l’estimation du risque résumé de l’incidence de la maladie BCG systémique parmi la 
sous-population infectée VIH a été évaluée à 979 pour 100'000 (IC 95%: 564 à 1'506) 
individus vaccinés, soit environ 1%. Ce risque est plus de mille fois plus élevé que 
chez les enfants séronégatifs. L’OMS a changé de recommandations en 2007 et 
considère désormais le vaccin BCG comme une contre-indication chez les personnes 
infectées par le VIH, si leur statut d’infection au VIH est connu. La mise en œuvre 
d’un programme de vaccination BCG sélectif basé sur le statut VIH présente plusieurs 
défis opérationnels pour les pays pauvres et à haut risque. Des efforts pour diminuer la 
vaccination BCG chez les enfants infectés par le VIH devraient être rendus possibles 
dans les situations où des tests VIH sont effectués chez les nourrissons et où des 
programmes de prévention VIH et de traitement sont prévus.  
 
Plus de 80 années d’expérience dans la vaccination BCG ont permis de décrire un 
spectre d’effets indésirables liés à ce vaccin. Le chapitre 9 évalue de manière plus 
approfondie cette problématique par une étude des informations sur la gestion clinique 
des maladies BCG iatrogéniques chez les enfants. Un point clé de la gestion est 
l’évaluation  du statut immunitaire de l’individu affecté, étant donné que les personnes 
dont le système immunitaire est déficient ont une probabilité plus élevée de développer 
des maladies BCG graves bien qu’elles présentent souvent des signes non-spécifiques. 
De manière générale, la maladie BCG locale et régionale chez les individus immuno-
compétents peut être approchée de manière conservative. 
 
Conclusions 
Les résultats de cette thèse contribuent à une meilleure compréhension du rapport 
risque-bénéfice de deux des principaux vaccins distribués à l’échelle mondiale. La pre-
mière partie de cette recherche résume les informations disponibles et met en évidence 
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que, durant des années, certaines souches de virus de la grippe ont présenté un risque 
de morbidité et de mortalité plus élevé durant la grossesse. Les données disponibles 
sont limitées mais n’ont pas révélé d’effets indésirables graves dus aux vaccins 
inactivés contre la grippe durant la grossesse. Des études de plus grande envergure 
avec des résultats confirmés en laboratoire ainsi que des données sur le long terme 
concernant des aspects particuliers de la vaccination sont nécessaires. Le deuxième 
volet de cette thèse calcule la première estimation du risque résumé de maladie BCG 
systémique chez les nourrissons infectés par le VIH, par une étude systématique de la 
littérature et une méta-analyse des études réalisées dans les hôpitaux. Ce volet insiste 
sur les défis de la mise en œuvre de programmes de vaccination BCG plus sûrs et 
sélectifs pour des régions à faibles ressources et présentant une endémicité du VIH 
élevée. Il est nécessaire de conduire des recherches opérationnelles afin d’évaluer de 
telles transitions dans les politiques de vaccination. La troisième partie de cette thèse 
fournit une synthèse de la gestion des effets indésirables observés liés au BCG, en vue 
d’établir des directives standard qui améliorent la gestion de la situation selon les cas. 
 
Des évaluations continues des observations actuelles pour établir le rapport risque-
bénéfice d’un vaccin dans différentes sous-populations, telles que celles traitées dans 
cette thèse, sont absolument essentielles pour mettre à jour les indications et les 
contre-indications pour les vaccins, et pour identifier les lacunes dans la recherche. 
Ces évaluations permettent le ré-examen de la politique des vaccins et, finalement, 
renforcent la raison d’être et les responsabilités de programmes d’immunisation bien 
compris et acceptables par le public. 
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3  Zusammenfassung 
Hintergrund 
Impfstoffe gegen Infektionskrankheiten werden weltweit eingesetzt und stellen eine 
der wirksamsten und kostengünstigsten Interventionsmöglichkeiten des öffentlichen 
Gesundheitswesens dar. Das Ziel jeder vorbeugenden Impfung ist es, durch den be-
wussten Einsatz von Mitteln einen wirksamen Schutz vor potentiell behindernden oder 
tödlichen Krankheiten zu erreichen, wobei der Eingriff tragbar und mit minimalen un-
erwünschten Erscheinungen (nachteilige Nebenwirkungen) verbunden sein soll. Wie 
andere medizinische Produkte sind auch Impfstoffe weder vollkommen wirksam noch 
vollends sicher. 
 
Viele Impfstoffe werden routinemässig in der Bevölkerung eingesetzt, insbesondere 
während der Kindheit. Für bestimmte Subpopulationen allerdings können die natürli-
chen Krankheiten und/oder die entsprechende Impfung mit einem höheren Risiko be-
züglich nachteiliger (Neben-)Effekte behaftet sein als für die Allgemeinheit. Um eine 
maximale Sicherheit und Wirksamkeit von Impfstoffen (und anderer präventiver Stra-
tegien) in Programmen der öffentlichen Gesundheitsversorgung erreichen zu können, 
ist es unerlässlich, die Folgen einer Krankheit und die entsprechenden Impffolgen spe-
zifisch für Subpopulationen zu identifizieren. Wesentlich für das Erstellen eines spezi-
fischen Risiko-Nutzen-Profils eines Impfstoffes für bestimmte Bevölkerungsgruppen, 
und entscheidend für ein umfassendes Verständnis des Spektrums unerwünschter (ne-
gativer) Impferscheinungen ist die Erfassung und Auswertung wissenschaftlicher 
Nachweise aus allen Stufen der Arzneimittelüberwachung während des Zulassungsver-
fahrens, nach Inverkehrbringen, aus Pharmakovigilanzsystemen und aus epidemiologi-
schen Studien. 
 
In der vorliegenden Dissertation werden - mittels Reviews der vorhandenen publiziert-
en und unpublizierten Literatur - die nachweisbare Wirksamkeit und Sicherheit des 
Einsatzes von Influenza-Impfstoffen bei schwangeren Frauen und Tuberkulose-Impf-
stoffen bei HIV-infizierten Kindern dargestellt, verbunden mit einer Analyse der ent-
sprechenden Immunisierungsstrategien bzw. -politiken.  
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Ziele 
1. Risiko-Nutzen-Analyse der Impfung schwangerer Frauen mit inaktiviertem In-
fluenza-Impfstoff und Vergleich verschiedener nationaler Strategien. 
2. Systematische Bewertung des Risikos attenuierter BCG-Lebendvakzinen bei 
HIV-infizierten Kindern und Durchführung einer Meta-Analyse des Risikos einer 
disseminierten BCG-Infektion. 
3. Zusammenfassende Auswertung der vorhandenen Datenlage zum Management 
BCG-bedingter unerwünschter Erscheinungen (nachteiliger Nebenwirkungen) im 
Hinblick auf die Erarbeitung von Therapie-Richtlinien. 
4. Eine auf diese Ergebnisse gestützte Darstellung der Erkenntnisse und Beurteilung 
der Tragweite von Influenza-Impfstragtegien bei schwangeren Frauen und BCG-
Impfstrategien bei HIV-infizierten Kinder.  
 
Ergebnisse 
In den Kapiteln 7 und 11 wird die Problematik des Einsatzes von inaktivierten In-
fluenza-Vakzinen während der Schwangerschaft untersucht. Historische Berichte und 
epidemiologische Befunde aus zwei Pandemien des 20. Jahrhunderts dokumentieren 
eine hohe Influenza-bedingte Mortalität (bis zu 50%) und schwere Folgekomplikatio-
nen bei schwangeren Frauen. Während der jährlich auftretenden saisonalen Influenza 
werden gemäss den breitesten Kohort-Studien besonders häufig schwangere Frauen 
wegen Grippe hopsitalisiert; ihre Exzess-Eintrittsrate ist vergleichbar mit jener nicht 
schwangerer Frauen, die an einer chronischen Krankheit leiden, wobei letztere als Ri-
siko-Gruppe gelten, für die Influenza-Impfungen im Allgemeinen empfohlen wird. Das 
Risiko von Influenza-bedingten Spitaleintritten während einer Grippewelle ist erhöht 
im Fall von Komorbiditäten und während fortgeschrittener Schwangerschaft, wobei die 
höchsten Exzess-Raten während des dritten Trimesters festzustellen waren. Eine 
kleine, randomisierte klinische Studie mit Frauen, die im dritten Trimester gegen 
Grippe geimpft wurden, liess weniger Fälle von grippeähnlichen und von durch Labor-
befunde bestätigten fieberhaften Influenza-Erkrankungen bei deren Kleinkindern er-
kennen. Zur Impfstoff-Sicherheit beim Einsatz von Influenza-Vakzinen während der 
Schwangerschaft existieren nur wenige Studien. Aus diesen ergeben sich jedoch keine 
Hinweise auf schwerwiegende unerwünschte Impferscheinungen bzw. Nebenwirkun-
gen. Verschiedene Länder sind dazu übergegangen, in nationalen Immunisierungsemp-
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fehlungen schwangere Frauen als eine stark gefährdete Gruppe und damit als Ziel-
gruppe für inaktivierte Influenza-Impfungen zu identifizieren. Wo Impfungen während 
der Schwangerschaft empfohlen werden, sind stabile Überwachungsmechanismen mit 
der Erfassung von Langzeitfolgen zur gewährleisten.  
 
Dem Problemkreis Sicherheit und Wirksamkeit attenuierter BCG-Lebendimpfstoffe in 
der pädiatrischen, HIV-infizierten Subpopulation widmen sich ihm Rahmen eines 
systematischen Reviews, einer Meta-Analyse und eines Kommentars die Kapitel 8a 
und 8b. Ob der BCG-Impfstoff auch gegen disseminierte Formen von Tuberkulose bei 
HIV-infizierten Kindern wirksam ist, wurde bislang nicht adäquat untersucht. Diese 
Wirkung gilt bei nicht HIV-infizierten Kindern als Hauptverdienst des Vakzins. Ge-
stützt auf internationale Studien wurde in einer zusammengefassten Risikoschätzung 
die Wahrscheinlichkeit des Eintretens einer disseminierten BCG-Erkrankung in der 
HIV-infizierten Subpopulation auf 979 pro 100'000 (95% KI: 564 bis 1'506) HIV-infi-
zierte Geimpfte berechnet, oder ungefähr 1%. Dieses Risiko ist mehr als tausendmal 
höher als für HIV-negative Kinder. Die WHO änderte ihre Empfehlungen im Jahr 2007 
und erklärte BCG-Impfungen als kontraindiziert für HIV-infizierten Menschen, sofern 
der HIV-Infektionsstatus bekannt ist. Für ressourcenarme Hochrisiko-Länder ergeben 
sich verschiedene operative Herausforderungen bei der Implementierung eines selekti-
ven BCG-Impfprogramms, will man den HIV-Status berücksichtigen. Bestrebungen, 
BCG-Impfungen in HIV-infizierten Kindern zu reduzieren, sollten Hand in Hand ge-
hen mit dem Ausbau der HIV-Diagnostik im frühen Kindesalter und dem Angebot von 
HIV-Präventions- und Behandlungsprogrammen. 
  
Nach über 80 Jahren Erfahrung mit BCG-Impfungen ist ein Spektrum von begleiten-
den unerwünschten Impferscheinungen beschrieben. Das Kapitel 9 befasst sich weiter 
mit diesem Thema in Form einer Review der Behandlungsansätze und -verläufe iatro-
gener BCG-Erkrankungen bei Kindern. Ein früher und zentraler Entscheidpunkt im 
Behandlungsverlauf ist die Untersuchung des Immunstatus des Patienten, zumal 
Immunsupprimierte besonders gefährdet sind für eine schwerwiegende, wenn auch im 
Krankheitsbild unspezifische BCG-Erkrankung. Bei immunkompetenten Patienten ist 
eine konservative Behandlung lokaler und regionaler BCG-Erkrankungen in der Regel 
ausreichend. 
 
3. Zusammenfassung 
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Schlussfolgerungen 
Die Ergebnisse dieser Dissertation tragen zu einem umfassenderen Verständnis des Ri-
siko-Nutzen-Profiles von zwei bedeutenden Impfstoffen bei, die weltweit eingesetzt 
werden. Das erste Review wertet den verfügbaren Pulk von wissenschaftlichen Bele-
gen aus und zeigt auf, dass in früheren Jahren gewisse Influenza-Virus-Stämme ein 
höheres Morbiditäts- und Mortalitätsrisiko während der Schwangerschaft darstellten. 
Verfügbare Daten sind zwar beschränkt, aus ihnen ergeben sich jedoch keine Hinweise 
auf irgendwelche ernsthaften nachteiligen Effekte infolge inaktivierter Influenza-Imp-
fungen während der Schwangerschaft. Breiter angelegte Studien mit laborgestützten 
Influenza-Diagnostik und eine Erfassung von Langzeitdaten in spezialisierten Impfre-
gistern sind vonnöten. Im zweiten Review wird mittels einer systematischen Auswer-
tung und einer Meta-Analyse spitalbasierter Studien die erste zusammengefasste Risi-
koschätzung für disseminierte BCG-Erkrankungen in HIV-infizierten Kleinkindern er-
rechnet. Das Review skizziert die Herausforderungen der Umsetzung sichererer selek-
tiver BCG-Impfprogramme in Gebieten, die knapp an Ressourcen sind und in denen 
HIV hochendemisch ist. Operationale Untersuchen müssen durchgeführt werden, um 
derart bedeutende Wechsel der Impfstrategie zu evaluieren. Das dritte grössere Review 
in dieser Dissertation bietet eine Darstellung eines evidenzbasierten Managements 
BCG-bedingter nachteiliger Nebenwirkungen im Hinblick auf die Erarbeitung von 
standardisierten Therapie-Richtlinien. 
 
Wie in den Reviews gezeigt, sind kontinuierliche Bewertungen neuer wissenschaftli-
cher Nachweise unerlässlich für ein zielgruppenspezifisches Risiko-Nutzen-Profil ei-
nes Impfstoffs. Sie sind essentiell für die Aktualisierung von Anwendungsgebieten und 
Kontraindikationen von Vakzinen sowie zur Identifizierung von entsprechenden For-
schungslücken. Diese Bewertungen erlauben es, Impfstrategien ständig zu überprüfen 
und dadurch letztlich die argumentative Begründung und die Verantwortlichkeiten zu 
stärken für Impfprogramme, die von der Öffentlichkeit verstanden und akzeptiert wer-
den. 
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4 Abbreviations 
 
 
AEFI Adverse event following immunization 
AFB Acid fast bacilli 
AIDS Acquired immune deficiency syndrome 
ARR Adjusted relative risk 
ART Antiretroviral therapy 
dBCG Disseminated BCG disease 
BCG Bacille Calmette-Guérin 
CI Confidence interval 
CIOMS Council for International Organizations of Medical Sciences 
CONSORT Consolidated Standards of Reporting Trials 
EPI Expanded Programme on Immunization 
GACVS Global Advisory Committee on Vaccine Safety 
GAVI Global Alliance for Vaccines and Immunization 
GBS Guillain-Barré syndrome 
GIVS Global Immunization Vision and Strategy 2006-2015 
HAART Highly active antiretroviral therapy 
HIV Human immunodeficiency virus 
H Haemagglutinin 
ICH International Conference on Harmonisation of Technical  
 Requirements for Registration of Pharmaceuticals for Human Use 
IPT Isoniazid preventive therapy 
IRIS Immune reconstitution inflammatory syndrome 
IUATLD International Union Against Tuberculosis and Lung Disease  
M. bovis Mycobacterium bovis 
M. tuberculosis Mycobacterium tuberculosis 
MDR Multi-drug resistance 
MedDRA Medical Dictionary for Regulatory Activities 
MIC Minimum inhibitory concentration 
MTBC Mycobacterium tuberculosis complex 
N Neuraminidase 
OR Odds ratio 
PCR Polymerase chain reaction 
PID Primary immunodeficiency disorder 
RCT Randomised controlled trial 
RD1 Region-of-difference 1  
SCID Severe combined immunodeficiency 
UCI Universal Childhood Immunization 
UMC Uppsala Monitoring Centre 
UNICEF United Nations Children’s Fund 
VAERS Vaccine Adverse Event Reporting System 
WHO World Health Organization  
WHO-ART WHO Adverse Reaction Terminology 
XDR  Extensively drug-resistant 
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5 Introduction 
This dissertation examines post-licensing vaccine safety and effectiveness against two 
major respiratory diseases in specific subpopulations, with emphasis on safety. First, 
inactivated influenza vaccination in pregnant women is reviewed, and a comparison is 
made of national influenza vaccine policies. Second, a systematic review is conducted 
and the pooled risk estimate calculated on the risk of disseminated disease from bacille 
Calmette-Guérin (BCG) vaccination in infants infected with human immunodeficiency 
virus (HIV). Potential impacts on immunisation programmes are considered for 
settings with different burdens of disease and levels of resources. Third, a review of 
the evidence-based management of BCG-related adverse events is performed, towards 
developing useful guidelines for healthcare providers. An introduction and historical 
background are provided on vaccines, vaccine development, national immunisation 
policy and programmes, vaccine safety and surveillance, clinical disease and 
epidemiology of influenza and tuberculosis, the current influenza and BCG vaccines, 
and the pregnant and HIV-infected infant subpopulations, which form the basis of 
enquiry. 
 
5.1 Vaccines 
History and development 
Vaccines are biological medicines derived from living organisms and their products, 
which are not easily characterised molecularly, as compared with chemical or synthe-
sised drugs. The manufacturing process of medical products obtained from complex 
living organisms requires additional safeguards due to inherent variability and lack of 
full characterisation of source materials. Vaccines, like other complex biologicals such 
as blood and cell tissue products, are regulated by international standards to ensure the 
highest quality and safety of biological products are achieved (Shin et al. 2007; WHO 
2007c). 
 
The aim of vaccination against an infectious disease is to induce an appropriate and ef-
fective immune response that protects against a clinically significant disease upon na-
tural exposure. Vaccines have been called one of modern medicine’s miracles, with a 
leading impact in reducing mortality and morbidity worldwide (Henderson 1997). A 
prominent success was the eradication of smallpox disease (certified in 1979) through 
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global mass vaccination, signifying the first and only eradication of a human infectious 
disease. 
 
The term “vaccination” originated with the act of inoculation (in oculus, Latin for 
“into a bud” (Last 2001)) of vaccinia (cowpox) viral materials that offers immune 
cross-protection against variola (smallpox) disease in humans. Principles of smallpox 
vaccination existed centuries ago, but in the late 1700s was most famously and convin-
cingly introduced in Europe by Jenner, who is considered the founder of vaccinology 
and immunology; there were several lesser known predecessors who also conducted 
vaccinations against smallpox, such as Boylston, Jesty and Rabaut-Pommier 
(Theodorides 1979; Pead 2003; Riedel 2005). 
 
Scientific research classically follows the path from etiologic discovery of a new, seri-
ous pathogen to investigation of methods to propagate the pathogen in the laboratory. 
Products of the pathogen are then used to try and induce appropriate long-term im-
mune responses for an effective and safe vaccine. An early debt is owed to Pasteur’s 
experiments and serendipitous discoveries that led to one of the founding principles of 
vaccine development. The first actively manufactured vaccines were developed by at-
tenuation of the live pathogen, at that time by in vitro serial passage. Teams led by 
Salmon, Smith and Roux followed with the development of completely inactivated 
(killed pathogen) vaccines. Further discovery of extracellular bacterial toxins led to the 
development of toxoid (inactivated toxin) vaccines in the early 20th century. Over the 
past 50 years, major advances have accelerated vaccine development, starting with cell 
culture passage, the ability to purify and extract components of the pathogens for sub-
unit vaccines, the ability to conjugate proteins with polysaccharides to improve im-
mune responses in infants, and most recently, vaccine technologies using recombinant 
DNA and novel vaccine delivery systems (Hilleman 2000; Plotkin 2005). 
 
Thus, in general there are four ways vaccines have been or are being developed: by 
inactivated or killed organisms; attenuated live organisms; toxoids; or purified sub-
units (eg proteins, glycoproteins, carbohydrates) of the pathogen. The biological goal 
of vaccination is to achieve an appropriate and effective host memory immune res-
ponse. An effective vaccine can require three components: 1) a suitable antigen from 
the pathogen; 2) an immune potentiator (also known as an adjuvant) may be required 
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to assist in activating the innate immune system to generate long-term adaptive im-
mune responses against the antigen; and 3) a delivery system to help present and dis-
tribute antigens (with or without immune potentiators) to the target cells of the im-
mune system (Pashine et al. 2005). 
 
In addition to antigens, and sterile water or saline, vaccines contain several ingredients 
that are introduced during the production process and that are also scrutinised for reac-
togenicity and vaccine-related adverse events. These include solvents such as glycerin, 
detergents such as triton N-101, stabilisers such as sorbitol, preservatives such as thio-
mersal and adjuvants such as aluminium phosphate. Vaccines may also contain trace 
amounts of materials from growth media (eg. ovalbumin from embryonated chicken 
eggs). Comprehensive lists of excipients and growth media used in vaccine production 
are available (CDC 2008). Certain compounds can be introduced at different points 
during the manufacturing process for different purposes, such as thiomersal (sodium 
ethylmercurithiosalicylate) which may be used to inactivate the pathogen, or intro-
duced during production to reduce bacterial and fungal contamination, or only added 
to the final product as a preservative in multidose vaccine vials. 
 
Recent, rapid technologies for vaccine development are exemplified by current re-
search on adjuvants. For over 70 years, the main licensed and available adjuvants were 
aluminium salts adsorbed with antigens; the mechanisms of immune potentiation were 
incompletely understood (HogenEsch 2002). Newer technologies have permitted vac-
cines based on fewer and more purified antigens having low inherent immunogenicity. 
This led to the need for new adjuvants that can provide a more effective and targeted 
immune response, improve safety and decrease reactogenicity (Kenney & Edelman 
2003; Sesardic & Dobbelaer 2004). For example, MF59TM is a recently licensed, oil-
in-water emulsion that was tested as an adjuvant in split and subunit influenza vaccines 
(Schultze et al. 2008). 
 
There are now dozens of potential vaccines in the pipeline applying novel technologies 
and many licensed vaccines have received updating according to safer and more mod-
ern methods of vaccine manufacturing. Half of all vaccines now licensed were devel-
oped in the past 25 years (Ulmer et al. 2006).  
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The number of different vaccines given in immunisation programmes has increased, 
but the total exposure to vaccine antigens has sharply decreased because of newer 
technologies developing more purified products. As a comparison, in the 1960s the 
total immunogenic proteins contained in 5 recommended vaccines was ~3017, whereas 
the current sum for 11 currently recommended vaccines (including these 5) is ~126 
proteins (Offit et al. 2002). The reduction in vaccine antigen exposure is mainly due to 
the development of acellular pertussis vaccine, although whole-cell pertussis is still 
used in many countries worldwide. 
 
In addition to improved technologies, it is important to note that vaccine manufactur-
ing has also become safer with the increasing number of national regulatory agencies, 
which provide manufacturing oversight and rigorous requirements including independ-
ent laboratory testing of vaccine lots. The early history of vaccine production carries 
examples of major accidents from vaccine manufacturing that affected patients, and 
such past unfortunate errors are considered increasingly remote (Duclos et al. 2005). 
 
The history of BCG vaccines includes a grave manufacturing error. In 1930, 72 of 250 
children in Lübeck, Germany died of tuberculosis following peroral BCG vaccination. It 
was later discovered that during production, the BCG vaccine suspension was contam-
inated with Mycobacteria tuberculosis. After this accident, a general manufacturing prin-
ciple arose that BCG for vaccine use would never again be maintained in a laboratory 
having other mycobacterial cultures (Comstock 1994).  
 
The fragility of annual supplies of influenza vaccines was shown when regulators shut 
down a major vaccine production plant near Liverpool, United Kingdom in 2004, due to 
breaches in good manufacturing practices. During inspection, some vaccine batches were 
found to be contaminated with gram-negative bacteria including Serratia. The suspension 
resulted in the loss of 48 million doses of influenza vaccine, which was nearly half the ex-
pected US vaccine supply for that winter. Sterility issues continued with the closure of a 
second plant in Marburg, Germany, and the loss of 12 million more doses in 2005. The 
lessons learnt included the need to support several vaccine suppliers and to improve the 
collaboration and communication among international regulatory agencies to safeguard 
vaccine quality during production (FDA 2004; Sheridan 2005; Wilkie 2005). 
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Global immunisation programmes and strategies 
It is important to consider the major initiatives that established vaccinations as an in-
tegral component of primary healthcare worldwide. The concerted effort of vaccination 
campaigns worldwide to eradicate smallpox was a major influence. By 1974, buoyed 
by the impending successful eradication, the Expanded Programme on Immunization 
(EPI) was proposed as the next step in global immunisation. Member states at the 
World Health Assembly aimed to reduce vaccine-preventable deaths in childhood by 
establishing long-term immunisation programmes (Henderson 1997). The EPI would 
routinely provide (originally) six vaccines to the general population: BCG, polio, mea-
sles, pertussis, tetanus toxoid, and diphtheria toxoid, according to a suggested immuni-
sation schedule that has hardly changed to this day. In the 1970s, less than 5% of the 
world’s children received these vaccines (Hardon & Blume 2005). As countries began 
establishing national immunisation programmes, global vaccination efforts were 
boosted by a reaffirmation by countries in 1984 to accelerate EPI towards the “Univer-
sal Childhood Immunization” (UCI) target of 80% coverage worldwide by 1990. Fur-
ther funds and motivation arrived in 1988, when the World Health Assembly resolved 
to target polio as the next disease for global eradication through vaccination. 
 
The overall UCI target of 80% global coverage was reached in the 1990s, but disaggre-
gated data  revealed that coverage was not uniformly distributed and the target was not 
reached in more than half of countries (Hardon & Blume 2005). EPI vaccines were 
clearly underused. The EPI prevented 3 million pediatric deaths annually but one quar-
ter of the world’s children still remained unvaccinated. The number of deaths prevent-
ed by EPI vaccines could have been potentially doubled (Kapp 2002). Disconnected 
immunisation services in developing countries have highlighted the increasing dispar-
ity and the “unused potential” of vaccination as an effective life-saving intervention, 
without even considering the addition of new and costlier vaccines to the programme 
(Keegan & Bilous 2004).  
 
With 130 million children born each year, the momentum for sustained immunisation 
coverage is a continual challenge. There is currently an unprecedented mobilisation of 
financial resources to boost immunisation programmes in developing countries. The 
global value of vaccines is recognised, and public and private sectors have partnered to 
form the Global Alliance for Vaccines and Immunizations (GAVI) and the Global 
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Fund for Children’s Vaccines. The aims are to strengthen immunisation services by 
sustaining and improving the global commitment for high coverage and ensuring long-
term funds and secure vaccine supplies (Wittet 2000). The Global Immunization Vi-
sion and Strategy, developed by the World Health Organization (WHO) and United 
Nations Children’s Fund (UNICEF), anticipates more than 20 new or improved li-
censed vaccines by 2015, and lists four main goals: increasing global coverage to 90%, 
ensuring access for eligible populations within 5 years of introducing new vaccines 
into programmes, integrating immunisation with health systems and surveillance, and 
understanding global interdependence of immunisations. Of importance is a specific 
aim (Strategy 5) addressing all aspects of safe immunisation, and to establish surveil-
lance and appropriate timely response to adverse events following immunisation 
(WHO/UNICEF 2005a). 
 
5.2 Vaccine safety  
Monitoring vaccine safety is an integral part of immunisation programmes. Vaccine 
pharmacovigilance, also called “vaccinovigilance” (Lankinen et al. 2004), is described 
as “the science and activities relating to the detection, assessment, understanding, pre-
vention, and communication of adverse events following immunization, or of any other 
vaccine- or immunization-related issues” (CIOMS 2007). This also includes monitor-
ing aspects of safe immunisation practices to ensure the quality of vaccines produced, 
proper storage, safe injection, and appropriate handling and disposal of vaccine-related 
products.  
 
Terminology and Case definitions 
There are several important terms used in vaccine safety. An adverse event following 
immunization (AEFI) is defined as “an untoward medical event temporally associated 
with immunization that causes concern and is believed to be caused by immunization 
but might not be actually caused by the vaccine or the immunization process” (Duclos 
et al. 2005).  
 
A signal is described as “reported information on possible causal relationship between 
AEFI and vaccine; relationship previously unknown or incompletely documented” 
(WHO 2008a). A signal may be a single event or a cluster of events that require clinic-
al and epidemiological investigation. 
5. Introduction 
 
 
 
21 
Commonly used adjectives to describe frequency of the adverse event have also been 
standardised: “very common” ???? ???????? common” ??? ??? 100 and <1 in 10; “uncom-
mon”  ??????1000  and <1 in 100; “rare” ????????????????????????1000; and “very rare” 
<1 in 10,000 (CIOMS 2005). 
 
Finally, a distinction is also made in describing a “serious” event for regulatory report-
ing. A serious AEFI results in a life-threatening or fatal condition, hospital admission 
or prolongation of hospitalisation, or a persistent or significant disability. A severe 
AEFI is not synonymous and is not a term used in classification and reporting of seri-
ous AEFI. Severity describes not the event itself but the intensity, which may be 
graded as mild, moderate or severe, and does not indicate the seriousness of the medic-
al condition. An example commonly given is a severe headache, which indicates high 
intensity but not necessarily serious medial consequence (ICH 1994). 
 
The need for standardised terminology to describe vaccine-related adverse events was 
recognized by WHO and the Council for International Organizations of Medical Sci-
ences (CIOMS), with joint efforts made to provide clear, consistent definitions of vac-
cine-related adverse reactions in order to improve the quality, comparability, and sig-
nal detection from the variety of sources of safety data available. Some definitions and 
standards for reporting safety data and adverse events management were outlined in 
1994 by the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), as an essential component of 
good practices in all clinical investigations, and applicable to adverse events from bio-
logicals or chemical drugs (ICH 1994).  
 
Clinical terminology has been standardized by international dictionaries for pharmaco-
vigilance used by regulatory authorities and industry, such as the WHO-Adverse Reac-
tion Terminology (WHO-ART, www.umc-products.com) and the Medical Dictionary 
for Regulatory Activities (MedDRA www.meddramsso.com).  
 
WHO developed a number of case definitions of AEFI (WPRO 1999), but there are 
many remaining AEFI that are not defined. In 2000, a global network of scientists in 
academia, industry and governmental agencies launched The Brighton Collaboration 
(www.brightoncollaboration.org), and assigned volunteer working groups to the task 
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of forming a standardised case definition for up to 100 known vaccine-related AEFI 
(Bonhoeffer et al. 2002). The aim is to develop globally accepted definitions to im-
prove the quality of vaccine safety data collection, analysis and reporting. So far, over 
20 Brighton case definitions of vaccine-related adverse events have been published. 
 
Pre-licensing safety data collection and reporting 
Even with the largest pre-licensing randomised controlled trials (RCTs), there will be 
limits in the representativeness of the study population and in adverse events detection. 
Potentially vulnerable groups may have little representation or are actively excluded 
from participation in these trials, resulting in little or no data on these groups prior to 
vaccine licensing. Analyses of subgroups that are included in the study may also be 
limited for several methodological reasons.  
 
Assessment of safety is inherently more difficult than efficacy, because safety is not 
measured by the presence but inferred by the absence of reported events. For example, 
a Phase III trial of 105 subjects is well powered to determine vaccine efficacy. To as-
sess safety, 105 will likely detect events occurring more often than 1 in 33,333 doses. 
This follows the so-called Rule of Three or Hanley’s formula, where 3/N (or 3/(N+1) 
(Jovanovic & Levy 1997)) approximates the upper limit of the 95% confidence inter-
val for an unknown binomial probability having no events occurring in N independent 
observations, if N>30 (Hanley & Lippman-Hand 1983; Eypasch et al. 1995). The trial 
is unlikely to capture events that are less frequent, nor can it capture events with a de-
layed onset beyond the usual study period of 42 days. Even a single serious adverse 
event in a clinical trial serves as a signal of a potential vaccine-related AEFI that re-
quires careful assessment for causality and further studies. There have been some 
examples after licensing of serious adverse events determined to be linked through 
observational studies and vaccine pharmacovigilance systems, such as rhesus rotavirus 
vaccine and the risk of intussusception (Offit et al. 2008).  
 
In addition to limitations in study design, there are issues of reporting. As part of 
regulatory requirements, the conduct of trials requires an increasingly comprehensive 
collection of safety data. These data, however, are often not publicly accessible or well 
explained in the eventual scientific publications. A systematic review on the reporting 
of chemical drug adverse events in RCTs, found the safety content lacking in several 
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areas of medical research published up to the mid 1990s. The inadequacy of reporting 
was both quantitative, with the average allocated written space was one third of a sin-
gle page; and qualitative, with more than 60% of RCTs were assessed as having insuf-
ficient safety reporting, such as lack of grading of severity or the lack of reporting 
negative results (Gellin & Schaffner 2001; Ioannidis & Lau 2001).  
 
Since these limitations were recognised, the opportunity to assess vaccine and drug 
safety data in current phase III clinical trials has improved. Depending on the indica-
tion, larger study samples approaching N=106 and more extensive safety data collec-
tion and analysis are required prior to submission of a new vaccine or drug for licens-
ing approval. Safety of an intervention is measured in the entire trial population, in 
contrast to earlier trials, where assessments were often limited to common (minor) re-
actions or only assessed in a subsample (Duclos et al. 2005).  
 
Post-licensing safety data and surveillance systems 
For these above reasons, vaccine safety data obtained from post-licensing observation-
al studies are important, particularly for recently licensed medicinal products and in 
determining specific effects in subpopulations. Furthermore, non-controlled observa-
tional studies may be the most appropriate design, as ethical issues are raised in con-
trolled studies after a new vaccine has been licensed, determined beneficial and widely 
recommended (Ioannidis et al. 2001). In addition to classic cohort and case-control 
studies, risk-interval and self-controlled case series are two alternative study designs 
used to evaluate vaccine safety, each having different study limitations (Glanz et al. 
2006; Whitaker et al. 2006). Actively conducted studies are essential because of the 
limitations of post-licensing passive surveillance systems (Fontanarosa et al. 2004; 
Varricchio et al. 2004).  
 
In 2004, only 68% of all countries had a national system to report AEFI 
(WHO/UNICEF 2005b). Of those existing in non-industrialised countries, only 25% are 
considered to be adequately functioning (WHO 2006c). Most industrialised countries have 
both a general passive scheme (such as UK’s Yellow Card reporting or the US Vaccine 
Adverse Events Reporting System (VAERS) (Chen et al. 1994)), that is augmented by 
epidemiological studies and active surveillance registries, for example to monitor new 
vaccines or new indications of current vaccines. However, a recent survey of European 
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vaccinovigilance systems found many gaps in AEFI reporting and analysis even in in-
dustrialised countries (Lankinen et al. 2004). Passive surveillance databases can pro-
vide a valuable source for signal detection from computer-based data-mining pro-
grammes (Niu et al. 2001). 
 
To augment passive surveillance, large, population-based health databases are also ex-
amined as another important source of vaccine safety data. With the increasing com-
puterisation of medical records, there are now administrative longitudinal electronic 
databases available that link patient health records, including their vaccination history. 
Retrospective studies and signal detection programmes can then be conducted (Chen et 
al. 1997). Linked electronic databases that can monitor vaccine safety have been 
shown to be feasible in lower income settings (Ali et al. 2005).  
 
Conducting an AEFI investigation shares several similarities with an outbreak investi-
gation of an unconfirmed disease in a single case or cluster of cases. The main goals 
are chiefly to determine if the AEFI is causally related to the vaccine or if there are 
programmatic concerns; to manage the situation in a timely, appropriate and transpar-
ent manner; and to communicate findings well to maintain public confidence (WHO 
2008b). A main challenge is timely collection and analysis of available evidence to 
determine if there is a causal association between the vaccine and the adverse event, 
and there can be delays before careful conclusions are reached. Causes of AEFI can be 
categorised in one of five groups: the AEFI may be due to a “true” adverse event from 
inherent properties of the vaccine (it may be then called a vaccine “reaction”); from 
programmatic errors related to vaccine storage, dose preparation, or administration; 
from reactions related to receiving the injection (an injection reaction); coincidental 
only and unrelated; finally, the cause may remain undetermined (WHO 2008a). 
 
WHO recognised the need to respond to global vaccine safety issues in a timely, effi-
cient manner. In 1999, WHO established the Global Advisory Committee on Vaccine 
Safety (GACVS, www.who.int/vaccine_safety/en). GACVS is an active scientific ad-
visory that convenes to make independent expert assessments on topical vaccine safety 
issues (Folb et al. 2004). GACVS has published a substantial number of conclusions 
on vaccine safety issues that have influenced global and national vaccine policies 
(Duclos et al. 2005).  
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WHO also established an international pharmacovigilance database (WHO 2006b). 
Following the thalidomide disaster, in 1968 the WHO Programme for International 
Drug Monitoring was set up initially for chemical drugs, then expanded to include 
AEFI in the 1990s, relying upon spontaneous adverse event reporting from countries. 
The database is physically maintained by WHO’s collaborating centre in Sweden, 
known as the Uppsala Monitoring Centre (UMC). An analysis of the UMC database up 
to 2005 revealed that 10% of reports are related to AEFI, and that just three countries – 
the United States, United Kingdom and Canada - have contributed 82.1% of all AEFI 
reports. The average time between the event onset date and the UMC report date was 
2.4 years database (Letourneau et al. 2008). Some countries’ national pharmacovigi-
lance centres are clearly disconnected from EPI, indicated by discrepancies in AEFI 
data reported on UMC forms and the duplicate data requested by WHO/UNICEF on 
annual EPI monitoring forms (WHO 2006c). This indicates several areas to tackle, 
such as streamlining and harmonising reporting to WHO, establishing AEFI nosologic 
codes, improving timeliness and signal detection of AEFI, and building a truly inter-
national database. WHO also aims to support the establishment of networks of national 
post-marketing surveillance specifically for newly licensed vaccines and recognises 
the need for networks in non-industrialised countries (Bentsi-Enchill 2007). 
 
5.3 Influenza and influenza vaccination 
Certain subpopulations are at higher risk from influenza-related complications and are 
targeted for vaccination. There is a need to review the safety and effectiveness of in-
fluenza vaccine safety in the pregnant subpopulation. An overview of influenza, clinic-
al disease and epidemiology and inactivated vaccines is now provided. 
 
Clinical disease and epidemiology 
Influenza viruses are single-stranded RNA viruses (Family: Orthomyxoviridae), with 
three genera affecting humans, classified according to major antigens as Influenzavirus 
A, B, or C. Types A and B are considered of main clinical importance, causing serious 
respiratory illnesses and epidemics. Type A is largely responsible for severe epidemics 
and pandemics. Only A viruses are subtyped by distinct differences in two glycopro-
tein spikes on the viral surface: haemaglutinin (H), with subtypes identified from H1 to 
H16; and neuraminidase (N), subtyped from N1 to N9 (Cox & Subbarao 1999; 
Nicholson et al. 2003; Fouchier et al. 2005). Only certain H and N subtypes are known 
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to infect humans and other mammals, whereas all subtypes have infected wild avian 
species, as birds are likely the evolutionary hosts for the A viruses. 
 
 
 
 
 
 
 
 
The etiology of influenza was only discovered and transmission confirmed with swine 
influenza in 1930 by Shopes and the type A virus conclusively determined in human 
infections by Smith and colleagues in 1933, with demonstration of direct transmission 
of disease from infected human nasopharyngeal washings to ferrets (Smith et al. 1933; 
Taubenberger et al. 2007). Influenza types B and C were later discovered in 1940 and 
1950 (Hilleman 2002).  
 
Human influenza is a contagious respiratory disease that, after an incubation of 1-5 
days, classically presents as a sudden onset of fever, chills, dry cough, muscle pain 
(myalgia) and diarrhoea. Human-to-human transmission of influenza occurs in three 
ways: from airborne droplet nuclei, from ?????? ????????? ??? ??? ???? ????????? ?????
coughing or sneezing, or from contact transmission that is direct (person-to-person) or 
indirect (fomites) (Salgado et al. 2002; Bridges et al. 2003). It is important to note that 
influenza exposure and infection affects individuals differently, ranging from subcli-
nical to life-threatening illness. Primary influenza pneumonia usually presents early 
during the course, with dry cough becoming productive and haemorrhagic, and with 
increasing respiratory distress. A secondary bacterial pneumonia can occur usually 
during the convalescent period, commonly caused by H. influenzae, Streptococcus 
pneumoniae, and Staphylococcus aureus. Influenza can affect many organs, and is no-
tably associated with serious neurological complications (Guillain-Barré syndrome, 
Reye’s syndrome, other encephalopathies and myelitis) and muscular inflammatory 
diseases (myocarditis and myositis) (Cox & Subbarao 1999; Turner et al. 2003). De-
Figure 1:  
3D electron tomography of the influenza 
virus (120 nm) 
 
Haemagglutinin spikes are in green; neur-
aminidase spikes are in yellow. Reproduced 
with permission from Alasdair Steven. 
 
5. Introduction 
 
 
 
27 
tailed clinical case descriptions of influenza disease and complications in pregnancy 
have been described for both influenza type A and B (Parkins et al. 2007; Yusuf et al. 
2007). 
 
Influenza pandemics have occurred probably much earlier, but in recorded western 
history, there were 13 probable or possible pandemics (global outbreaks) since the 17th 
century (Potter 2001). Three pandemics occurred during the 20th century, all by sub-
types of influenza A: 1918/9 (H1N1), 1957/8 (H2N2) and 1968/9 (H3N2), while se-
vere but less widespread epidemics (or “pseudopandemics”) occurred in 1947/8, 
1975/6 and 1989/9 (Nicholson et al. 2003; Kilbourne 2006). The pandemic between 
1918-20 is estimated to have killed 20 to 50 million people worldwide, and was one of 
the most devastating infectious disease events in history (Johnson & Mueller 2002). 
 
Influenza is one of the major infectious diseases in the world, having an enormous so-
cioeconomic toll. An estimated 5-15% of the population is infected during average 
yearly epidemics, leading to severe respiratory illness in 3 to 5 million people and 
250,000 to 500,000 deaths worldwide, occurring mainly in those >65 years of age 
(WHO 2003). The disease burden and affected higher-risk subpopulations are thought 
to be similar worldwide, although much less is known about its impact in many non-
industrialised countries (WHO 2005a). Measures to assess mortality and morbidity 
from influenza are considered to underestimate the true burden. Influenza circulates 
among other respiratory pathogens and causes non-specific exacerbations of cardiopul-
monary diseases, leading to “hidden” deaths from influenza (Nicholson et al. 2003). 
Antigenic variation, level of protective immunity in the population and the virulence of 
the strain (Cox & Subbarao 1999) are some key factors in determining the impact of 
influenza epidemics.  
 
There are several vulnerable subpopulations with increased likelihood of influenza 
complications and death (WHO 2005a). These include the elderly, those in acute and 
long-term care facilities, or individuals with immunocompromising or chronic condi-
tions (Salgado et al. 2002). For many years there have been scientific discussions whe-
ther there is sufficient evidence to include pregnancy as a higher risk condition for 
complications from pandemic and seasonal influenza (MacDonald et al. 2004). This 
open question was the basis of one of the reviews in this dissertation. 
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Young children are “efficient transmitters” of the infection, having the highest attack 
rates and are prolonged viral shedders (WHO 2005a). Influenza-attributed hospitalisa-
tion rates for cardiopulmonary were highest in infants under 12 months of age in the 
United States (Neuzil et al. 2000). This was supported by similar findings for children 
under 5 years using laboratory-confirmed influenza in Germany (Weigl et al. 2002). 
Although estimated influenza-related mortality is highest in those aged over 65 years 
(Thompson et al. 2003), laboratory-confirmed influenza mortality in children is 
substantial; during the 2003/4 season, of 153 laboratory-confirmed influenza deaths in 
US children (mainly from pneumonia, bronchiolitis, and encephalopathy), the highest 
mortality rate was in infants < 6 months old at 0.88 per 100,000 (Bhat et al. 2005). 
 
Inactivated influenza vaccines 
Vaccination is considered the mainstay of preventing influenza and mitigating the im-
pact of outbreaks (Germann et al. 2006; WHO 2008c). In the 1930s, the successful 
propagation of the virus in the allantois of embryonated chicken eggs soon led to the 
development of the first crude, inactivated influenza vaccines (Bramwell & Perrie 
2005). These were initially used to vaccinate American military staff.  
 
Inactivated influenza vaccines are given as an intramuscular injection. The inactivated 
vaccines against seasonal influenza are trivalent, composed of antigens of 3 different 
influenza strains (usually two influenza type A strains, and one type B). Each antigen 
contained in the vaccine is classified by its lineage: “serotype/geographic origin/strain 
number/year first isolated (subtype)”, such as A/New Caledonia/20/99 (H1N1). One of 
the reasons for the epidemic nature of influenza is the frequent mutation in the viral 
surface antigens. Immunity from exposure to previous influenza antigens can offer 
some or no protection against infection by other strains. One factor in the effectiveness 
of vaccination is how well the selected antigens contained in the vaccine correspond 
with the antigens of circulating wildtype strains. Vaccine mismatch and reduced vac-
cine effectiveness due to antigenic variation has been recognised for many years 
(Francis et al. 1947). The frequency of viral mutations is reflected by the fact that 
WHO has recommended a change in composition of the annual influenza vaccine 
nearly every year since 1972. 
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There is an internationally accepted process for deciding upon the composition of an-
nual influenza vaccines for the upcoming season for each of the hemispheres (WHO 
2008c). A strict timeline is met each year following the decision on the predicted cir-
culating strains and the production of adequate vaccine supplies for the next winter 
season. The process takes up to 6 months for manufacturers to produce 250-300 mil-
lion vaccine doses from about the same number of embryonated chicken eggs. World-
wide annual capacity is constrained by egg-based vaccine production and manufactur-
ing infrastructure (Ulmer et al. 2006). Vaccination coverage is considered paramount 
for influenza control. In the event of a pandemic, influenza vaccine production is a 
critical issue and an unprecedented number of doses will be urgently needed. There are 
efforts to increase manufacturing capacity and to develop novel, non egg-based 
production of influenza vaccines to maximize efficiency and safeguard supplies and 
quality (Bramwell & Perrie 2005; WHO 2005b). 
 
Of serious adverse events following influenza vaccination, the risk of anaphylaxis is 
very rare (one study estimated 0.025 per 100,000) (Prosser et al. 2005). In 1976-7 a rise 
in cases of Guillain-Barré syndrome (GBS) was noted about 6-8 weeks after influenza 
vaccination. GBS is an acute, autoimmune demyelination of peripheral nerves, pre-
senting as progressive ascending paralysis, requiring hospitalisation and often ventila-
tory support. With adequate supportive care, recovery is usually full after several 
weeks. The concern that GBS was an influenza-related AEFI led to the suspension of 
mass “swine flu” vaccine campaigns in the United States, which had been conducted fol-
lowing concerns that the 1976/7 circulating influenza strain would trigger the next pan-
demic (this did not occur). A total of 581 GBS cases was reported, and an authoritative US 
review concluded there was evidence favouring a causal link between the 1976/7 influenza 
vaccine and GBS. The estimated vaccine-related excess GBS was 0.6 per 100,000 above 
the estimated baseline incidence of 1-2 cases per 100,000. The excess risk remained sub-
stantially lower than the annual number of excess deaths attributed to influenza (Institute 
of Medicine 2004). One hypothesis is that during vaccine manufacturing using fertilised 
chicken eggs, the vaccine product may have been contaminated with Campylobacter jejuni 
(an endemic bacterial infection harboured in about 50% of chickens). Exposure to C. je-
juni in humans is known to be associated with GBS (Marwick 2003; Haber et al. 2004; 
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Prosser et al. 2005). Since the swine flu vaccine, GBS has been listed as a possible ad-
verse event from influenza vaccine. 
 
5.4  Tuberculosis and BCG vaccines 
Clinical disease and epidemiology 
Human tuberculosis is an infectious disease primarily caused by Mycobacterium tuber-
culosis. Mycobacteria are slow-growing intracellular, atoxic, aerobic acid-fast bacilli. 
Human tuberculosis is less commonly caused by other closely related mycobacteria 
that mainly infect other mammals: M. bovis, M. africanum, M. canetti, M. microti, M. 
caprae and M. pinipedii. All these mycobacterial species causing tuberculosis in im-
munocompetent humans are considered members of the “M. tuberculosis complex” 
(MTBC) (Wirth et al. 2008). MTBC are distinguished from environmental mycobacte-
rial species that can cause opportunistic disease in humans with immunodeficiencies, 
but are usually non-pathogenic in individuals with normal immune systems. 
 
Most immunocompetent individuals are able to contain a primary M. tuberculosis in-
fection and remain asymptomatic. About 90% of infected immunocompetent individu-
als will have latent tuberculosis without progression to reactivated tuberculosis in their 
lifetime. In contrast, tuberculosis progresses to active disease in about 50% of HIV-
infected adults (WHO 2004c). Persistence of latent tuberculosis arises from the co-ex-
istence and co-evolution M. tuberculosis and the human host for thousands of years, 
and is one of the main obstacles to eliminate tuberculosis. Reactivation disease most 
commonly occurs as pulmonary tuberculosis in adults, which is the main infectious 
form. Classic presentation is cough, blood in sputum (haemoptysis), fever, sweats, and 
weight loss. Any organ system may be affected by tuberculosis, with the most serious 
forms of tuberculosis being disseminated disease and tubercular meningitis, which can 
occur at any age but are highest in young children. 
 
Tuberculosis is the most common cause of death from a curable infectious disease. 
One third of the world’s population is latently infected and an estimated 8.9 million 
new cases of tuberculosis disease occur each year. WHO declared tuberculosis a global 
health emergency in 2003 and emphasised two years later the situation was dire in Af-
rica, which has 13 of the 15 countries with the highest annual incidence of tuberculosis 
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(>300/100,000) and where an estimated 1500 deaths from tuberculosis occur each day 
(WHO 2005c; Dye 2006; WHO 2007b). Global incidence of tuberculosis is on the rise, 
fueled by the HIV epidemic. Tuberculosis co-infection is now the leading cause of 
HIV-related morbidity and mortality. There is also an increasing number of individuals 
with multidrug-resistant (MDR) tuberculosis who are non-responsive to isoniazid or 
rifampicin, two first-line antitubercular drugs. Even more alarming is the emergence 
since 2006 of extensively drug-resistant (XDR) tuberculosis in several regions of the 
world, particularly seen in HIV-infected individuals. XDR M. tuberculosis strains have 
additional resistance to three of the six classes of second-line antitubercular agents, 
which severely restrict options for curative therapy (WHO 2007a).  
 
Although tuberculosis in children can represent a substantial proportion of the total 
caseload and is associated with a more aggressive course, research in childhood tuber-
culosis is neglected (WHO 2006a). In a cohort of HIV-infected Ivorian children the 
cumulative incidence of tuberculosis by 3-years follow up was 5930 per 100,000, indi-
cating the high risk of progression of tuberculosis disease in HIV-infected children 
(Elenga et al. 2005). 
 
BCG vaccines 
BCG is the oldest live attenuated vaccine still in use and the most widely given, with 
more than 3 billion individuals vaccinated since first use (Andersen & Doherty 2005). 
The story of BCG vaccine began more than 100 years ago. A M. bovis strain was isola-
ted by Nocard and passaged in vitro for over a decade by Calmette and Guérin. After 
230 passages, the organism had adequately attenuated to the sub-species named M. bo-
vis bacille Calmette-Guérin, or BCG. The first human vaccination was in 1921 when 
Weill-Hallé administered a suspension of live BCG perorally to a tuberculosis-exposed 
infant who remained tuberculosis-free (Grange et al. 1983; Comstock 1994). It is now 
known that the selected M. bovis organism attenuated to BCG from the loss of genetic 
material mainly in RD-1 (region of difference-1) and RD-2 (Behr et al. 1999). BCG 
exemplifies the increased complexity and inherent variability of biological medicines. 
In the 1920s, daughter strains of BCG were shared with several laboratories around the 
world, and propagated by > 1000 serial cultures for 30 additional years prior to BCG 
seed lots being preserved by lyophilisation. This has resulted in several BCG vaccine 
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strains manufactured in the world with substantial genetic variation, which can trans-
late to differences in effectiveness and related AEFI.  
 
 
 
Figure 2:  History of BCG geneology.  
Vertical axis is time, horizontal lines indicate geographic location (and name) of BCG strains being propa-
gated. RD indicates regions of genetic deletion. Reproduced from Behr et al. 1999. 
 
BCG effectiveness against adult pulmonary tuberculosis has been observed to range 
from 0 to 80% depending on country, thus a summary efficacy rate is inappropriate. 
It remains unclear to what extent BCG vaccines prevent primary infection with M. 
tuberculosis or reactivation of latent pulmonary disease. Lower effectiveness may be 
partially explained by increased exposure to environmental mycobacteria in tropical 
settings (Fine 2001). The landmark large-scale field trial in Chingleput found 0% or 
even a negative BCG efficacy in preventing culture-positive adult pulmonary tuber- 
culosis in HIV-uninfected adults followed for 15 years (Tuberculosis Research Centre 
(ICMR) Chennai 1999). The Malawi trial confirmed similar findings and also raised 
concern for the small HIV-infected adult subgroup included in the trial, whose risk of 
pulmonary tuberculosis possibly even increased after BCG revaccination (Karonga 
Prevention Trial Group 1996; Rieder 1996).  
 
Few studies have examined BCG effectiveness in HIV-infected adults and findings 
are inconsistent. There is limited evidence that BCG provided to HIV-uninfected in-
fants may protect against later disseminated tuberculosis in those who later acquire 
HIV/AIDS in adulthood (Marsh et al. 1997). However, childhood BCG vaccination 
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did not appear to protect HIV-infected adults against extrapulmonary tuberculosis 
(Arbelaez et al. 2000). The limitations of these studies on BCG effectiveness in HIV-
infected adults include their retrospective nature, small sample size, the potential 
bias from selective non-vaccination and the suboptimal choice of BCG scarring as a 
surrogate indicator for vaccine-induced immunity. 
 
The WHO rationale for BCG vaccination is based on the consistent, reasonable protec-
tion against serious forms of primary, progressive tuberculosis in the general pediatric 
population (WHO 1980; Brimnes 2008). A meta-analysis found summary protection 
against meningeal and military tuberculosis of 86% (95% CI: 65-95%) from RCTs and 
75% (95% CI: 61-84) from case-control studies (Rodrigues et al. 1993). Another cal-
culated a pooled vaccine efficacy of 74% (95% CI: 62-83%) against all forms of child-
hood tuberculosis from RCTs and 52% (95% CI: 38-64%) from case-control studies 
(Colditz et al. 1995).  Since the inception of the EPI, WHO has recommended BCG at 
or soon after birth in countries with high tuberculosis burdens (WHO 2004b).  
 
Currently BCG is part of immunisation programmes in over 150 countries endemic for 
tuberculosis. In contrast, most industrialised countries offer BCG selectively to high-
risk subpopulations rather than routinely. There are guidelines to consider such shifts 
in BCG vaccine policy if epidemiological indicators of low-burden tuberculosis are 
met (IUATLD 1994). In 2008, a global mapping exercise was initiated in order to 
document changes in BCG policies and practices for each country (www.bcgatlas.org). 
 
As BCG vaccination has not demonstrated a major impact against spread of infec-
tion, this vaccine does not have a substantial role in tuberculosis control strategies 
(WHO 2004a). With the spectre of MDR and XDR tuberculosis and a currently limi-
ted armamentarium of effective anti-tubercular drugs, it is clear that a tuberculosis 
vaccine is needed that effectively prevents reactivation disease to have an impact on 
disease control, and particularly one that is proven effective and safe in HIV-infected 
individuals, a subpopulation facing one of the highest risks from tuberculosis. 
 
5.5   The issue of subpopulations 
Pregnant women and HIV-infected children are two subpopulations examined in this 
dissertation. There may be little pre-licensing data on a chemical drug or vaccine’s 
5. Introduction 
 
 
 
34 
profile in subpopulations, although certain groups may be more vulnerable to the di-
sease. As described, post-licensing studies that evaluate subpopulations provide vital 
information because these groups are often excluded in clinical trials as well as neglec-
ted in drug development (Fisk & Atun 2008). The immunological mechanisms of vac-
cine safety and effectiveness play a key underlying role in the differential risk of ad-
verse events from the natural disease or from the vaccination in certain subpopulations. 
 
Subpopulation of pregnant women 
Pregnancy is an altered immune state. Several physiological and immunological 
changes occur in pregnant women, with immune tolerance mechanisms to the foreign 
paternal antigens in the fetal allograft. These changes are not well understood, but a 
shift from cell-mediated adaptive immunity to innate immunity occurs. This relative 
imbalance in immune response may explain the increased morbidity seen in pregnant 
women with some infections, particularly intracellular pathogens (Sacks et al. 1999). 
There are several infectious diseases in pregnancy that also are known to carry a risk 
of fetal malformations, including varicella, rubella, syphilis, cytomegalovirus, and par-
vovirus B19 infections (Price 2008).  
 
During pregnancy, embryonic organogenesis and fetal development take place in a 
programmed sequence of events. Research in teratology aims to define periods of risk 
and the outcomes related to the timing of an insult during gestation. An area of investi-
gation explores how insults to intrauterine programming or in early childhood may 
predispose to certain health conditions in later life (Brent 2006; Price 2008). 
  
It is well known that passive immunity with maternal pathogen-specific antibodies ac-
quired from transplacental and lactational transfer offers protection to the newborn 
against infectious diseases in the vulnerable first months of life (Munoz & Englund 
2001). Newborns are particularly susceptible to infections because of reduced, age-de-
pendent antibody responses to a range of pathogens. Most of the world’s neonatal 
deaths occur in poor countries, and infectious diseases are the leading cause (Anon 
1999). In general, vaccination in early infancy also does not induce strong antibody 
responses, due to immunological immaturity as well as the persistence and interference 
of maternal antibodies. Vaccination in early life can, however, provide immunological 
priming that can lead to improved responses against later antigen-specific exposures 
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(Siegrist 2001). Except for BCG, all other current vaccines administered before the age 
of 6 months require repeated doses.  
 
Inactivated vaccination in pregnancy and passive transfer of vaccine-derived maternal 
antibodies is considered a potential alternative means of protecting young infants 
(Healy & Baker 2006). Such a strategy has been called the “quintessence” of preven-
tive medicine (Brent 2003). For several decades, tetanus toxoid vaccination during 
pregnancy has been considered a safe, effective EPI strategy to prevent neonatal teta-
nus in endemic countries (Roper et al. 2007). Despite this long-standing example, 
there remain several scientific, societal, legal and regulatory barriers to provide vac-
cines in pregnancy, particularly in industrialised countries (Glezen 2003). 
 
Live attenuated vaccines are contraindicated in pregnancy due to concern that live vac-
cine strain replication in the maternal host and “vaccinemia” can potentially infect the 
placenta and fetus, leading to adverse pregnancy outcomes. Cases of fetal infection 
have been well documented after live attenuated rubella vaccine was given inadver-
tently in pregnancy (Hofmann et al. 2000; Hamkar et al. 2006). There have been no 
documented cases of congenital rubella syndrome, however, from inadvertent maternal 
vaccination or congenital adverse events from any other live attenuated vaccination 
except for smallpox. About 50 documented cases of fetal vaccinia have been reported 
worldwide, with some cases leading to fetal or neonatal death (Napolitano et al. 2004). 
 
Subpopulation of HIV-infected and primary immunosuppressed children 
Limited information is available about safety and effectiveness of most vaccines in the 
HIV-infected immunocompromised subpopulation (Clements et al. 1987; Moss et al. 
2003). Immunodeficiency is defined as either primary immunodeficiency disorders 
(PIDs) or secondary, with HIV being one form of acquired immunosuppression (others 
include leukaemia, lymphoma, generalised malignancies, or drug-induced such as 
high-dose steroids or chemotherapy). Each disorder has its own underlying immuno-
pathogenic mechanisms. Because the immune system is very complex, there are po-
tential deficiencies with a variety of different mechanisms, such as abnormal function 
of white blood cells or the complement system. New PIDs continue to be discovered. 
Since the first was identified in the 1950s, the molecular basis of more than 100 PIDs 
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are now known. Although PIDs form a heterogenous group, there are less than 20 dis-
orders that account for most cases (Lindegren et al. 2004).   
 
In general in industrialised countries, live vaccines are contraindicated in immuno-
compromised individuals, out of concern that replication of the vaccine strain may oc-
cur unchecked and lead to serious vaccine-induced infections. One of the complicating 
features of HIV is that left untreated, the immune dysfunction from HIV is progres-
sive. Uncertainty remains if there is an early safe window in which to administer live 
attenuated vaccines. Current guidelines for live measles vaccination in industrialised 
countries, for example, are based on a threshold age-specific CD4+ count in HIV-in-
fected children (Department of Health 2006). Inactivated vaccines are empirically con-
sidered safe; there have been some conflicting reports of viral load increasing tran-
siently after inactivated influenza vaccination in HIV-infected adults (Stanley et al. 
1996), but the clinical relevance has not been demonstrated. Immune responses in the 
immunodeficient vaccinee are related to the level of suppression. In general, responses 
to live or inactivated vaccines are reduced. 
 
Prior to the HIV epidemic, disseminated BCG disease (dBCG) were known to occur 
(Lotte et al. 1984), almost exclusively in children with primary cellular immunodefi-
ciencies. Retrospective reviews have defined a group of PIDs associated with dBCG: 
Severe combined immunodeficiency (SCID), chronic granulomatous disease, partial 
or complete Di George syndrome, and partial or complete interferon gamma deficien-
cies have been found to be at increased risk of opportunistic mycobacterial infections, 
among other infections (Casanova et al. 1996; Afshar Paiman et al. 2006; Liberek et 
al. 2006). 
 
5.6  Summary 
The field of vaccinology has seen major public health successes and technological ad-
vancements over its 200 years. Vaccines are valued as essential, cost-effective inter-
ventions in global public health and there are many novel vaccine candidates on the 
horizon. Like other medical interventions, a vaccine has benefits and risks. Safety in-
formation of a new vaccine is limited by pre-licensing studies that are insufficiently 
powered to assess safety or that report on adverse events incompletely. Subpopulations 
suspected of having a special vaccine risk-benefit profile may not be represented in 
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trials, or are actively excluded, or arise later as a concern, such as with HIV infection. 
Post-licensing surveillance studies and pharmacovigilance systems are thus crucial in 
providing more complete information on safety and effectiveness.  
 
Influenza and tuberculosis are respiratory infections having enormous global health 
impacts. Pregnant women and HIV-infected subpopulations are groups known to be 
vulnerable to certain infectious diseases. The risk-benefit profile of inactivated influ-
enza vaccines in pregnancy and of live attenuated BCG vaccination in HIV-infected 
children are important research questions for full consideration. Continual, careful ap-
praisal of the evidence for vaccine safety informs policy and upholds the public trust 
placed in immunisation programmes. 
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6 Rationale, aim and specific objectives  
6.1 Rationale 
It is essential to continually gather and evaluate current evidence to improve under-
standing of a vaccine’s risk-benefit profile and to inform vaccine policy and practice. 
The dissertational research areas were topical and conducted during recent changes to 
WHO vaccine policy recommendations. Countries are in the process of evaluating na-
tional influenza vaccine policies, spurred also by WHO guidance to prepare pandemic 
plans that include identifying higher-risk groups for priority vaccination. BCG vaccine 
safety concerns in HIV-infected children have been raised in light of accumulating 
evidence, and a full review of BCG’s risk-benefit profile in this subpopulation was 
warranted. 
 
6.2 Aim 
The aim is to contribute towards informed policy and practices in immunisation by 
synthesising current available evidence through systematic reviews on the safety and 
effectiveness of vaccines against influenza and tuberculosis in specific subpopulations. 
 
6.3 Specific Objectives 
? To assess the evidence of the risks and benefits of inactivated influenza vac-
cines in pregnant women, and compare different national vaccine policies. 
 
? To assess the evidence of the risks and benefits of live attenuated BCG vac-
cines in HIV-infected infants, to perform a meta-analysis for a pooled risk esti-
mate of disseminated BCG disease in this subpopulation, and to consider impli-
cations in settings with different levels of resources and burdens of disease. 
 
? To collate and assess the current available evidence for management of the 
spectrum of BCG-related adverse events following immunisation, with the aim 
of contributing to useful evidence-based guidance for health care providers. 
 
? Based on a synthesis of these findings, to provide useful commentary on influ-
enza and BCG vaccine policies for pregnant women and HIV-infected infants, 
respectively, and to identify further research areas to improve the study of vac-
cine safety in subpopulations. 
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7.1 Abstract 
 
In several countries, pregnant women are recommended seasonal influenza vaccination 
and identified as a priority group for vaccination in the event of a pandemic. We re-
view the evidence for the risks of influenza and the risks and benefits of seasonal in-
fluenza vaccination in pregnancy. Data on influenza vaccine safety in pregnancy are 
inadequate, but the few published studies report no serious side-effects in women or 
their infants, including no indication of harm from vaccination in the first trimester. 
National policies differ widely, mainly because of the limited data available, particu-
larly on vaccination in the first trimester. The evidence of excess morbidity during sea-
sonal influenza supports vaccinating healthy pregnant women in the second or third 
trimester and those with comorbidities in any trimester. The evidence of excess mor-
tality in two previous influenza pandemics supports vaccinating in any trimester during 
a pandemic. 
 
 
Keywords 
Influenza; influenza vaccines; adverse effects; pregnancy; pregnancy complications; 
pregnancy trimesters; infant, newborn; health policy; risk assessment 
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7.2 Introduction 
Certain population groups are known to be at higher risk of morbidity and mortality 
from influenza infection. Pregnancy is considered to be one of the conditions confer-
ring increased risk; however, several countries, including the UK and Germany, do not 
routinely vaccinate in pregnancy,1,2 whereas others, such as the USA and Canada, re-
commend vaccinating healthy pregnant women regardless of trimester.3,4 In Australia, 
the vaccine is offered to healthy pregnant women in any trimester who will be in the 
second or third trimester during the influenza season.5 WHO's current position paper 
recommends that all pregnant women should be immunised during the influenza sea-
son.6 There has been no indication that inactivated vaccines given during pregnancy 
harm the fetus; however, safety data are limited. 
 
Information on the burden of disease from seasonal influenza in healthy pregnant wo-
men is also limited. This is by contrast with the possible burden that may occur in an 
influenza pandemic, which is of international concern.7 The 2005 UK Health Depart-
ments' Influenza Pandemic Contingency Plan8 identified pregnant women in the third 
trimester as a provisional priority group for immunisation, recognising that morbidity 
and mortality patterns from a new pandemic strain cannot be predicted. 
 
We examine the risks from both seasonal and pandemic influenza infection together 
with the benefits and risks of inactivated vaccine to the mother and fetus. The UK 
Yellow Card data (the UK's passive reporting system on adverse events associated 
with medicines), current WHO recommendations, and the policies of selected coun-
tries are also reviewed. All references to influenza vaccines in this Review refer to in-
activated vaccines only. “Comorbidity” is used to describe medical conditions that are 
associated with increased risk of influenza-related complications. 
 
7.3 Search strategy and selection criteria 
Data for this Review were identified by searches of the PubMed database without date 
restriction up to August, 2007, for relevant articles in English, with the following me-
dical subject headings: (1)“influenza, human” OR “influenza A virus”, (2) “influenza 
vaccine”, (3) “pregnancy”, “pregnancy trimesters”, OR “pregnancy outcome”, OR 
“pregnancy maintenance”, OR “pregnancy complications”, alone and in combination 
with major topic subheadings: “administration and dosage”, “adverse effects”, “contra-
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indications”, “epidemiology”, “immunology”, “mortality”, “pathology”, “prevention 
and control”, “therapeutic use”, “therapy”, or “toxicity”. The Cochrane Library and 
System for Information on Grey Literature in Europe (SIGLE) and selected countries' 
influenza vaccination policies were also searched. Bibliographies of key articles and 
the authors' own extensive files were reviewed. Citation hits were found through the 
Web of Science. This study obtained permission from the UK Medicines and Health-
care products Regulatory Agency to review a summary of Yellow Card reports from 
June, 1994, to June, 2004. 
 
7.4 The risks of influenza viral infection in pregnancy 
7.4.1 Risk of seasonal influenza in pregnant women 
Women are commonly exposed to influenza during pregnancy. 11% of 1659 women in 
the 1993/94 influenza season in the UK had a four-fold rise in antibody titres indica-
tive of new influenza infections.9 Following the 1989/90 severe influenza season in the 
UK, a one in 15 random sample of records of all fatal cases was compared with a “re-
gular” season in 1985/86.10 Using these methods, eight deaths in pregnant women were 
counted in the severe season and two in the regular season, suggesting a four times 
higher risk of death during a severe influenza season. These figures were extrapolated 
to an excess of 90 deaths in pregnant women out of the 25 185 total excess deaths esti-
mated in the 1989/90 influenza season.11 
 
Although several observational studies using routine hospital admission data have no-
ted a higher risk of hospital admission in pregnancy with influenza-like illness, the 
precise level of risk and the extent that risk varies by trimester are unclear because of 
varying outcome definitions and difficulty in controlling for unknown underlying mor-
bidity. In one of the first observational studies, directly standardised rates of acute car-
diorespiratory illness in hospitalised pregnant women with no known comorbidities 
were compared with those in hospitalised postpartum women in the winter when influ-
enza was not circulating, using Tennessee Medicaid data from 1974-93.12 Peri-influen-
za season rates were subtracted from those in the influenza period to obtain excess 
hospital admission rates attributable to influenza. Women in the second and third tri-
mesters had excess hospital admission rates of 6.32 (95% CI 2.90-9.74) and 10.48 
(6.70-14.26) per 10 000 woman-months, respectively. Women in the first trimester and 
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women in the postpartum period had excess hospital admission rates of only 3.06 
(0.44-5.68) and 1.16 (-0.09 to 2.42) per 10 000 woman-months, respectively, similar to 
the rate in non-pregnant women of 1.91 (1.51-2.31) per 10 000 woman-months. The 
excess hospital admission rate attributable to influenza in healthy women in the last 
trimester was equivalent to that seen in non-pregnant women with chronic medical 
conditions.13 Medicaid provides health care for those without personal insurance and 
poorer sociodemographic groups are therefore over-represented in this population. Re-
sidual confounding - eg, by tobacco - is likely to bias upwards any effect observed. 
 
Excess hospital admission rates attributable to influenza were calculated by similar 
methods in a 1990-2002 population-based record linkage study of 134 188 pregnant 
women from Nova Scotia.14 Rates of hospital admission and medical visits during de-
fined influenza, peri-influenza, and non-influenza seasons were compared per trimes-
ter. The influenza-attributable excess rates of hospital admissions because of respira-
tory illness were 1.1 (-0.1 to 2.3), 0.4 (-1.1 to 1.9), and 2.0 (-0.3 to 4.3) per 10 000 
healthy woman-months in the first, second, and third trimesters, respectively, after 
subtracting the background peri-influenza season rates. The results from this study 
were lower than those from the Tennessee study, which could partly be explained by 
the conservative definition of hospitalisation (admissions that included delivery were 
omitted, as were admissions for asthma exacerbation without influenza-related dia-
gnostic codes); adjustments for confounders such as smoking and socioeconomic 
status made no difference to the risk of hospital admission. 
 
Two other studies examined outpatient medical visits reported in US health mainte-
nance organisation (HMO) databases as opposed to hospital admissions.15,16 The first, 
on a small study population from a Washington HMO, examined rate differences in in-
fluenza-like illness diagnosed in an inpatient or outpatient visit, compared with influ-
enza-unexposed weeks in healthy pregnant women during defined weeks when influ-
enza circulated from 1991-97. Excess rates attributable to influenza were 5.8, 9.8, 
14.1, and 11.0 per 10 000 woman-weeks in the first, second, and third trimesters, and 
postpartum period, respectively, but with only 5.4% of episodes considered severe - 
eg, pneumonia or requiring an emergency visit.15 Low admission rates for influenza 
and pneumonia in pregnancy were also noted in another HMO dataset.17 
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In the second study, Oregon HMO data were used to compare outpatient medical visits 
for acute respiratory disease in pregnant women with non-pregnant women. Four se-
vere influenza seasons (1975, 1976, 1978, 1979) and one regular season (1977) were 
included.16 During the 1978 season, influenza A H1N1 reappeared, a subtype that had 
not circulated for 20 years. Pregnant women had a significant excess rate of medical 
visits of 48.1 per 1000 visits categorised as influenza, pneumonia, upper respiratory 
illness, and respiratory symptoms. By contrast, pregnant women did not have an ex-
cess acute respiratory disease rate in the 1975, 1976, and 1979 seasons when predomi-
nant circulating strains were all H3N2 variants. This finding suggests that different 
strains or previous exposure to subtypes could selectively affect the impact of an influ-
enza season. Nearly all acute respiratory disease medical encounters were supernume-
rary visits and therefore not attributable to increased opportunity to report a respiratory 
illness during the regular prenatal encounters. 
 
Secondary effects of influenza-like illness or pneumonia in pregnancy on the fetus 
were examined in 6 277 508 hospital admissions for pregnant women, representing a 
20% sample of US public hospitals from 1998-2002.18 2.3% of hospital admissions 
during influenza seasons included pneumonia or influenza compared with 1.2% during 
the rest of the year, excluding hospital stays in which a delivery occurred. Hospitalised 
pregnant women with respiratory illness had higher odds of preterm delivery, fetal 
distress, and caesarean section (adjusted odds ratios (OR) 4.08 [95% CI 3.57-4.67], 
2.48 [1.84-3.35], and 3.91 [3.48-4.39], respectively) compared with hospitalised preg-
nant women without respiratory illness. 
 
7.4.2 Risk to pregnant women with comorbidities 
In the US public hospitals study of admissions for pregnancy and respiratory illness, 
pregnant women with a comorbid condition were three times more likely to have a 
respiratory illness compared with healthy pregnant women (OR 3.2 [3.0-3.5]) during 
defined influenza months (1998-2002).18 In a separate cohort analysis of 297 pregnant 
women with respiratory hospitalisation in the Tennessee Medicaid database (1985-93), 
pregnant women with a history of asthma had the highest rate of respiratory hospital 
admission at 597 per 10 000 (OR 10.63 [8.18-13.83]) compared with pregnant women 
without comorbidities during defined influenza seasons.19 Most recently, nearly 13 500 
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pregnant women with one or more comorbidities were reviewed in the Nova Scotia 
study (1990-2002).14 Their influenza-attributable rate of hospital admission was 3.9  
(-6.4 to 14.2), 6.7 (-4.1 to 17.5), and 35.6 (21.1 to 50.1) per 10 000 woman-months for 
the first, second, and third trimesters, respectively, when comparing influenza and 
peri-influenza seasons. Based on an average season of 3.4 influenza-exposed months 
during the study, excess hospital admissions during the third trimester would occur in 
121 per 10 000 pregnant women with comorbidities and in 6.8 per 10 000 healthy 
pregnant women. 
 
7.4.3 Risk to pregnant women in pandemics 
During the influenza pandemic of 1918/19, more than 20 million people died, with 
pregnant women among those at high risk for complications or death. For example, 
1350 pregnant women diagnosed with influenza were ascertained from a mail survey 
of members of the American obstetrical societies and all physicians in Maryland.20 
Overall, the case fatality rate was 27%, but all deaths occurred within the 678 cases 
complicated by pneumonia. The case fatality rate within the pneumonia subgroup was 
54%. A similarly high rate was noted in Chicago (IL, USA) in 101 hospitalised preg-
nant women with influenza illness complicated by pneumonia compared with a 32% 
case fatality rate in 2053 non-pregnant patients admitted with pneumonia in the same 
7-week period.21 
 
Eickhoff and colleagues22 noted in 1961 that “An association of influenza-associated 
deaths and pregnancy is a common clinical impression”. For instance, of a total of 216 
influenza deaths during the 1957/58 pandemic documented in New York City (NY, 
USA), 22 deaths were in unvaccinated pregnant women, only seven of whom had 
rheumatic heart disease.23 Deaths from all causes in pregnant women were double the 
expected number compared with the number of deaths in pregnant women in the pre-
ceding 4 years. A similar doubling of risk of death from all causes in pregnancy com-
pared with previous years was seen in England and Wales in 1957, where 12 of the 103 
women aged 15-44 years who died from influenza were pregnant. These 12 deaths 
were within the 477 deaths reported to the Central Public Health Laboratory Service 
(now known as the Health Protection Agency), accounting for 3% of all excess 
deaths.24 In Minnesota, USA, 11 deaths in unvaccinated pregnant women accounted 
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for over half of this state's deaths in women of child-bearing age during the 1957/58 
pandemic.25 All fatal pregnant cases in this last study had fulminant, in most cases 
haemorrhagic, pulmonary oedema. 
 
There is an absence of evidence of an increased risk of influenza-associated morbidity 
or mortality in pregnant women in the 1968/69 pandemic that had variable global im-
pact. Previous immunity against the influenza A N2 neuraminidase of the 1968/69 pan-
demic strain possibly had a role in the different risk patterns observed.26 
 
7.4.4 Risk to the fetus from maternal infection 
In general, the viral risk to the fetus from maternal influenza infection is low, since 
transplacental transmission of influenza infection is rare. Although there have been 
one or two case reports of in-utero infection confirmed by viral culture at fetal au-
topsy,27 a seroepidemiological study in Nottingham, UK, found no IgM anti-influenza 
antibodies or autoantibodies in the cord sera of 138 infants whose mothers had acute 
influenza infection confirmed by serology.9 By contrast, a cluster of 12 fetal deaths 
within 3 weeks (eight spontaneous abortions and four stillbirths) was reported in one 
UK general practice where an average of 84 births and hence 12-14 fetal losses are ex-
pected per year. Serological evidence of exposure to influenza A during pregnancy was 
seen in all the 12 mothers, compared with none in nine randomly selected postpartum 
mothers of live babies born in the same time period and registered with the same prac-
tice.28 
 
There is a lack of clear evidence for an association between maternal influenza infec-
tion or influenza-induced maternal high fever and congenital abnormalities in human 
beings. Influenza infection induces pyrexia greater than 37.8°C in 50-100% of cases, 
usually persisting for 3 days (up to 5 days) with a range between 38°C and 40°C.11 
Suggestions of a teratogenic link with pyrexia are difficult to discern in the presence of 
important causes such as genetic disease or drugs. There are few studies29 assessing 
the risk to the fetus using serological confirmation of maternal influenza infection, 
which is a major limitation when up to half of influenza infections are mild or sub-
clinical. 
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7.4.5 Risk to the neonate from maternal infection 
Infants are at high risk of morbidity from influenza. In a prospective cohort study in 
three American counties, 160 (5.7%) of 2797 children under the age of 5 years pre-
senting to selected clinics and hospitals with respiratory illness in 2000-04 had posi-
tive nasal or throat viral swabs for influenza.30 Hospital admission rates for laboratory-
confirmed influenza in children aged 0-5 months, 6-23 months, and 24-59 months were 
4.5 (3.4-5.5), 0.9 (0.7-1.2), and 0.3 (0.2-0.5), respectively, per 1000 children. The rates 
of influenza in non-hospitalised young children revealed a different trend. Children 
aged 0-5 months had the lowest annual rates of outpatient clinic visits and laboratory-
confirmed influenza, whereas those aged 6-23 months had the highest. Other cohort 
studies of hospital admissions with laboratory-confirmed diagnoses suggest a rate of 
about 2 per 1000 children under 12 months of age; however, with only 60-70% of ad-
missions being laboratory investigated, there is scope for biased ascertainment of vi-
rologically proven cases and overestimation of the rates.31,32 The differences in infant 
hospital admission rates in seasons with circulating influenza compared with no circu-
lating influenza in the USA were of similar magnitude.33 
 
7.5 The benefits and risks of influenza vaccination in pregnancy 
The potential benefits of protecting against the increased risk from influenza in preg-
nancy need to be balanced against any actual or theoretical concerns of vaccination 
during pregnancy. 
 
7.5.1 Evidence for influenza vaccine immunogenicity in pregnancy 
The few serological studies on pregnant women suggest that antibody response to in-
fluenza vaccine is similar in pregnant and non-pregnant women.34,35 Antibody 
response measured in 15 pregnant women 4-6 weeks following vaccination in the 
second or third trimester was similar to titres in non-pregnant vaccinated adults.36 In a 
small randomised trial, maternal seroconversion to one or more antigens was seen in 
all 13 women given influenza vaccine in the last trimester of pregnancy and in none of 
13 women who received tetanus toxoid in the control arm.34 
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7.5.2 Evidence for influenza vaccine efficacy and effectiveness in pregnancy 
Based on evidence of higher risk of mortality in pregnant women from two previous 
influenza pandemics, it is assumed that vaccinating this population against a pandemic 
influenza strain will prevent a substantial number of deaths. The assumed benefits of 
vaccinating pregnant women against seasonal influenza include reduced maternal mor-
bidity and the possibility of reduced mortality in a severe influenza season. An additio-
nal benefit of vaccinating a pregnant woman may be the reduced risk of clinically sig-
nificant influenza illness in the young infant. 
 
Early studies on healthy military recruits provide clear evidence of influenza vaccine 
efficacy and reduced morbidity in (non-pregnant) young adults.37 A Cochrane systema-
tic review concluded that inactivated influenza vaccines prevented 67% (51-78%) of 
serologically confirmed and 25% (13-35%) of clinically apparent cases in non-preg-
nant healthy adults.38 Limitations of summarising across studies from 1966-2003 were 
acknowledged. For example, vaccine standardisation and composition changed in the 
same period. A separate systematic review found influenza vaccine efficacy to be even 
higher if summarised across more recent studies.39 
 
In pregnant women, a recent randomised trial in Bangladesh found that influenza vac-
cine effectiveness against febrile respiratory illness in women immunised in the third 
trimester was 28% (4-46%).40 Vaccine efficacy based on laboratory-confirmed influen-
za illness is awaited.40 
 
Two studies have shown transplacental influenza-specific antibodies and some protect-
tion to infants from naturally acquired maternal influenza infection.41, 42 The first 
study, from Texas, USA (1975-78), found that where cord blood influenza IgG titres 
were 1/8 or more, infants did not have laboratory-confirmed, clinically apparent acute 
influenza before 8 weeks of age.41 The second study, from Florida, USA, followed 39 
mother-infant pairs in the 1978/79 influenza season. Although no reduction in the rate 
of clinically apparent, serologically proven acute infection occurred in infants born to 
infected mothers, there was evidence to suggest that their respiratory illness was mil-
der and with delayed onset.42 
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In 13 immunised pregnant women, vaccine-acquired influenza-specific maternal anti-
bodies had high transplacental transfer ranging from 87% to 99%, depending on the 
IgG antibody.34 The half-life of antibodies in the babies was 43-53 days, similar to the 
half-life of transplacental antibodies from naturally acquired maternal influenza infec-
tion.34 The cord titres in 26 maternal-newborn serum pairs did not differ significantly 
if maternal vaccination occurred in the second or third trimester.36 
 
Results from the small Bangladesh randomised trial in immunised pregnant women in-
dicate protection against laboratory-confirmed febrile illness caused by influenza in 
the infants (vaccine efficacy 61% [9-84%]).40 A 2003-05 database review from Texas 
found that infants under 6 months of age born to immunised pregnant women were less 
likely to have a medically attended acute respiratory illness (not laboratory confirmed) 
during the peak of the 2004/05 influenza season, when compared with those infants 
born to non-immunised pregnant women matched by age and date of delivery (10.9% 
vs 31%, p<0001).43 Two retrospective reviews (1997-200217 and 1995-200144) from 
the USA using managed care databases did not find a reduction in the incidence of 
medically attended acute respiratory illness (not laboratory confirmed) in immunised 
mothers17 or their infants.17,44 Both studies were, however, based on easily measured 
but, by their nature, non-specific outcomes and they were also underpowered because 
of lower outcome rates or lower maternal vaccine coverage than expected. 
 
7.5.3 Evidence for influenza vaccine safety in pregnancy 
There are only a handful of studies on the safety of influenza immunisation in human 
pregnancy. Two studies have provided long-term data after first trimester vaccinations. 
The largest, from the USA, analysed 650 mother-child pairs registered within the US 
Collaborative Perinatal Project (1959-65) who had received influenza vaccine in the 
first trimester. The project followed 50 897 pregnant women at more than 20 weeks' 
gestation attending antenatal clinics in several US hospitals. The main aim was to exa-
mine factors in pregnancy related to cerebral palsy and other damage to the central 
nervous system.45 The immunised cohort was exposed to some or all of these immuni-
sations: trivalent inactivated influenza, oral polio, inactivated polio, tetanus toxoid, 
and diphtheria toxoid vaccines. In the first week of life and at 12 months of age the 
children were assessed by a paediatrician and at 4, 8, 12, and 24 months of age their 
mothers were interviewed. Thereafter, the children were followed for deaths up to the 
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age of 4 years (autopsy data were available on just over 80% of deaths) and followed 
up to the age of 7 years for hearing impairment, learning disabilities, and malforma-
tions. Influenza vaccination was not associated with any excess minor or major malfor-
mations.46 Based on a total of 2291 pregnant women vaccinated in all trimesters in the 
same study, there was no evidence for an excess incidence of childhood malignancies 
up to 1 year of age and cancer mortality up to 4 years of age.47 
 
A smaller study (1976-77) found no difference between 41 mothers vaccinated in the 
first trimester and 517 non-vaccinees followed up at 8 weeks for physical and neurolo-
gical development or maternal, perinatal, or infant complications.48 Similarly, no diffe-
rences were noted in 58 women vaccinated in the second and 77 women vaccinated in 
the third trimester.48 There were no serious adverse events in the vaccinated group 
with an incidence of side-effects (eg, fever, headache, myalgias) under 3%. 
 
Further evidence of vaccine safety in the second and third trimesters is available from 
a third more recent, historical cohort database study of five influenza seasons in Texas 
(1998-2003). No serious adverse events were noted up to 42 days post-vaccination in 
252 pregnant women immunised in the second or third trimester, and there were no 
differences in outcomes of pregnancy or infant hospital admissions up to 6 months of 
age compared with matched, unvaccinated healthy controls.49 Information on two fur-
ther years (2004-05) were recently reported with similar follow-up of infants to 6 
months of age.43 In this larger study no serious adverse events in pregnancy were de-
tected in 1006 vaccinated pregnant women compared with 1495 matched unvaccinated 
pregnant controls. 
 
Other studies have only looked at immediate post-vaccine adverse events. Some safety 
studies followed the US experience of mass immunisation with swine influenza vac-
cine in 1976. One study followed 11 pregnant women vaccinated in the second trimes-
ter and 45 women vaccinated in the third trimester.36 40 of the 56 women were fol-
lowed for 24 h after immunisation. Seven vaccinated pregnant women had side-effects, 
of whom three reported mild fever. Other side-effects included coryza, influenza-like 
symptoms, headache, and dizziness. The type and number of vaccine reactions were 
described as similar to other clinical trials, and pregnancy outcomes as identical to 
controls. 
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Finally, in the randomised immunogenicity trial during the 1988/89 season, 30 healthy 
women in the third trimester received either trivalent influenza or tetanus toxoid vac-
cine. No significant reactogenicity was noted in any recipient, including fever, pain, or 
health-care seeking.34 
 
7.5.4 Other potential risks from influenza vaccination in pregnancy 
By contrast with the risk of fever from naturally acquired maternal infection, a low-
grade fever rarely occurs in response to influenza vaccination. In one study, 13% of 
189 vaccinated pregnant women had a temperature of more than 37.8°C, which lasted 
between 1 and 2 days.48 In view of the possible teratogenic effect of hyperthermia in 
pregnancy based on observations from animal models,50 there may be a theoretical risk 
of teratogenicity from maternal pyrexia secondary to vaccination.5 In trials of influ-
enza vaccine in other, older populations, however, no difference in fever was noted in 
904 patients in the active arm compared with 902 patients in the placebo control arm 
(1.3% vs 0.7%, p=0.15).51 There is also the possibility of fetal hypoxia associated with 
maternal anaphylaxis, for example in reaction to the vaccine's egg protein or other 
constituents. 
 
Other adverse events associated with influenza vaccine in the general population 
should also apply to pregnant women and include local reaction, headaches, and ma-
laise. Antigenic determinants can change annually and manufacturers' formulations of 
influenza vaccines can also change and vary in safety profile, as seen with the 1976 
swine influenza vaccine. 
 
Finally, thiomersal, an organic mercury compound, has been used since the 1930s as a 
preservative in some vaccines, including influenza, to prevent contamination during 
the production process. Neither a UK retrospective cohort of more than 100 000 chil-
dren52 nor a UK prospective study of more than 14 000 children53 followed from birth 
to more than 7 years of age found any causal association between thiomersal-contain-
ing vaccines and neurodevelopmental disorders. In 2001, the US Institute of Medicine 
(IOM) reviewed fetal exposure to mercury and found insufficient evidence to suggest a 
causal relation between vaccines containing thiomersal and neurodevelopmental disor-
ders; however, the IOM considered the risk to be biologically plausible.54 In 2004, the 
IOM reviewed cumulative paediatric exposure to thiomersal-containing vaccines (in-
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cluding data from new population-based epidemiology studies), which led them to re-
ject the hypothesis of a causal link between infants exposed to thiomersal-containing 
vaccines or the measles, mumps, and rubella vaccine and autism.55 The European 
Medicines Agency also concluded there was no evidence of a risk of autism or speech 
disorders associated with the use of thiomersal-containing vaccines.56 The Global Ad-
visory Committee on Vaccine Safety (GACVS), an advisory body to WHO, concluded 
that there is currently no evidence of mercury toxicity from thiomersal in vaccines and 
no reason to change current immunisation practices on the grounds of safety, but noted 
the paucity of safety data for malnourished or preterm infants.57 
 
The UK Health Departments, while noting the lack of evidence of toxicity, currently 
recommend use of the thiomersal-free vaccine in pregnant women, where this is avail-
able, based on the precautionary principle. If only thiomersal-containing vaccine is 
available, however, the benefit of vaccination is felt to outweigh any theoretical risk 
and the vaccine is not considered contraindicated in pregnant women.1 
 
7.6 UK data: Yellow Card reporting 1994-2004 
For this Review, the Post Licensing Division of the UK Medicines and Healthcare pro-
ducts Regulatory Agency (MHRA) searched the Yellow Card database from June 1, 
1994 to June 22, 2004. A causal link between influenza vaccination and adverse events 
cannot be formed from these case reports and, as with other passive reporting schemes, 
inherent limitations in these systems include lack of information on the denominator, 
under-reporting, and incomplete information on confounders. Among 1366 reports of 
adverse reactions to influenza vaccine in 10 years, eight occurred in pregnancy. Seven 
of these eight cases were vaccinated in the first trimester. Six of the pregnant women 
were documented as having a medical history of asthma (four women), pleurisy (one), 
or diabetes (one). Four women received other medications, of whom two were exposed 
to other vaccines; the remaining four cases did not provide medication history. The 
adverse outcomes reported were one stillbirth, three spontaneous abortions, and three 
cases of fetal growth retardation, of which two delivered prematurely. The eighth case 
was a congenital urinary tract anomaly at an 18-week ultrasound scan that resolved or 
was artifactual, since the outcome was a healthy delivery and normal postnatal renal 
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scan. In view of the reporting and denominator limitations to these data, firm conclu-
sions cannot be made from these eight case reports. 
 
7.7 Recommendations from WHO and selected countries 
In 2004 and 2006, the GACVS recommended that authorities reconsider their national 
policies and review the risk-benefit of influenza vaccination in pregnancy, “given the 
high risk to the mother - and thus to the fetus - of the disease itself and the likely small 
risk to mother and fetus of the inactivated influenza vaccine”.58,59 The 2005 WHO po-
sition paper contains a stronger statement that “influenza vaccination in pregnancy is 
considered safe and is recommended for all pregnant women during the influenza sea-
son” and it specifies that this recommendation aims to protect the mother as well as the 
infant in the first months of life.6 
 
In the USA, influenza vaccine in pregnancy was considered safe and practised in the 
1950s and 1960s. Official recommendation was provided in 1997 by the Advisory 
Committee on Immunization Practices (ACIP) for routine immunisation in the second 
or third trimester. The ACIP now recommends (since 2004) routine influenza vacci-
nation in all trimesters for healthy pregnant women during the influenza season.3 Ca-
nada's national advisory committee has expanded its recommendations to vaccinate 
women in all trimesters for the 2007-08 season.4 In previous years, this practice was 
“encouraged” for any healthy pregnant Canadian woman wishing to avoid influenza 
morbidity, and explicitly recommended for women in the third trimester expecting to 
deliver during the influenza season, with the rationale that they were household con-
tacts to their infants.60 In Australia, vaccination is recommended for healthy women 
who will be in the second or third trimester during the influenza season, including 
those in the first trimester at the time of vaccination.5 In the UK, vaccination is rec-
ommended for pregnant women with any condition listed as a high-risk comorbidity 
regardless of trimester, but no routine recommendation for healthy pregnant women 
has been made;1 this policy is currently under review. Many countries, however, pro-
vide no routine recommendation to vaccinate in pregnancy. For example, Germany's 
Standing Commission on Vaccination (STIKO) does not routinely recommend influen-
za vaccine in pregnancy.2 and 61 STIKO notes the safety evidence is incomplete but no 
teratogenic effect has been clearly identified. Although pregnancy is not considered as 
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a contraindication, STIKO recommends individual risk-benefit assessment and avoi-
ding first trimester vaccination if there is no urgent indication. 
 
7.8 Discussion 
In two previous influenza pandemics (1918/19 and 1957/58), pregnant women were at 
higher risk of morbidity and mortality from influenza-related complications compared 
with non-pandemic years. In seasonal influenza, pregnant women are at increased risk 
of influenza-related hospital admission compared with non-pregnant or postpartum 
women during influenza-exposed periods and occasionally increased mortality in a se-
vere season. This risk rises with increasing length of gestation, and even more strongly 
with comorbidity. 
 
Research on influenza vaccines is limited in pregnant women. This population is ex-
cluded from controlled randomised trials and reproductive toxicity testing until now 
has not been a regulatory requirement for existing vaccines.62 The few prospective stu-
dies of women immunised in the second or third trimester suggest the vaccine is safe. 
 
Safety data for the use of any inactivated vaccine in pregnancy, particularly in the first 
trimester, are limited but have not clearly identified any risk to the fetus. Some reas-
surance is provided by the inactivated tetanus toxoid vaccines, for which there is more 
evidence for safety in pregnancy; these vaccines are widely used in all trimesters to 
prevent neonatal tetanus.46, 63 
 
There is less evidence about harmful effects of seasonal influenza infection in healthy 
women in the first trimester compared with the second and third trimesters. A recom-
mendation to routinely immunise healthy women in the first trimester remains deter-
mined more by theoretical risks and benefits than by available current evidence. A 
practical concern is spontaneous abortion, which occurs more often in early pregnancy 
and could be misattributed to the vaccine. 
 
Vaccination of women before knowledge of a first trimester pregnancy does occur – 
perhaps more frequently in countries that recommend influenza vaccine for their 
health-care workforce - and there is no current evidence to suggest harm to the fetus. A 
recommendation to offer first trimester immunisation routinely would be strengthened 
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if future studies demonstrate adverse effects from early maternal influenza exposure. 
One seroepidemiological study provided evidence suggestive of a higher risk to the fe-
tus of adult schizophrenia if maternal influenza exposure occurred in the first half of 
pregnancy.29 
 
The USA reached just 16% influenza vaccination coverage of pregnant women in 
2005.3 Improvements in vaccine uptake will require practical efforts to reduce barriers 
and address any concerns of pregnant women and their health providers.64 
 
Since the current evidence base to fully assess the risk-benefit of influenza immunisa-
tion in pregnancy is incomplete, countries have produced different recommendations. 
These guidelines do not apply to pandemic influenza, where pregnant women are ex-
pected to be at much higher risk of infection, disease, and mortality. 
 
7.9 Conclusions 
There is evidence to support seasonal influenza vaccination in pregnancy in two 
groups: healthy pregnant women in the second or third trimester and pregnant women 
with comorbidities in any trimester. There is also good evidence that pregnant women 
are more vulnerable during pandemic influenza. Further evaluation of the assumed be-
nefits from maternal immunisation is needed. It is encouraging that the first random-
ised effectiveness trial of maternal influenza immunisation in the third trimester found 
significant protection to the mother from febrile respiratory illnesses and indirect pro-
tection to their young infants against clinically apparent and influenza-proven febrile 
respiratory illness.40 
 
No serious adverse effects of influenza immunisation in pregnancy have been reported 
in the few published studies on vaccine safety. There are, however, limited data on 
safety in the first trimester. Furthermore, the risk from infection and hence the as-
sumed benefit of vaccination in the first trimester are unclear. Influenza vaccines con-
taining thiomersal are not contraindicated in pregnant women. Preference for the use 
of thiomersal-free influenza vaccines in pregnancy is a precautionary measure only. 
Further research on the risk of influenza in pregnancy and longer term safety data on 
influenza immunisation are needed. Consideration should be given to developing 
mechanisms for following up pregnancy outcomes after maternal immunisation to aug-
7. Influenza vaccination in pregnancy 
 
 
 
68 
ment passive surveillance, particularly if national recommendations are broadened for 
this group. 
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8a.1 Abstract 
 
Attenuated, live bacille Calmette-Guérin (BCG) is the only currently licensed vaccine 
against tuberculosis. The WHO recently revised BCG vaccination recommendations, 
making HIV infection a full contraindication to BCG vaccination, even in highly tu-
berculosis-endemic settings. HIV-infected infants face an appreciably increased risk of 
disseminated BCG disease (dBCG), the most serious BCG vaccine-related adverse 
event. We performed a systematic review and calculated a pooled estimated risk of 
dBCG in vaccinated HIV-infected infants of 979 per 100,000 (95% CI: 564-1506 per 
100,000). Implications of this policy revision are different in Canada and other low-
burden countries, compared with resource-constrained countries with high incidences 
of HIV and tuberculosis. For the latter, we address the requirements to implement a se-
lective BCG vaccination program based on the infant’s HIV status. Local programs for 
immunization and the prevention of HIV and tuberculosis must be coordinated. Safer 
and more effective strategies should be investigated and existing programs streng-
thened in order to prevent tuberculosis in HIV-infected and HIV-exposed infants. 
 
Keywords 
BCG vaccines; infant, newborn, tuberculosis; HIV; AIDS-related opportunistic infections; 
immunization programs; risk factors, risk assessment, meta-analysis; review 
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8a.2  Background 
In May 2007, WHO revised global vaccination recommendations for bacille Calmette-
Guérin (BCG), following safety concerns in HIV-infected children.1 The change in 
guidance has added complexity to the decision-making on whether to provide BCG 
vaccination, and affects approaches to childhood tuberculosis prevention and immuni-
zation programs worldwide. 
 
Although contributing up to 25%2 of the total tuberculosis caseload in high-burden 
countries, childhood tuberculosis has been called an “orphan disease”3 when compared 
with the attention given to adult tuberculosis. Children under 3 years of age are the 
highest risk group for developing disseminated tuberculosis.4 If co-infected with HIV, 
children have at least a 6-8 times higher risk of developing tuberculosis in settings 
with high tuberculosis burden.5 In 2007, nearly 90% of the 350,000-540,000 children 
with new HIV infections were from sub-Saharan Africa, mainly due to mother-to-child 
transmission.6  
 
BCG is the only currently licensed vaccine against tuberculosis. This vaccine was de-
rived from a live attenuation of Mycobacterium bovis and has been used for 87 years. 
In 2005, BCG was part of immunization programs in over 150 reporting countries, in-
cluding all African countries.7 About 100 million doses are given each year worldwide. 
BCG vaccination in HIV-uninfected infants is effective,8,9 cost effective,10 and esti-
mated to avert almost 40 cases of serious childhood tuberculosis per 100,000 doses, 
globally equivalent to about 30,000 cases of tuberculous meningitis and 11,000 cases 
of miliary tuberculosis.10  
 
Until 2007, WHO advised countries with high tuberculosis incidence to provide a sin-
gle dose of intradermal BCG vaccine at or soon after birth to all infants, including 
those who were HIV-infected but asymptomatic.11 This longstanding routine policy 
was maintained during the escalation of the HIV epidemic. The rationale was based on 
the population risk of tuberculosis and the assumption that HIV-infected children 
would have a similar risk-benefit ratio from BCG vaccination as the general pediatric 
population, namely, BCG-induced protection against disseminated tuberculosis and a 
comparable low risk of serious BCG-related complications. 
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The most serious adverse event from BCG vaccination is systemic BCG disease, clas-
sified as “distant” (regional disease +1 remote site) or “disseminated” (regional disease 
+ ??????????????? (remote i.e. spleen or bone marrow), and here collectively referred to 
as “dBCG”.12 Nearly 30 years ago, the background estimated risk of dBCG in HIV-
uninfected infant vaccinees in Europe was 0.429 per 100,000.13 However, recent data 
provided in this review have indicated that this risk in HIV-infected infant vaccinees is 
more than a thousandfold higher than in the general pediatric population. The outcome 
of dBCG in HIV-infected children is poor, with an all-cause mortality of about 
75%.12,14-17 
 
In 2007, WHO responded to mounting risk data and made HIV infection a full contra-
indication to BCG vaccination, including in HIV-infected infants asymptomatic at 
birth and in settings with high tuberculosis burden.1 This major revision was supported 
by the Global Advisory Committee on Vaccine Safety18 and the Strategic Advisory 
Group of Experts,19 both independent scientific advisory committees established by 
WHO.20 The Box below shows the updated list of contraindications to BCG vaccine. 
 
We conducted a systematic review and meta-analysis to estimate the risk of dBCG in 
HIV-infected infants. We further highlight several issues surrounding this full BCG 
vaccine contraindication and in particular, the feasibility of its implementation in HIV-
endemic, resource-limited settings where maternal and infant HIV status is not routine-
ly determined. Program requirements are outlined to allow for selective BCG vaccine-
tion programs based on maternal and infant HIV status in such settings. Policy impli-
cations in resource-rich, low-burden settings are also compared. In particular, we con-
sider Canada’s experience with BCG vaccination, which highlighted the need for ro-
bust surveillance and dBCG risk estimates in specific populations. 
Box 
 
WHO Contraindications to BCG Vaccination  
 
? Persons with HIV infection§ 
? Persons with impaired immunity (known or suspected congenital immunodefi-
ciency, leukemia, lymphoma or generalized malignant disease)* 
? Persons under immunosuppressive treatment (corticosteroids, alkylating agents, 
antimetabolites, radiation)* 
? In pregnancy* 
 
§
   Replacing WHO’s previous recommendation that asymptomatic HIV-infected infants 
should receive BCG vaccine in settings with high tuberculosis burden (WHO 20071)  
8a. Disseminated BCG disease risk in HIV-infected infants  
 
 
 
79 
8a.3 Methodology 
We conducted a PubMed search of the literature (from Jan 1990 to July 2008) for En-
glish language articles with following strategy: ((HIV*) OR (Immunologic Deficiency 
Syndromes) OR (AIDS-Related Opportunistic Infections)) AND (Mycobacterium bo-
vis* OR BCG OR "Guerin" OR "Calmette"), searched with and without the following 
limitation “(adverse effect*) OR ("injurious effect*" OR "undesirable effect*" OR 
"side effect*" OR "adverse reaction*" OR "adverse event*")”. All available Abstracts 
and the bibliographies of selected articles were reviewed.  
 
In order to calculate a pooled risk estimate of disseminated BCG disease (dBCG), we 
included all cohort studies of HIV-infected infants that assessed BCG-related adverse 
events. dBCG cases were counted if confirmed by biochemical or molecular methods; 
suspected dBCG cases without laboratory confirmation were not counted. With per-
mission, we accessed materials collected for a global review of BCG vaccine-related 
adverse events conducted by WHO in 2005, which included published and unpublished 
studies, and search results from WHOLIS, the Uppsala Monitoring Center database. 
Congress proceedings, the authors’ own libraries, Google Scholar and Web of Science 
citation hits of key articles were also reviewed. The meta-analysis was conducted us-
ing StatsDirect 2.6.8 software (StatsDirect Ltd, Cheshire, England). 
8a.4 The risk of disseminated BCG disease in HIV-infected infants 
We performed a systematic review with the aim to calculate a pooled risk estimate of 
dBCG in HIV-infected vaccinated infants based on the available literature. The diag-
nosis of dBCG usually requires tertiary health services. Limitations of hospital-based 
studies should be considered and include selection bias. For identified data presented 
only at conferences, limitations include potential lack of rigorous peer review. Finally, 
detection of dBCG improved after molecular diagnosis became available after about 
1997.21 
 
We identified a total of 14 hospital-based cohort studies on HIV-infected children, 
with 7 studies in 5 countries reporting dBCG cases.14-17,22-24 (see Table) Two other stu-
dies were not considered; one study had a cohort < 5 HIV-infected BCG-vaccinated 
children25 and the other had incomplete information.26 The two studies from South 
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Africa provide the only population-based estimates of dBCG risk in HIV-infected 
infants from active surveillance and using denominators based on the estimated annual 
number of HIV-infected infants born in the province during the study period.16,17 The 
first study from 2002-2004 was an estimate based on one reporting tertiary hospital.16 
The second study from 2004-2006 provided an improved population-based estimate 
based on three reporting provincial tertiary hospitals, and found an estimated popul-
ation incidence of dBCG at 992 per 100,000 (95% Confidence Interval (CI): 567 to 
1495 per 100,000).17 This South African population estimate provided a comparator 
for the pooled estimate risk of studies included in the meta-analysis . 
 
The remaining 10 international studies were all based on denominators of hospital co-
horts and included in the meta-analysis. Four of these included studies reported cases 
of dBCG. An early, small study of 68 inadvertently-vaccinated HIV-infected infants 
were followed in a French hospital and had the highest rate of dBCG of nearly 3%.22 
Of 9 resulting BCG-related complications, 2 children had dBCG confirmed by bioche-
mical methods or PCR testing for M. tuberculosis complex (MTBC). The  second early 
study was published in a non-PubMed-indexed but internationally peer-reviewed jour-
nal.23 Of 355 HIV-infected children admitted to a Thai hospital from 1989-94, 9 had 
BCG vaccine-related complications with one confirmed as dBCG and 5 with suspected 
but non-confirmed pulmonary lesions. Mycobacterial isolates were sent to the Johns 
Hopkins laboratory for biochemical speciation. Three more recent published abstracts 
from South American hospitals,14,15,24 have further indicated the generalisability of an 
increased dBCG risk in vaccinated HIV-infected children. Five, mostly earlier studies 
of vaccinated HIV-infected children reported no dBCG cases.27-31 The absence of 
dBCG cases in these studies may have occurred by chance, the small sample sizes (all 
cohorts were less than 50 HIV-infected children) and short follow-up period.  
 
We performed a random-effects meta-analysis based on these 10 studies. (Figure 1) 
The pooled risk estimate of dBCG in hospitalized, HIV-infected infant vaccinees was 
979 per 100,000 (95% CI: 564 to 1506 per 100,000), or about 1% of vaccinated HIV-
infected infants. The estimate was stable, with the fixed-effects model producing the 
same result. There was no suggestion of publication bias using the Egger test (intercept 
=0.06, p=0.84) or heterogeneity of studies (Cochran Q (9) = 4.9, p=0.84, I2 = 0%). 
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Table  
Summary of studies reporting disseminated BCG disease (dBCG) in HIV-infected vaccinated infants 
 
Year  
Authors  
(Country) 
Type of study and duration  
Number of vaccinated HIV-
infected children 
Confirmed 
cases of 
dBCG 
Number of confirmed dBCG 
cases in HIV-infected 
vaccinees per 100,000 
Number of deaths in HIV-infected 
children with dBCG, during follow 
up period (% all-cause mortality) 
1993 
Besnard et al.22  
FRANCE 
 
Prospective study, 1983-1993 
Single hospital centre, 68 children 
 
2 
 
2941 per 100,000 
 
2 (100%) 
1995 
Sirisanthana23 
THAILAND 
 
Retrospective study, 1989-1994 
Single hospital centre, 355 children 
 
1 
 
282 per 100,000 
 
1 (100%) 
2002 
Casanueva et al.14 
ARGENTINA 
 
Retrospective study, 1989-2001  
9 hospital centres, 656 children 
 
6 
  
915 per 100,000 
 
4 (67%) * 
 
2005 
Fallo et al.15 
ARGENTINA 
 
Retrospective study, 1992–2004 
Single hospital centre, 310 children 
 
4 
 
1290 per 100,000 
 
 
3 (75%) 
2007 
Siciliano et al.24 
VENEZUELA 
 
Prospective study, 2002-2004 
Single hospital centre, 130 children 
 
1 
 
769 per 100,000 
 
0 
2007 
Hesseling et al.16 
SOUTH AFRICA 
 
Prospective, active surveillance, 
2002-2004. Single hospital centre. 
Denominator = estimated provincial 
total newly HIV-infected infants. 
 
7 
 
 
110 to 417 per 100,000 
 
 
6 (86%) 
2008 
Hesseling et al.17 
SOUTH AFRICA 
 
Similar methodology as in 2007, 
now 3 reporting hospitals from 
2004-2006 
 
32 
 
567 to 1495 per 100,000 
 
25 (78.1%) 
* personal communication     
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Figure 1 
 
Pooled incidence of disseminated BCG disease in HIV-infected infants 
from hospital-based cohort studies 
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Size of the solid rectangles represents the weight given to each study in the meta-analysis, based on cohort size. Diamond and 
vertical dashed line indicate the combined risk estimate. Clear rectangle indicates population-based estimate of one multi-centre 
study. Horizontal lines are the 95% confidence intervals (// indicates full interval not shown). The pooled estimated risk was identical 
using the random or fixed effect models. 
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Our pooled risk estimate is nearly identical to the population-based estimate from 
South Africa.17 Data from 5 different countries on dBCG in HIV-infected children 
shared several common features. At the time of dBCG diagnosis, children had signifi-
cant CD4 depletion and were not receiving (or had only recently started) antiretroviral 
therapy. dBCG presents several months after vaccination (median age of 10 months; 
age range 5-36 months). In the more recently reported and larger cohorts of HIV-
infected children, the all-cause mortality of the dBCG cases was 67-86%. 
 
8a.5  Background risk of disseminated BCG disease in HIV-negative infants 
The widely-cited background risk of dBCG in the general infant (HIV-negative) popu-
lation is based on two large studies conducted in the pre-HIV era. The International 
Union Against Tuberculosis and Lung Disease (IUATLD) reviewed adverse events re-
trospectively from global reports (1948-1974)32,33 and prospectively in six European 
countries (1979-1983).13 The prospective study calculated an overall dBCG risk of 
0.429 per 100,000 vaccinees.13 This background European incidence of dBCG is main-
ly attributed to infants with rare primary immunodeficiencies (PIDs) that are also 
associated with higher risk of dBCG,34-36 but not diagnosed before vaccinetion. 
 
8a.6 Limited data on BCG efficacy in HIV-infected and HIV-exposed children 
BCG efficacy in HIV-infected infants has not been adequately studied.5,15 It is un-
known if non-vaccinated HIV-infected infants could lose potential BCG-associated 
vaccination benefits that are characterized in the HIV-uninfected populations, inclu-
ding reduced protection against tuberculosis and other mycobacterial diseases,37,38 po-
tential reduced all-cause morbidity and mortality,39 and enhanced immune response to 
other vaccines.40 However the excess risk of dBCG is expected to outweigh any such 
potential benefits in HIV-infected children. 
 
BCG vaccine efficacy in HIV-exposed infants (i.e. infants born to HIV-infected mo-
thers) is also unknown. Most infants born to HIV-infected women will escape HIV 
infection themselves, but may have an increased risk of tuberculosis compared with 
HIV-unexposed infants. HIV-exposed infants have altered immune responses to myco-
bacteria41 and a high risk of household tuberculosis exposure.42 If BCG vaccination is 
determined to be effective in preventing tuberculosis in HIV-exposed but uninfected 
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infants, it is a concern that deferred or simply missed vaccination may lead to an in-
crease of tuberculosis cases in this group.  
 
The impact of changing immunization policy and its implementation therefore need to 
be carefully evaluated in countries with high tuberculosis and HIV endemicity where 
infants routinely receive BCG vaccination. If countries proceed to implement the re-
vised recommendation hastily, a selective BCG vaccination program in settings with 
inadequate resources could potentially disrupt appropriate BCG vaccination of HIV-
uninfected infants, who are the vast majority of infants. Avoiding dBCG in a consider-
ably smaller number of HIV-infected infants should not be achieved at the cost of in-
creased tuberculosis incidence in inadvertently non-vaccinated HIV-uninfected infants. 
 
8a.7  Improving surveillance and reporting of BCG vaccine-related adverse  
events  
Improved surveillance and new diagnostic tools have played important roles in identi-
fying the increased risk of dBCG in HIV-infected children. Diagnosing and reporting 
dBCG depend on several factors: clinical suspicion, standard case definitions, ade-
quate sampling, culture yields, laboratory facilities for definitive diagnosis of M. bovis 
BCG, and established mechanisms to report events. PCR-based speciation21 now 
allows rapid definitive differentiation of M. bovis BCG from other species of the 
MTBC although in resource-limited countries, this capacity is mainly situated in terti-
ary centres.12,14,15,24 Biochemical speciation is more readily available. 
 
There are several reasons to expect that dBCG is underdiagnosed in most settings. In a 
2002-2005 retrospective study, all routinely banked mycobacterial isolates were speci-
ated following routine culture of samples obtained from 466 hospitalized children 
diagnosed and treated for “MTBC disease”; 25 cases (5.4%) had PCR-confirmed M. 
bovis BCG disease.12 Of these 25 cases, 8 cases originally diagnosed as disseminated 
MTBC disease were retrospectively identified as dBCG. Only 298 children had their 
HIV status recorded; of the 108 children confirmed to be HIV-infected, 6 (5.6%) had 
dBCG. The 2 remaining dBCG cases that were retrospectively diagnosed occurred in 
children with PIDs.  
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With increasing awareness of the need for improved surveillance and reporting, the 
IUATLD’s BCG Working Group was established in 2006 to coordinate surveillance 
activities and to support improved data generation on global BCG vaccine safety, effi-
cacy and policy, especially in countries with high HIV and tuberculosis burdens and 
neonatal BCG vaccination programs. Consistent with this initiative, a recent European 
review of BCG vaccination policies and safety monitoring found substantial scope to 
improve surveillance mechanisms for serious BCG vaccine-related adverse events 
even in industrialized countries.43 
 
8a.8  BCG vaccination policy in industrialized countries 
In contrast with low-income countries, selective BCG vaccination of targeted higher-
risk groups has been recommended, feasible, and established for years in wealthier 
low-burden countries. In many industrialized settings, BCG vaccination in infants at 
risk for HIV infection is explicitly contraindicated,44,45 and BCG is postponed until 
testing HIV-negative, and often with repeated confirmation of negative status.43,46  
 
In low-burden countries where selected infant populations are targeted for BCG vacci-
nation and there is a low incidence of pediatric tuberculosis, the BCG risk-benefit mar-
gin narrows. For countries with falling tuberculosis incidence, IUATLD’s epidemiolo-
gical criteria47 should be met before discontinuation of a routine BCG vaccinetion pro-
gram in favour of individualized or selective vaccination strategies for high-risk 
groups. These criteria include an efficient notification system and a low annual tuber-
culosis incidence of 0.1%.47 In addition, IUATLD criteria assume that the incidence of 
dBCG is rare, based on surveillance estimates of 0.429 cases per 100,000 vaccinations 
in HIV-negative European infant populations.13  
 
8a.9 BCG vaccination policy and disseminated BCG disease surveillance 
in Canada  
Canada’s experience highlights several issues and the importance of rigorous surveil-
lance for dBCG in targeted populations. In Canada, tuberculosis remained endemic 
among certain First Nation and Inuit reserves. Previously, Aboriginal infants in these 
communities were routinely BCG-vaccinated.48 The Immunization Monitoring Pro-
gram-Active (IMPACT), an active surveillance network of Canadian pediatric hospi-
8a. Disseminated BCG disease risk in HIV-infected infants  
 
 
 
86 
tals, identified 21 children admitted for BCG-related adverse events between 1993-
2002.35 Of 6 dBCG cases, 5 were vaccinated Aboriginal children and the sixth case 
was an immigrant; all children subsequently died. Five had PIDs (severe combined im-
munodeficiency [SCID] or interferon-?? ???????????? ???? ???? ?????? ???? ???-infected. 
dBCG negatively affected the clinical management and eligibility for bone marrow 
transplantation, a potentially curative therapy for immune restoration in SCID pa-
tients.49,50 Several other countries have also reported on children with a range of PIDs 
associated with dBCG, having similar complications and high all-cause mortali-
ty.34,51,52  
 
The risk of dBCG in Canadian Aboriginal infants was estimated to be 20.5 per 100,000 
doses (95% CI: 4.2-60 per 100,000), more than 40 times higher than the incidence 
estimated in European populations.13 Based on these findings, Canada’s National 
Advisory Committee on Immunization (NACI) recommended in 2004 that BCG no 
longer be offered routinely to infants on Aboriginal reserves. NACI recommended 
BCG only if certain criteria were met for poor tuberculosis control and management, 
and if maternal HIV status and family history of immunodeficiency were first 
determined.44,48 Emphasis was placed on the mainstays of tuberculosis control and 
management such as early case detection, directly observed therapy, and surveillance. 
NACI stated that “BCG vaccine is intended only to prevent serious consequences of 
unrecognized infection in young children when tuberculosis identification and control 
programs are suboptimal.”48 With falling tuberculosis notification rates, several 
Canadian provinces and territories have discontinued routine BCG programs in favour 
of individualized decision-making.53  
 
Canadian Aboriginals appear to have an unexpectedly higher incidence of PIDs and 
therefore higher risk of dBCG. Rigorous surveillance of vaccine-related adverse events 
was essential in influencing BCG policy in Canada, and demonstrated the need to 
determine population-specific estimates for dBCG incidence. 
 
8a.10 Towards a selective BCG vaccination program in resource-limited 
countries? 
In resource-limited countries facing high tuberculosis and HIV burdens, it has been 
routine practice for HIV-exposed newborns to receive BCG vaccination. The former 
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WHO recommendation to vaccinate only asymptomatic HIV-infected infants had limi-
ted practical application, since most infants acquiring HIV infection are asymptomatic 
at birth.  
 
WHO revised guidance now makes the infant’s HIV status a determinant of BCG vac-
cination, if the status is known. Until local programs are able to implement this new 
contraindication and selectively defer BCG vaccination with timely determination of 
the at-risk infant’s HIV status, and if BCG remains scheduled soon after birth, both 
WHO1 and IUATLD54 recommend continuing routine BCG vaccination of asymptoma-
tic newborns. 
 
If implementation of selected deferred vaccination is feasible in certain resource-con-
strained settings with high tuberculosis burdens, immunization providers must consider 
the main objectives of a transition towards a selective BCG vaccination program. Most 
importantly, appropriate BCG vaccination of HIV-uninfected infants should continue 
undisrupted and other fundamental measures to protect HIV-infected (and HIV-ex-
posed) infants from tuberculosis should be implemented, eg. improved screening for 
and management of maternal tuberculosis exposure.55 In our algorithm (Figure 2), we 
outline the programmatic requirements for deferring BCG vaccination until infant HIV 
status has been determined. Effective coordination between maternal and child health 
programs is essential. Key questions for local policymakers considering implementa-
tion of a selective BCG vaccine policy include the following: 
 
1.  Is routine early HIV testing in infants feasible? A single HIV DNA PCR test has 
a sensitivity <40% for infants under 48 hours of age and reaches >90% at 2-4 
weeks of age in non-breastfed infants.56 New, simpler strategies using dried blood 
spot samples on filter paper have been applied in resource-limited settings.46 In 
most prevention of mother-to-child transmission of HIV infection (PMTCT) pro-
grams in such settings, infant HIV PCR testing occurs at ??? ??? ks of age with 
additional delay for turnaround time of results. Although the infant’s HIV exposure 
risk can be largely determined by maternal status, some pregnant women testing 
negative for HIV will seroconvert or acquire HIV before delivery in highly ende-
mic areas.57 
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An additional consideration is the feasibility of repeated HIV testing in HIV-ex-
posed infants who are breastfed by an HIV-infected mother, and who have ongoing 
risk of post-natal HIV infection. If HIV-infected mothers choose to breastfeed, ex-
clusive breastfeeding is currently recommended for the first 6 months of life in set-
tings where safe formula feeding is not feasible.58 The effects of late postnatal HIV 
infection superimposed on earlier BCG administration are not known.  
 
The main goals of universal HIV testing57 are timely identification of HIV infec-
tion in pregnant women and infants, timely initiation of ART, and now, more 
appropriate tuberculosis preventive strategies.  
 
2.  Are PMTCT and other HIV programs effective? Effectiveness includes full ac-
cess to counseling, safe feeding options, and adequate antiretroviral therapy access 
in mothers and their infants. One of the main goals of PMTCT programs - to mini-
mize the number of HIV-infected infants - will also then effectively minimize inad-
vertent BCG vaccination. In South Africa, an effective, well-integrated PMTCT 
clinic has lowered vertical transmission to just 2.9% in HIV-exposed infants who 
are tested at 6 weeks of age by HIV-DNA PCR.59 However, long-term follow up of 
HIV-exposed infants remains a challenge. If access to infant HIV treatment is poor 
or available only in later clinical stages, the full benefits of early infant HIV 
screening may be limited.60  
 
3.  Can the infant vaccination program be adequately coordinated with PMTCT 
programs? A strategy where the infant’s HIV exposure status directs the potential 
tuberculosis preventive measures requires confidential, integrated42 management 
shared among local programs for immunization and HIV/tuberculosis prevention 
and treatment.  
 
8a.11 Research priorities regarding alternative strategies to prevent 
tuberculosis in HIV-infected and HIV-exposed infants 
In the current situation of unconfirmed benefit and confirmed increased risk of harm 
from BCG vaccination in HIV-infected infants, other effective and safe interventions to 
prevent tuberculosis should be investigated and prioritized. It is important not to over-
look the need to strengthen existing HIV and tuberculosis control programs in high-
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burden settings. Of key importance is improving maternal tuberculosis screening dur-
ing the antenatal and postpartum period, which may reduce the risk of exposure and 
the incidence of tuberculosis in young children. 
 
Isoniazid preventive therapy (IPT) is safe and effective in preventing tuberculosis and 
routinely recommended for infants having documented tuberculosis exposure.61 How-
ever, the benefits of routine primary IPT are not clear in HIV-infected and HIV-ex-
posed infants in the absence of reported tuberculosis exposure. The first randomized, 
controlled trial (RCT) of 263 South African HIV-infected children (median age 29.6 
months) found that IPT in combination with co-trimoxazole was well-tolerated and re-
duced both all-cause mortality and tuberculosis incidence.62 However, these results 
were not reproduced in a larger, phase II/III randomized controlled trial in southern 
Africa that enrolled more than 1350 HIV-infected or HIV-exposed uninfected infants 
at 3-4 months of age. Interim analysis demonstrated that IPT together with cotrimoxa-
zole was safe but did not lower tuberculosis incidence or death in infants when a tuber-
culosis contact was excluded at enrolment.63 The trial was recently discontinued early 
and full data analyses are ongoing. (personal communication, M.F. Cotton) 
 
A landmark South African RCT has now shown that early ART in HIV-infected in-
fants <12 weeks of age profoundly reduced all-cause mortality by 75% in the first year 
of life, compared with infants started on ART only when standard criteria based on 
CD4 depletion or severe clinical disease were met.64 In April 2008, based on consistent 
findings from two RCTs,64,65 the WHO Technical Reference Group has issued new 
guidance urging earlier initiation of ART in HIV-infected children.66  
 
The available data therefore indicate a significant benefit of early ART initiation and a 
limited effect of routine IPT in reducing all-cause mortality in HIV-infected infants. It 
is not determined if timely ART will reduce tuberculosis incidence or alter BCG safety 
profile and enhance BCG immunogenicity and efficacy in HIV-infected children 
through improved cellular immunity and delayed HIV disease progression. dBCG can 
be viewed as a serious opportunistic disease in severely immunocompromised chil-
dren. HIV-infected children inadvertently BCG-vaccinated but who receive early ART 
should be prospectively studied for rates of tuberculosis disease, BCG complications 
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and all-cause mortality. Another hypothesis is that timely ART may reduce the risk of 
dBCG and affect the risk of BCG Immune Reconstitution Syndrome (IRIS). BCG IRIS 
is a complication observed in some HIV-infected patients during cellular immune 
restoration with ART, but usually associated with a good prognosis.67-69 Preliminary 
data from the early vs. deferred ART infant randomized trial indicate a significantly 
lower incidence of BCG IRIS in infants who received early ART.70  
 
BCG efficacy data are not available for HIV-infected and HIV-exposed uninfected 
infants. There is currently no available vaccine against tuberculosis for HIV-infected 
infants that is proven effective and safe. As new vaccines against tuberculosis become 
available, they should be studied for safety, immunogenicity and efficacy in HIV-
infected and HIV-exposed infants.  
 
8a.12 Discussion 
Based on the higher risk of dBCG, HIV infection has become a universal contraindica-
tion to BCG vaccination, including in settings with high tuberculosis burdens. We esti-
mated a pooled risk of dBCG in HIV-infected infants of 979 per 100,000 (95% CI: 564 
to 1506 per 100,000) based on cohort studies from tertiary centres, which was very 
close to the population-based estimate in South Africa of 992 per 100,000 (95% CI: 
567 to 1495 per 100,000).17 These findings indicate the generalisability of the risk of 
dBCG in vaccinated HIV-infected children in several different countries. The true inci-
dence of dBCG in this subpopulation is likely under-reported as these represent cases 
detected at tertiary hospitals. 
 
We have outlined the goals and prerequisites for a selective BCG vaccination program, 
and the benefits of early determination of HIV status. Countries with adequate re-
sources and low HIV and tuberculosis burdens can offer selective and postponed BCG 
vaccination, with screening for immunodeficiency disorders. We believe that routine 
HIV testing and selective BCG vaccination based on the test result should also be 
made feasible in middle-income countries with established infant BCG vaccination and 
PMTCT programs. The timing of BCG in the immunization schedule should be care-
fully considered. Unfortunately, the programmatic requirements make this guidance 
less feasible and unlikely to be prioritized in most settings with severely limited re-
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sources. HIV and tuberculosis burdens may be highest in these settings and routine 
BCG vaccination at birth currently continues irrespective of maternal HIV status. 
However, where resources for HIV and tuberculosis screening and treatment programs 
are now being scaled up, a selective infant BCG vaccination program should be incor-
porated when feasible. Programmatic research should closely monitor the effects of 
such potential transitions. 
 
Other tuberculosis preventive strategies that are safe and effective should be priori-
tized in HIV-exposed and HIV-infected infants. Beyond the issues of decision making 
regarding BCG vaccination, it is now even more crucial to strengthen the existing ca-
pacities to screen for and manage HIV and tuberculosis infections, and to provide 
timely antiretroviral and anti-tuberculosis therapies to both mothers and infants. Im-
proving antenatal tuberculosis screening and management will lower the risk of tuber-
culosis in the general infant population. Timely ART initiation in HIV-infected infants 
will delay HIV disease progression and reduce mortality. It remains to be determined 
whether HAART can lower the  risk of tuberculosis71 or the risk of dBCG in BCG-vac-
cinated HIV-infected infants and children, or both. The new awareness of dBCG risk 
in HIV-infected infants provides added incentive to ensure coordination of existing im-
munization, tuberculosis screening and PMTCT programs, and to investigate alterna-
tive effective and safe strategies in reducing tuberculosis in children, especially where 
HIV is highly prevalent. 
 
8a.13  Summary 
? BCG vaccination is now a full contraindication in HIV-infected infants, including 
settings with high tuberculosis burdens.1  
 
? The pooled estimated risk of disseminated BCG disease in HIV-infected infants 
is 979 per 100,000 (95% CI: 564 to 1495 per 100,000) vaccinations, or about one 
serious vaccine-related adverse event every 100 doses. 
 
? For HIV-uninfected infants, effectiveness of BCG vaccination in preventing 
childhood disseminated tuberculosis is well established, and prevents about 40 
cases of tuberculosis meningitis or miliary tuberculosis per 100,000 doses.10 
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? For HIV-infected infants, effectiveness of BCG vaccination is not established and 
is not adequately studied. 
 
? A transition towards a selective BCG vaccination program based on HIV status in 
resource-limited settings requires accessible, effective and coordinated maternal 
and infant public health programs.  
 
? An important goal is that established BCG vaccination programs should continue 
undisrupted for HIV-uninfected children who have no vaccine contraindications.  
 
? Existing public health programs for HIV and tuberculosis need to be strengthened 
and other strategies considered, towards the goal of reducing these infections in 
high-risk children. 
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8b.1 Comment 
Last year, WHO stopped recommending live, attenuated bacille Calmette-Guérin (BCG) 
vaccination at birth for asymptomatic HIV-infected infants, even where there is a risk of 
tuberculosis exposure early in life.1 Data show that about 417 HIV-infected infants per 
100 000 are affected by disseminated BCG disease,2 a rate that is about 1000 times higher 
than in healthy HIV-uninfected infants (table). Disseminated BCG disease typically pre-
sents several months after vaccination in infants with rapid progression of HIV disease, 
and has an all-cause mortality of 75–86%.2,6 Clinical features of disseminated BCG di-
sease are similar to those of severe tuberculosis, and sophisticated laboratory facilities are 
needed to distinguish Mycobacterium tuberculosis from M bovis BCG. 
 
Table 
BCG vaccination: benefit versus risk in HIV-negative and HIV-positive infants 
HIV status Main benefit (miliary tuberculosis or 
tuberculous meningitis prevented,or 
both, worldwide)* 
Most serious risk (disseminated  
BCG disease caused, worldwide)* 
Negative 40 per 100 000 (40 000 cases)3 0.429 per 100 000 (429 cases)4 
Positive No available data 417 per 100 000 (1751 cases)2 
*On the basis of annual estimates that BCG vaccine is given to 100 million4 HIV-negative children and 0.42 
million5 children are newly infected with HIV. 
 
The Expanded Programme on Immunization (EPI) schedule recommends infant BCG vac-
cination soon after birth in countries with a high burden of tuberculosis, on the basis of 
evidence that vaccination averts 40 cases of miliary tuberculosis or tuberculous meningi-
tis, or both, per 100 000 vaccinations in HIV-negative children.4 With 100 million BCG 
doses given every year worldwide, BCG is cost effective and prevents 40 000 cases of 
childhood tuberculosis (table).4 
 
In 2007, about 420 000 new HIV infections occurred in children younger than 15 years of 
age.5 Most were caused by perinatal transmission in sub-Saharan Africa, which is also the 
region with the highest burden of tuberculosis. If HIV-infected children continue to re-
ceive BCG vaccination, about 1700 HIV-infected infants will develop disseminated BCG 
disease every year. The effectiveness of BCG vaccination against disseminated 
tuberculosis in HIV-infected infants is unknown, but even if it is confirmed, the efficacy 
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rate would not be expected to approach that observed in immunocompetent children, and 
would still be exceeded by the risk of disseminated BCG disease. Concerns about the 
vaccine’s safety coincide with the push for greater access to early HIV testing, and new 
guidance from WHO and UNAIDS7 that urges prompt initiation of antiretroviral therapy 
in HIV-infected infants, which is shown to reduce their mortality.8 The recommended test 
is HIV-DNA PCR between 4 and 6 weeks of age, but the cost of testing and turn around 
time for results can be considerable. In countries with HIV epidemics, universal antenatal 
HIV testing is recommended. To expand access, the health encounter rather than the type 
of health centre should be considered as a standard opportunity to test mothers for HIV, 
helped by an opt-out approach and rapid tests.9 
 
The EPI can be expanded. In a Kenyan study, nearly all mothers (96%) who brought their 
children for vaccinations or acute care felt that provider-initiated HIV testing and counsel-
ling for mothers should be available onsite. Only rarely did mothers feel that the health 
centre for children was “the place for vaccines, not for testing”.10 The benefit and feasibi-
lity of routine HIV screening in infants have already been proven in immunisation clinics 
in South Africa.11 EPI managers could link HIV-test information with the decision to pro-
vide BCG vaccination, if test results are well coordinated between EPI and other health 
programmes. 
 
Safer BCG programmes are well established, but not where they are most needed. In most 
countries, BCG has been a routine public-health intervention since the inception of the EPI 
in 1974. Wealthy countries, such as the UK,12 with a low burden of HIV and tuberculosis, 
have already established policies to exclude HIV before BCG is given.13 Although a safe 
and selective policy for BCG vaccination on the basis of an infant’s HIV status should be 
implemented in poor countries, action has not been forthcoming. This new understanding 
of BCG’s risk-benefit has been described as a double-edged sword.14 Delays in imple-
menting the revised policy are mainly because of feasibility and the fear of losing the 
greater public-health good, if the overall immunisation programme is disrupted. There is a 
concern about potentially reduced BCG coverage for the vast majority of infants (ie, not 
HIV infected) if the public has less confidence in immunisation programmes or if selective 
vaccination is poorly implemented. 
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The HIV epidemic has changed the risk-benefit ratio of BCG, especially in settings with 
generalised HIV epidemics in which a considerable proportion of infants are exposed to or 
infected with HIV. 
 
BCG vaccination remains an important and effective intervention. Introduction of selec-
tive BCG vaccination on the basis of HIV status should be done cautiously, to minimise 
the potential loss of BCG coverage in HIV-negative children. There are convincing exam-
ples of programmes that provide best-health practices even within poorly functioning 
health systems.15 
 
Changes are now needed for what has been a routine childhood health practice for the past 
30 years, because of the HIV epidemic. Many experts are concerned that an alarm raised 
over BCG safety in HIV-infected children could damage the uptake of all immunisations. 
The opposite might be true. If EPI managers lead and support responsible adaptations to 
make BCG vaccination selective and safer, public trust placed in childhood immunisations 
could grow even stronger. 
 
Chapter 8b: Making BCG vaccination programmes safer in the HIV era 
 
 
 
107 
8b.2  References 
1 WHO. Revised BCG vaccination guidelines for infants at risk for HIV infection. 
Wkly Epidemiol Rec 2007; 82: 193–96. 
2 Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-
Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 14–18. 
3 Trunz BB, Fine P, Dye C. Eff ect of BCG vaccination on childhood tuberculous 
meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of 
cost-effectiveness. Lancet 2006; 367: 1173–80. 
4 Lotte A, Wasz-Hockert O, Poisson N. Second IUATLD study on complications in-
duced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 
47–59. 
5 UNAIDS, WHO. AIDS epidemic update: December 2007: 1–60. 
http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf  
6 Fallo A, Torrado L, Sánchez A, Cerqueiro C, Schargrodsky L, López E. Delayed 
complications of Bacillus Calmette-Guérin (BCG) vaccination in HIV-infected 
children. International AIDS Society Conference, Rio de Janeiro, Brazil; July 24–27, 
2005. www.ias-2005.org/planner/Presentations/ppt/749.ppt  
7 WHO. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care 
Guideline Group meeting, WHO HQ, Geneva, Switzerland, April 10–11, 2008. 
http://www.who.int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_mrep
ort_2008.pdf   
8 Violari A, Cotton M, Gibb D, et al, on behalf of the CHER Study Team. Antiretrovi-
ral therapy initiated before 12 weeks of age reduces early mortality in young HIV-
infected infants: evidence from the Children with HIV Early Antiretroivral Therapy 
(CHER) Study. Presentation at the 4th International AIDS Society Conference; July 
22–25, 2007; Sydney, Australia. www.ias2007.org/ pag/PSession.aspx?s=150. 
9 WHO/UNAIDS. Guidance on provider-initiated HIV testing and counseling in 
health facilities. World Health Organization, Geneva, Switzerland, 2007. 
www.who.int/hiv/pub/guidelines/9789241595568_en.pdf  
10 Chersich MF, Luchters SM, Othigo MJ, Yard E, Mandaliya K, Temmerman M. HIV 
testing and counselling for women attending child health clinics: an opportunity for 
entry to prevent mother-to-child transmission and HIV treatment. Int J STD AIDS 
2008; 19: 42–46.  
Chapter 8b: Making BCG vaccination programmes safer in the HIV era 
 
 
 
108 
11 Rollins N, Little K, Mzolo S, Horwood C, Newell ML. Surveillance of mother-to-
child transmission prevention programmes at immunization clinics: the case for 
universal screening. AIDS 2007; 21: 1341–47. 
12 Salisbury D, Ramsay M, Noakes K, eds. Chapter 32: Tuberculosis. Immunisation 
against infectious disease: the Green Book, 3rd edn. 2006: 391–408. 
www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_40
97254. 
13 Infuso A, Falzon D, on behalf of the EuroTB network. European survey of BCG 
vaccination policies and surveillance in children, 2005. Euro Surveill 2006; 11: 6–
11. 
14 Enserink M. Public health. In the HIV era, an old TB vaccine causes new problems. 
Science 2007; 318: 1059. 
15 Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a 
home-based AIDS care programme in rural Uganda. Lancet 2006; 368: 1587–94. 
 
 
  
109 
9 Review of the management of BCG-related adverse events 
following immunization 
 
 
Authors 
1. Tippi K. Mak, Department of Public Health and Epidemiology, Swiss Tropical and 
Public Health Institute, Basel Switzerland 
2. Adwoa D. Bentsi-Enchill, Department of Immunization, Vaccines and Biologicals, WHO 
Geneva Switzerland 
3. Philippe Duclos, Department of Immunization, Vaccines and Biologicals, WHO Geneva 
Switzerland 
4. Anneke C. Hesseling, Desmond Tutu TB Centre, Department of Paediatrics and Child 
Health, Stellenbosch University, Tygerberg, South Africa and Department of Infectious 
and Tropical Diseases, London School of Hygiene and Tropical Medicine, United 
Kingdom 
5. Gregory D. Hussey, Institute of Infectious Diseases and Molecular Medicine, Faculty 
of Health Sciences, University of Cape Town, South Africa  
6. Marcel Tanner, Department of Public Health and Epidemiology, Swiss Tropical and 
Public Health Institute, Basel Switzerland  
7. Punam Mangtani, Infectious Diseases Epidemiology Unit, London School of Hygiene 
and Tropical Medicine, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Working manuscript
 
9. Management of BCG-related adverse events 
 
 
 
110
9.1 Introduction 
 
In countries with high tuberculosis burden, WHO recommends vaccination with live 
attenuated Mycobacterium bovis bacille Calmette-Guérin (BCG) in all infants soon 
after birth, if there are no known contraindications.1 BCG vaccines are proven effect-
tive against serious disseminated forms of tuberculosis in young children2 and are of-
fered routinely or in higher-risk selected populations in most countries. (see Figure 1) 
With over 80 years of experience and 3 billion3 people worldwide having received 
BCG vaccines since 1921, a spectrum of BCG-related adverse events following immu-
nization (AEFI) is known. BCG-related AEFI range from the common local reactions 
at the site of vaccination to the uncommon but serious, life-threatening disseminated 
infections. (see Figure 2) 
 
Discussions within WHO and external expert bodies have recognised variations and 
inconsistency in the approach taken by different countries on the clinical management 
of BCG-related AEFI, particularly on management of the most common events of local 
reactions and regional lymphadenitis. The need was identified to synthesise available 
published literature and to form preliminary guidelines on appropriate management 
that would be helpful to health care providers.  
 
There has been no previous review on the management of the range of BCG-related 
adverse events, nor a review on the emerging phenomenon of BCG Immune Reconsti-
tution Inflammatory Syndrome (IRIS). We thus conducted a systematic review on the 
available evidence for managing BCG-related AEFI. We also considered key issues in 
diagnosing M bovis BCG and potential BCG drug resistance. Our aim was to put 
forward evidence-based principles regarding BCG-related AEFI management for 
consideration by the global clinical and scientific community. We used the BCG 
adverse event framework established by Hesseling and colleagues4 of Local, Regional, 
Distant, Disseminated, IRIS and Other BCG diseases (see Figure 2). 
 
Hesseling and colleagues have recently published preliminary management guidelines for 
BCG AEFI in immunocompromised individuals, in particular their increased risk of 
dBCG, from a case series in HIV-infected children, while Juzi and colleagues described 
their early versus late surgical management.4,5 Therefore this present review focuses on 
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management of BCG AEFI in the general pediatric population, i.e. immunocompetent 
children and BCG-related adverse events other than dBCG.  
 
Figure 1 
Global coverage of BCG vaccination at birth in 2007, World Health Organization  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.2 Materials and Methods 
9.2.1 Identification of data 
We conducted a systematic review of the published literature for studies examining 
BCG vaccine-related adverse events, in the following databases: PUBMED, COCH-
RANE CENTRAL, Uppsala Monitoring Centre Database (VIGIBASE), and technical 
guidelines from the WHO library database (WHOLIS) and all WHO regional data-
bases. The defined strategy combined medical subject headings and keywords for addi-
tional articles up to 1 August 2008: “((adverse effect*) OR ("injurious effect*" OR 
"undesirable effect*" OR "side effect*" OR "adverse reaction*" OR "adverse event*")) 
AND (mycobacterium bovis OR BCG OR "Calmette*"), combined with “lymphadeni-
tis”, “osteitis”, “randomized controlled trials”, and “epidemiological methods”. Inter-
nal WHO documents were reviewed and experts were consulted. For key articles we 
also examined bibliographies and citations through the Web of Science. Of articles ex-
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amined by titles and then abstracts, those considered relevant were obtained for further 
assessment (TKM). Any uncertainties were discussed and resolved with other authors.  
 
9.2.2 Inclusion and exclusion criteria 
The criteria for inclusion were RCTs on the treatment of the range of BCG-related 
AEFI in immunocompetent vaccinees. For less common events, retrospective studies 
of BCG Distant Disease were included, as well as all case reports of the emerging phe-
nomenon known as BCG IRIS, and case reports and reviews of a diverse group of 
other adverse events classified as Other BCG Syndromes. Studies were excluded if 
they described practices that were not recommended by WHO, such as repeat BCG 
vaccinations or percutaneous administration. Review of the management of dBCG was 
not conducted as these preliminary guidelines have recently been published.4 
 
9.2.3 Case definitions and disease classification 
WHO documents have not specified a classification of the range of BCG-related AEFI, 
highlighting mainly on country reports of “outbreaks” of BCG-related adverse events 
such as lymphadenitis or osteitis, as well as reports dBCG (also described as “BCGi-
tis” or “BCGosis”). From the published literature, there have been three systems to 
classify and standardise reports covering the spectrum of BCG-related AEFI.4,6-8. The 
first classification by Lotte and colleagues,6,7 from International Union Against Tuber-
culosis and Lung Disease (IUATLD), which covered international reports of all BCG-
related AEFI between 1948-1982 and provided estimates of the adverse events inci-
dence in general vaccinated populations in the pre-HIV era. With minimal overlap, 
Talbot et al reviewed the available literature on dBCG between 1980-1995 and adapted 
a BCG-related AEFI classification similar to the scheme used for opportunistic M. 
avium complex disease.8 Hesseling and colleagues have recently proposed the first cli-
nically based classification that is more relevant for differential diagnosis and man-
agement, which we use here (Figure 2).4   
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Figure 2 
Framework for bacille Calmette-Guérin (BCG) disease in children 
Adapted from Hesseling et al4 
 
 
 
Local BCG disease  
A local process at the site of vaccination. This includes any of the following: 
? BCG injection site abscess conforming to EPI definitions: ? 10 mm x 10 mm 
? Severe BCG scar ulceration  
 
Regional disease 
? Involvement of any regional lymph nodes or other regional lesions beyond the 
vaccination site: ipsilateral axillary, supraclavicular, cervical and upper arm glands. 
Lymph node involvement must conform to EPI definitions and may include enlargement, 
suppuration and fistula formation. 
Background: Ipsilateral axillary lymph nodes are unlikely to be due to another cause in 
children < 1 year of age. Supraclavicular and cervical lymph nodes require exclusion of 
other causes. 
 
Distant disease  
? Involvement of any site beyond a local or regional ipsilateral process. This includes any 
of the following: BCG confirmed from at least 1 distant site beyond the vaccination site, 
e.g. pulmonary secretions (gastric aspirate, tracheal aspirate), cerebrospinal fluid, urine, 
osteitis and distant skin lesions. 
Background: The presence of clinically relevant systemic symptoms e.g. fever, may be 
helpful. The presence of symptoms in HIV-infected or other immunocompromised children 
may be non-specific; a high index of suspicion is therefore required. 
Disseminated disease 
? BCG confirmed from  >1 remote site, as described under distant disease, and/or from at 
least 1 blood or bone marrow culture. 
Background: The presence of clinically relevant systemic symptoms e.g. fever, may be 
helpful. The presence of symptoms in HIV-infected or other immunocompromised children 
may be non-specific; a high index of suspicion is therefore required. 
 
Dual disease 
? Dual disease with M. tuberculosis 
and M. bovis BCG may occur, e.g. 
BCG regional disease and 
pulmonary M. tuberculosis 
 
BCG IRIS 
? Immune reconstitution inflammatory 
syndrome (IRIS) is defined as BCG 
disease that presents in an HIV-
infected child within 3 months after 
the initiation of highly active 
antiretroviral therapy (HAART), 
with/without immunological or viral 
proof of immune reconstitution. 
Identical criteria apply for local, 
regional, distant or disseminated 
disease.  
Other BCG syndromes 
? Rare syndromes following vaccination in which bacteria are identified (e.g uveitis); these 
syndromes may have an immune basis. 
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9.3 Results 
A total of 692 potentially relevant articles were identified, of which 93 papers were 
examined further. Only 5 RCTs on lymphadenitis were identified. Most studies were 
small retrospective studies or case reports. Figure 3 below provides the search results. 
 
Figure 3: Search results and inclusion and exclusion of identified studies 
 
9.3.1 Normal BCG reactions 
WHO recommends a single dose of intradermal BCG vaccine.1 Proper administration 
is expected to lead to minor reactions of redness, induration and tenderness in > 90% 
of recipients.9 A small papule usually develops and progresses to a nodule that may 
ulcerate or can have minor drainage for several months. The “primary complex” 
consists of a cutaneous nodule at the site of injection and a degree of swelling of the 
regional lymph nodes.10 BCG is now the only commonly used vaccine that induces a 
local ulcer at the injection site.11 Small abscesses are common, and have been reported 
to occur in 41% of recipients.12 Usually only symptomatic, conservative management 
is required.1 The natural course of BCG lymphadenitis is spontaneous regression of the 
692 articles of potential interest 
87 Epidemiological studies 
32 prospective or retrospective studies, mainly local reactions and lymphadenitis 
22 case reports or series on disseminated BCG disease  
 21 case reports or series on other BCG syndromes 
 7 case reports or series on BCG IRIS 
5  retrospective reviews on BCG osteitis 
 
6  Randomized control trials or meta-analysis 
5  BCG lymphadenitis management (incl 1 as published letter) 
1  meta-analysis of BCG nonsuppurative lymphadenitis 
593 Excluded  
148  Bladder cancer or other indications 
122  Letters, Comments, non-related Case Reports 
104  Non-English (47 French, 23 German, 12 Russian, 8 Polish, 14 Other) 
59    RCTs on other outcomes or indications (eg. leukemia, melanoma), 
combined with other vaccines, or other outcomes of interest 
59 Epidemiological study with other outcome of interest (eg. leprosy, 
survival, immunologic) 
51  Animal studies 
36    Reviews 
5   Unable to obtain article 
5  RCTs only describe BCG adverse events (1), in pre-term infants (1), 
different strains (1), vaccinated older children or adult s (2) 
4      Other BCG methods of administration or revaccination 
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reaction usually within 9 months post-vaccination.13,14 A 2-10 mm diameter scar will 
develop in most immunocompetent children.12 Keloid scarring over the BCG admini-
stration site may be more common among Asian and African populations.15  
 
The range of normal responses to BCG vaccination includes uncomplicated ipsilateral 
enlarged lymph nodes. The most commonly affected nodes are axillary followed by su-
praclavicular nodes, related to the lymphatic drainage from the recommended site of 
vaccination over the deltoid region. A rule of thumb from observational data is that 
lymph nodes less than 1 to 1.5 cm in diameter are more likely to spontaneously re-
gress.15,16 
 
9.3.2 Management of BCG adverse events by disease classification 
Based on the evidence from this systematic review, a list of general and specific ma-
nagement considerations was formed for each classification of BCG-related AEFI. 
These preliminary guidelines are summarized below. Box 1 outlines general consid-
erations, while specific management suggestions for immunocompetent children are 
listed in Box 2, and for immunocompromised children in Box 3. These preliminary 
guidelines need to be further evaluated by clinicians and other health care providers 
managing BCG-related AEFI.  
 
There were insufficient reports on the disparate group of Other BCG Syndromes to 
formulate specific preliminary guidelines. These unusual syndromes include ophthal-
mic disease (eg. conjunctivitis, choroiditis, uveitis and optic neuritis) and dermatologi-
cal manifestations such as lupus vulgaris following BCG vaccination. Most of the ad-
verse events in this group are believed to represent systemic hypersensitivity pheno-
mena.4 It is important to note that reviews of cutaneous miliary tuberculosis were 
found to be associated with dBCG.6,8,17 Disseminated cutaneous lesions are more com-
mon in immunodeficient individuals and should be a signal to screen for such an un-
derlying condition. Inherent limitations of single case reports include the inability to 
make causal inferences of certain phenomenon, such as reports of basal cell carcinoma 
developing over a BCG vaccination scar. In general, these rare AEFI should be man-
aged by specialist referral if available and decisions made on an individual basis.  
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9.3.2.1 Local disease 
Local reactions such as ulcers and abscesses at or near the injection site are common. 
Abscesses following injection may be non-infected (sterile or “cold”) and may be re-
lated to incorrect depth of the needle insertion for vaccination or from poorly-recon-
stituted vaccine.18 Infected (“hot”) abscesses may arise from nonsterile vaccine tech-
nique or secondary bacterial invasion.  
 
There are no controlled studies on managing ulcerative lesions and abscesses at the 
injection site. Early small case series reported favourable results managing local ab-
scesses with needle aspiration and a course of oral erythromycin,19,20 however, the ef-
fect may have been explained by the benefit of aspiration alone or cases of erythromy-
cin-sensitive secondary bacterial infection. Hanley and colleagues’ non-controlled UK 
study randomized 18 adult vaccinees with BCG ulcers or abscesses (without regional 
disease) to one-month therapy of INH 6 mg/kg/day or erythromycin 250 mg four times 
daily. There was no difference in the blinded assessment of induration, erythema or 
time to resolution.21 More recently, Jeena and colleagues reported an overall rate of 
3.1% adverse events in a prospective study during the introduction of intradermal 
Danish 1331 BCG in South Africa.12 Small injection-site abscesses were noted in 41% 
of AEFI reports. Regardless whether abscesses were untreated or aspirated, all re-
solved within 42 days.12  
 
9.3.2.2 Regional disease eg. Lymphadenitis 
BCG lymphadenitis is the most commonly reported adverse event. Regional disease is 
usually under 4% of BCG vaccinations,6 but can be as high as 17.6%.18 The reported 
incidence can depend on active case finding (eg. during a mass vaccination campaign), 
and the presence or absence of a case definition for reportable lymphadenitis. It is im-
portant to keep in mind that Regional disease may be a sentinel sign for distant or dis-
seminated disease. 
 
There are several non-controlled studies on BCG lymphadenitis, but only 5 random-
ized controlled trials (RCTs) on therapeutic interventions for BCG-related adverse 
events, all on regional lymphadenitis.22-26 (Table 1) These RCTs were small, (total 
N=356), of varying quality, and examined different drugs or interventions. Only one 
trial considered and randomized needle aspiration as a therapeutic intervention, finding 
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a strong benefit in time to resolution at each interval of follow up at 2, 4, and 6 months 
(all p<0.002).25 It is unclear whether a single dose of INH 50 mg26 or streptomycin 20 
mg/kg24 instilled into the evacuated node had any additional benefit over aspiration. A 
review and meta-analysis27 limited by the heterogeneity of these RCTs, found reason-
able evidence, also well supported by observational studies, that prognosis and man-
agement could be sub-classified as “uncomplicated” or “complicated” lymphadenitis 
(see Box 2 for definitions).  
 
The majority of cases of uncomplicated lymphadenitis appears to spontaneously re-
gress and only requires watchful waiting over months. Of those progressing to suppu-
ration, particularly early or rapid presenters (under 2 months post-vaccination), a 
stepwise approach to intervention appears appropriate in immunocompetent individu-
als with limited regional disease. Under sterile technique, needle aspiration of suppu-
rative lymphadenitis is recommended, for shortened time to resolution,25 reduced 
spontaneous drainage,25,26 and the benefit of obtaining specimens to confirm the 
diagnosis. Banani & Alborzi empirically recommended inserting the needle 2-3 cm 
away from the enlarged node and not piercing overlying skin, with the intention of re-
ducing the risk of sinus formation, and to apply mild compression over the suppurative 
area to facilitate aspiration; different aspiration techniques were not tested formally.25 
The aspirate should be tested for acid fast bacilli and culture and sensitivity to rule out 
secondary bacterial invasion.  
 
In non-controlled surgical studies, incision and drainage or complete excision of af-
fected lymph nodes were provided as early interventions.14,28-30 In consideration of the 
reasonable likelihood of spontaneous resolution of lymphadenitis in immunocompetent 
individuals and from available RCTs, surgical intervention should be reserved for in-
dications of progressive lymphadenitis, i.e. rapidly enlargening matted nodes, adherent 
to erythematous overlying skin or chronic fistulae. 
 
9.3.2.3  Distant disease eg. Osteitis 
Distant BCG disease (i.e. single organ involvement) has been reported mainly as in-
fection of bone (osteitis) and bone marrow (osteomyelitis) that can affect both im-
munocompetent and immunodeficient vaccinees. Presentation may be delayed (> 12 
months) following vaccination, with usually swelling and pain over the affected 
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limb.31 BCG osteitis can affect many different bony sites, and particularly the epiphy-
sis of long bones. BCG vertebral osteitis is documented but may be a less common 
presentation than due to M. tuberculosis.  
 
Unusual BCG osteitis “outbreaks” occurred in Finland and in Sweden between 1971-
1978, associated with a change of manufacturer of the BCG Göteburg strain32,33 
(becoming a chief reason for Sweden’s discontinuation of their routine BCG vaccina-
tion program in 1975).34 The change in BCG strain led to the highest ever reported 
incidence of BCG osteitis in Finland at 72.9 per 100,000. More than half of the osteitic 
lesions were in the lower extremity.32 BCG osteitis outbreaks were also associated 
with a change in vaccine strain or manufacturer in former Czechoslovakia and in 
Chile.124 (Table 2). 
 
It is important to note the diagnosis of BCG osteitis in all reviews has not required 
laboratory-confirmation of a BCG isolate. Countries expressly used 4 main diagnostic 
criteria outlined by Foucard & Hjelmstedt: 1. positive BCG vaccination history; 2. no 
history of tuberculosis contact 3. radiographic changes and clinical picture typical of 
osteitis; and 4. a minimum of one of the following a) BCG strain isolated at the osteitic 
lesion, b) acid-fast bacteria demonstrated, c) histopathologic changes of tuberculosis 
process in the lesion.35 BCG-attributed osteitis should be classified as a confirmed case 
only if a BCG strain is isolated at the site, or as a probable case if other causes of tu-
bercular osteitis are not ruled out. The availability of PCR testing can improve the de-
tection and confirmation of BCG ostetitis.36 
 
There were no randomised or controlled studies on the management of BCG osteitis. 
These large retrospective studies are summarized in Table 2. Detailed management 
with drug dosages and durations were not fully described but in general, cases received 
long courses of multiple anti-tubercular drugs, usually for >6 months. Usual manage-
ment was to treat with 3 anti-tubercular drugs that include isoniazid and rifampicin. 
The outcome was usually complete recovery, but there was a possible risk of bony de-
formities or growth plate disturbances. Patients on prolonged anti-tuberculosis che-
motherapy should be monitored for drug toxicity.  
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9.3.2.4 Disseminated BCG disease (dBCG) 
Individuals at risk of disseminated BCG disease are almost exclusively those having 
underlying cellular immunodeficiency from primary disorders or acquired causes such 
as HIV. In light of mounting evidence, in 2007 WHO advised avoiding BCG vaccina-
tion if the recipient is HIV-positive, regardless of the local tuberculosis burden.37 
However inadvertent vaccination is expected to continue, particularly in low-resource 
HIV-endemic settings. Immunocompromised individuals face increased risk of BCG 
complications, in terms of incidence and severity, and the pooled estimated risk of 
dBCG from international studies is 979 per 100,000 HIV-infected vaccinees (95% CI: 
564 to 1506 per 100,000), a rate that is more than 1000 times the risk in the general 
HIV-uninfected population.38  dBCG has a high case fatality of about 75%, whether 
the underlying cause is PIDs or HIV, and the severity is related to the degree of immu-
nodeficiency and concomitant illnesses.4,8 
 
Management of dBCG is a medical emergency, requiring specialist care and aggressive 
multiple anti-tubercular drug therapy, considering the poor prognosis in the immuno-
compromised patient. Preliminary guidelines to manage dBCG are published, and indi-
cate the need to conduct a full diagnostic workup in suspected cases of Distant BCG 
disease or dBCG (nodal aspirates, gastric washings, and bone marrow aspirate or blood 
cultures) and to provide multiple anti-tubercular drug therapy.4 (see Box 3) 
 
9.3.2.5 Immune Reconstitution Inflammatory Syndrome (IRIS) 
IRIS is an important emerging adverse event that is not specific to HIV infection. The 
immunological and inflammatory mechanisms are not fully understood, but IRIS may 
occur when the presence of certain indolent opportunistic organisms in host tissues 
(subclinical or apparent infection) leads to a clinical exacerbation after improved im-
mune function. Key factors are the temporal relationship and rapidity of the immune 
reconstitution. The syndrome is associated with a range of opportunistic pathogens in-
cluding certain viruses and parasites, but in particular with mycobacteria; a possible 
reason is that mycobacterial organisms and antigenic particles can persist for extended 
periods in host tissues.39  
 
BCG-related IRIS has been mainly reported in immunosuppressed children infected 
with HIV and recently initiating anti-retroviral therapy, and in those with primary 
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immune disorders (such as severe combined immunodeficiency syndrome) following 
curative therapy with bone marrow transplantation. Only 47 cases of BCG IRIS in 
HIV-infected children have been published in the literature.4,40-45 An estimated 6% of 
BCG-vaccinated HIV-infected infants initiating highly active anti-retroviral therapy 
will develop BCG-related IRIS, with those younger (under 5 months of age) or with 
higher log viral loads at increased risk.45 The syndrome should be suspected if the 
adverse event occurs, or is exacerbated, between 1 week43 and up to 10 weeks41 after 
the initiation of immune restorative therapy, if the immune restoration is effective (eg 
increasing CD4 count) and when there is no other plausible explanation.39  
 
Management of BCG IRIS in HIV-infected infants available per case is summarized in 
Table 3. BCG IRIS may likely manifest in any class of BCG adverse events (see Fig-
ure 2), although the majority of cases are local reactions eg. site abscess, and regional 
lymphadenopathy which may lead to severe ulceration and drainage.44 In the largest 
case series from South Africa, one case of Distant Disease44 and one suspected but un-
confirmed case of possible dBCG associated with IRIS were reported.45 BCG-con-
firmed IRIS has presented in HIV-infected infants and children up to 9 years of age 
with a history of BCG vaccination at birth;41 there have been no reports of IRIS in 
adults with a remote history of BCG vaccination in childhood. 
 
The prognosis of BCG IRIS is generally good, assuming restorative immune therapy is 
achieved. As seen with the natural history of Local or Regional BCG disease in im-
munocompetent children, several cases of BCG IRIS in HIV-infected infants received 
watchful waiting, which led to drainage and spontaneous resolution of Local or Re-
gional BCG disease after several months. The largest series from South Africa 
indicates that BCG IRIS management remains inconsistent.44,45 A randomized 
controlled trial is warranted as there is sufficient clinical equipoise whether anti-
tubercular therapy or surgery play any role in improving outcomes. At present, 
conservative management likely applies to children with IRIS as for immunocompetent 
children, provided Distant or dBCG disease is not suspected. 
 
9. Management of BCG-related adverse events 
 
 
 
121 
Table 1   Summary of randomized controlled trials on the management of BCG-related lymphadenitis (Regional disease) 
1st Author 
Year 
SETTING Study description, enrolment criteria N Placebo 
Blind 
asses-
sor Control and intervention arms Findings, Comments 
Kuyucu26  
1998 
TURKEY 
 
LA > 1.5 cm diameter, nonsuppura-
tive 
 
 
45 N N I: Control, observation (15) 
II:  node aspiration + EM 40 mg/kg/day x 1 mo. 
(15) 
III:  node aspiration + single dose SM 20 mg/kg 
instilled by needle puncture into node (15) 
Outcome: average time to heal 
Control:  11.9 wks; of 12 (80%) led to fluctuance +spontaneous rupture, 6 
(50%) developed a sinus. 
Arm II:  9.4 weeks (NS); Arm III: 7.1 weeks (significant).  
NS difference in risk of suppuration, but Arms II & III resolved earlier  
Banani25 
1994 
IRAN 
 
Suppurative LA. Nodal fluid con-
firmed with ultrasound if uncertain. 
BCG Pasteur  
Assessments unspecified if blinded, 
followed at 2, 4, 6 mos 
77 N ? I:  Control, observation (34) 
II:  aspiration, repeated as necessary (43) 
Outcome: regression; spontaneous drainage, Arms II vs I 
2 mos:  58 vs 9 %, p<0.0001;  7 vs 15%, NS 
4 mos:  88 vs 26%, p<0.00001;  7% vs 38%, p<0.003 
6 mos:  95 vs 65%, p<0.002;  7% vs 44%, p<0.002 
The only RCT with aspiration as the therapeutic intervention.  
Size of nodes not given. 
Noah24 
1993 
JAMAICA 
 
LA +/-  suppuration at presentation, 
classified by size: 
A: “simple” (69) 
B: LA > 2 cm (27)  
All in B received aspiration. A devel-
oping suppuration during course of 
study either continued in Arm II or 
given single INH instillation    
96 Y N I:  Placebo flavoured coloured syrup (34 from A) 
II:  EM 50 mg/kg/day x 1 mo  (35 A, 14 B) 
III: node aspiration + EM 50 mg/kg/day x 1 mo + 
saline placebo instilled in abscess (14 B) 
IV:  node aspiration + EM 50 mg/kg/day x 1 mo +  
 INH 50 mg single dose instilled in abscess (13 
B) 
Outcome: average time to heal 
Control = 5.7 mos, EM did not improve time to heal (A or C) 
Arms II vs I progress to suppuration (47% vs 60%, p=0.14) 
Staphylococcus aureus and gram-ve bacteria cultured from aspirate in 
some cases; authors interpreted as secondary infections. Suppuration 
criteria not clearly defined, and small sub-groups. Aspiration potential 
therapeutic confounder. 
Caglayan23 
1987 
TURKEY 
 
LA > 1.5 cm, nonsuppurative at 
presentation, classified by onset 
post-vaccination 
Early: presenting ????  months 
Late: presenting > 2 months 
Assessment at 6 mos 
 
120 N Y I:  Control, observation (19 early, 23 late) 
II:  INH 10 mg/kg/day x 2mos (21) 
III:  INH + RIF at 10 mg/kg daily x 2mos (21) 
IV:  EM 30 mg/kg/day x 1 mo (36) 
Failures (progressing to drainage, change in skin 
colour or increased nodal size) led to complete 
surgical excision 
Outcome of interest: resolution 
I: 28/42 (67%) resolved spontaneously. Late presenters were more likely 
to have spontaneous resolution (83% vs. 47%) 
NS between controls and other groups. 10 subjects did not complete 
study due to drug adverse effects 
Close22 
1985 
DOMINICA 
Criteria not provided. Some cases at 
enrolment had suppurative LA 
18 N ? I: Control, observation (10) 
II: INH 10 mg/kg/day x ?duration (8) 
Any abscesses were drained  
States half the patients in both Arms I & II progressed to abscess, and 
healing time 2-7 months did not differ. States drainage hastened healing 
(technique and time interval). Published letter, missing some details. 
LA = lymphadenitis; NS = non-significance; EM = erythromycin; INH = isoniazid; RIF = rifampicin; SM = streptomycin 
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Table 2 Summary of retrospective reviews of BCG Distant disease: osteitis 
 
First author 
Yr, SETTING 
Study 
years 
Avg age at 
onset in  mos 
(range) BCG strain  
No. of 
cases 
(girls) Bones affected (# cases) 
Estimated 
Incidence  
Per 100, 000 
 
Management Outcome 
Kröger32,33 
1994, 1995 
FINLAND 
 
1960-
1978 
18  
(3 - 68) 
Gothenburg 
Swedish 
Lab 
 
 
Gothenburg 
SSI from 
1971-78 
222 
(106) 
Many bony sites, majority 
femur (63), also tibia (44), 
sternum (36), humerus (19), 
clavicle, vertebrae, scapula, 
metacarpal, metatarsal. 
15.3 - 72.9 Diagnosis on histopathologic results. 
113/201 cultures positive for BCG. 
Strepto + ethio OR Strepto + INH OR 
Strepto + INH + RIF x 1 mo; INH + 
Ethio OR INH + RIF x 4 mos; INH alone 
x remaining mos. 
Dosages not provided.Chemotherapy 6 
to 24 months, median duration of 12 
months.  
 
97% (216) cured without bony 
deformities. Serious sequelae: 
disturbances of growth (4), de-
formation of arm (1), keloid (1) 
Bottiger  
198231 
SWEDEN  
1973-
1975 
18 
4 - 144  
Gothenburg 
SSI from 
1971-78  
152 (70) Femur (44), also tibia, fibula, 
foot, sternum, rib, forearms, 
vertebra, scapula. Multiple 
sites (11) 
25 - 33 
 
In 1971 changed manufacturer but used 
same Gothenburg strain Management 
not fully described  
Surgical and prolonged anti-TB 
therapy > 12 months in 2 re-
lapses. 
Castro-
Rodriguez46 
1997 
CHILE  
1976-
1995 
 
11  
(6.5 - 21) 
Several 
BCG 
strains 
used 
10 (4) Proximal tibia (3), 1st metatar-
sal (3), hip, humerus 
3.2 Followed guidelines for extra-pulmo-
nary tuberculosis. INH 10/mg/kg/d + 
PZA 30 mg/kg/day daily x 2 months, 
followed by RIF+ INH twice weekly x 
4.5 mos (total 6.5 mos).  
All recovered, no bony deformi-
ties. Two had fistulous tracts and 
relapse and required longer ther-
apy. 
Vitkova47 
1995 
CZECH 
region  
1981-
1993 
 
16  
(7 - 45) 
Moscow  
 
46 (18) Femur (10), tibia (9), humerus 
(7), sternum, foot, fibula, 
spinal 
2.1 – 3.7 Unspecified anti-tubercular chemother-
apy and in most cases surgical inter-
ventions. Dose of BCG Moscow was 
reduced to 0.025 mg at birth. 
No deaths recorded.  
INH = isoniazid; RIF = rifampin; E = ethambutol, Strepto = streptomycin, Ethio = ethionamide
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Table 3   Management and outcomes of BCG-related Immune Restoration Inflammatory Syndrome (IRIS) in HIV-infected children: 
 A total of 47 cases reported in the published literature. 
 
First author, 
Yr, SETTING 
   
Age of  
onset, 
sex 
 Management   
No of 
Cases 
BCG  
strain Adverse event 
BCG disease 
classification 
    
Aspiration 
Excisional 
Surgery 
Dose mg/kg/day  Outcome  
INH RIF EMB PZA   
Duration 
 
Survived 
Time to 
Resolution Other Rx; Comments 
Sharp40  
1998 
AUSTRALIA 
1 Tokyo? Suppurative axillary LA, 
Supraclavicular LA, fever 
8 mo, M Regional -- biopsy Y Y Y Y ?  Y time? Doses not specified 
Puthanakit41 
2005 
THAILAND 
 
1 Tokyo Axillary LA 9 yr, F Regional Y -- 10 15 -- -- 36 wks  Y by 24 wks Improvement by 8 wks 
1 Tokyo Site abscess + Axillary LA 8 yr, F Local + Regional Y -- 10 15 -- -- 36 wks  Y by 16 wks Improvement by 8 wks 
1 Tokyo Site abscess 8 yr, F Local Y -- 10 -- -- -- 24 wks  Y by 15 wks  Improvement by 4 wks 
1 Tokyo 
Site abscess + Axillary LA 
10 mo, 
F 
Local + Regional Y -- -- -- -- -- --  Y by 16 wks Parents refused treatment 
Hesseling4 
2006 
S. AFRICA 
1 Danish Suppurative axillary LA 5 mo, F Regional -- Y 25 25 10 30 12 wks  Y ?  
1 Danish Suppurative axillary LA 11 mo, 
F 
Regional Y -- 20 10 10 -- 28 wks  N ? Died (due to unrelated bacte-
rial septicemia) 
1 Danish Suppurative axillary LA + 
Multiple abscesses 
5 mo, M Regional Y (IDx2 
) 
-- 20 10 15 20 28 wks  Y ? + Ethio 10 mg/kg/day + Oflox 
15 mg/kg/day 
1 Danish Site ulceration + Axillary LA  9 mo, M Local + Regional Y -- 20 15 25 15 >12 wks  Y ? + Cipro 15 mg/kg/day 
Puthanakit41 
2006 
THAILAND 
1 Tokyo Site abscess 8 yr, F Local Y ? ? ? ? ? ?  Y ?  
1 Tokyo LA 8 yr, F Regional Y ? ? ? ? ? ?  Y ?  
Siberry43 
2006 
ETHIOPIA 
1 ? Site abscess, drainage 9 mo, ? Local -- -- -- --   --  Y by 3 wks  
Alexander44 
2007 
S. AFRICA 
14 Danish  Not clearly described ? Local & Regional 
(?) 
? ? ? ? ? ? ?  Y (14)  Individual case management 
not described 
Nuttall45 
2008 
S. AFRICA 
 
21 Danish  5 Site abscess + Axillary LA  
14 Axillary LA  
2 Axillary LA + Supraclavi-
cular LA 
3.8-8.5 
mo, 14 
girls 
Local & Regional 
(5) 
 
Regional (16) 
? ? ? ? ? ? ?  Y (21)  Individual case management 
not described. One suspected 
case of disseminated disease 
LA = lymphadenitis; ID = incision and drainage; INH = isoniazid; RIF = rifampicin; E = ethambutol, PZA = pyrazinamide; Ethio = ethionamide; Oflox = ofloxacin, Cipro = ciprofloxacin 
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Box 1 
I.  General considerations for management of BCG-related adverse events in children 
1. The immune status of the affected individual determines the management  
2. Rule out an immunocompromising condition; suspect if severe, unexpected, or prolonged disease 
3. In many cases, cutaneous BCG disease indicates systemic BCG disease  
4. Refer to specialist care for systemic and disseminated BCG disease (dBCG) 
5. If HIV-positive, follow medical and surgical management and case reviews published elsewhere4,5 
6. Systemic M. bovis BCG disease may have a non-specific presentation from tuberculosis, and that 
dual M. bovis BCG and M. tuberculosis disease has been demonstrated 
7. Confirm the BCG infection. Under sterile technique, aspiration of abscesses or suppurative lymph 
nodes is both diagnostic and therapeutic (Ib). When indicated, take gastric aspirates and blood 
and/or bone marrow aspirates to rule out Distant Disease or dBCG 
8. Test specimens and swabs for acid fast bacilli, and culture and sensitivity. M bovis BCG may be 
diagnosed by biochemical methods; DNA spoligotyping can speciate BCG strains 
9. Test the BCG isolate’s drug susceptibility. BCG strains have inherent drug resistance (ie pyrazina-
mide, cycloserine)  
10. Acquired resistance to isoniazid and rifampin in BCG strains has been demonstrated  
11. Anti-tubercular monotherapy is never recommended 
12. Ensure corrective actions are taken, including investigation of apparent clusters, to reduce the risk 
of adverse events 
13. Report the information to the appropriate surveillance system 
 
 
 
Box 2 
II. Specific management considerations for BCG-related adverse events in 
 immunocompetent children 
A. Local disease: abscesses and ulcers 
1. Local abscesses and ulcers at the site of injection are common in immunocompetent individuals  
2. Conservative management is recommended with watchful waiting to ensure resolution 
3. Cleanse and cover oozing lesions 
4. Healing and scarring is expected to occur over several months 
5. Most abscesses resolve spontaneously. Large abscesses may be aspirated and contents should 
be sent for culture 
6. If an infected abscess is suspected or pathogenic bacteria cultured (eg. S. aureus), provide 
appropriate antibiotic therapy 
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Box 2 (continued) 
 
II. Specific management considerations for BCG-related adverse events in 
immunocompetent children  
B. Regional disease: lymphadenitis  
1. Lymphadenitis occurs in immunocompetent and immunocompromised individuals 
2. Immunocompromised individuals are more likely to have severe disease and systemic or dissemi-
nated complications associated with lymphadenitis, and management should be based on most se-
vere classification 
3. If immunocompromsed, refer to management algorithm for HIV-infected children4 
4. Classify lymphadenitis as 
? Uncomplicated (firm or small nodes < 1.5 cm, afebrile, no systemic signs), or  
? Complicated (suppurative, abscess formation, drainage, sinus formation, adherent overlying skin) 
5. Lymphadenitis is more likely to progress to complicated in individuals with early or rapid presentation 
< 2 months post- vaccination 
6. Uncomplicated nodes should be left untreated and reassurance provided 
7. Advise that normal resolution takes 2 - 9 months. Monitor for complications and progression to systemic 
disease 
8. If complicated lymphadenitis develops, the 1st line management should be aspiration and culture or 
swab of fluid contents  
9. Sterile aspiration of nodes that are suppurative is diagnostic, therapeutic, and hastens resolution  
10. In immunocompetent patients, anti-tubercular or other antibiotics do not hasten resolution  
11. Anti-tubercular therapy or surgery is not indicated in the majority of cases 
12. An appropriate antibiotic may be indicated if an infected abscess is suspected or pathogenic bacteria 
are cultured (eg. S. aureus) 
13. Seek a surgical opinion if multinodal and progressive disease, i.e. matted nodes and adherence to 
overlying skin 
14. Anti-tubercular monotherapy is never recommended 
 
C.  Distant disease: eg. osteitis 
1. Occurs in immunocompetent and immunocompromised individuals, the latter may have dBCG 
2. Refer to proposed management algorithm if an immunocompromsing condition is confirmed4 
3. Cases should be considered confirmed or probable with a bone aspiration biopsy prior to therapy. A con-
firmed case has isolated a BCG strain. A case is probable if there is a history of BCG vaccination, com-
patible clinical + histopathological picture of tubercular osteitis + no history of tuberculosis contact 
4. Most cases are managed with medical therapy: usually ???????? -tubercular drugs for a min of 6 months 
5. Monitor for drug toxicity 
6. Follow closely with imaging and to watch for progression i.e. disseminated disease 
7. Generally a good prognosis in immunocompetent individuals, though disruption to the bony growth plate 
can occur 
8. Seek a surgical opinion if medical therapy appears ineffective 
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Box 3  
III. Specific management considerations for BCG-related adverse events in 
immunocompromised children  
D.  Disseminated BCG disease – general comments  
1. Occurs almost exclusively in patients with an underlying immunocompromising condition 
2. Medical emergency and specialist management and aggressive multi-drug therapy are warranted 
3. Prognosis is generally poor, with a high case mortality rate 
 
 Management of BCG disease in HIV-infected or immunocompromised children: 
 reproduced from Hesseling et al.4 
I.  Local or regional disease 
? Treat medically: 
? Isoniazid 15-20mg/kg/day 
? Rifampicin 20mg/kg/day 
? Pyrazinamide 20-25 mg/kg/day (2 months, or until tuberculosis excluded) 
? Ethambutol 20-25mg/kg/day 
? Ofloxacin 15mg/kg/day or Ciprofloxacin 30mg/kg/day 
? Consider therapeutic aspiration if node fluctuant 
? 2-4 weekly follow-up; if no improvement, or deterioration of adenitis after 6 weeks 
antituberculosis therapy, consider excision biopsy 
? If on anti-retroviral therapy (ART), ensure ART is compatible with tuberculosis drugs 
? Refer to infectious disease service 
? Monitor for drug toxicity 
? Report as vaccine-related adverse event to EPI 
 
II.  Suspected or confirmed distant or disseminated disease 
? Treat medically as above 
? Consider expedited initiation of ART if HIV-infected 
? Monitor for drug toxicity 
? Report as vaccine-related adverse event to EPI 
 
E.  Immune reconstitution inflammatory syndrome (IRIS) 
1. BCG IRIS is an emerging phenomenon seen with other diseases in immunocompromised individuals 
receiving effective immune restoration therapy (i.e. highly active anti-retrovirals in HIV-infection or bone 
marrow transplantation in severe combined immunodeficiency) 
2. All classifications of BCG adverse events are possible (Local, Regional, Distant, Disseminated, Other) 
3. Diagnosis is made when cases present usually 1-10 weeks of initiating immune restorative therapy, im-
mune function improvement is proven, and there is no other plausible cause.  
4. IRIS has a good prognosis with low mortality 
5. Usually, BCG IRIS will present as Local or Regional exacerbations. One suspected though unconfirmed 
case of disseminated BCG IRIS was reported 
6. It is unclear whether antibiotics or surgery play any role in managing Local or Regional BCG disease 
(similar to management for immunocompetent children) 
7. Cases may be carefully followed without anti-tubercular therapy and observed for progressive disease 
8. Controlled studies on the clinical management are encouraged 
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9.3.3 Further key issues on managing BCG-related AEFI  
9.3.3.1 Transmission of BCG disease 
Ulceration of the vaccination site is common and even expected in normal reactions. Vi-
able BCG shed from the ulcer has been found in adult volunteers at least one month post-
vaccination.48  It is prudent to cover oozing sites and dispose of bandages appropriately.48 
WHO commented on the theoretical possibility that individuals recently BCG-vaccinated 
with draining ulcers could potentially infect unvaccinated contacts, particularly those who 
are immunocompromised.49  There have been no reported cases of adverse events from 
person-to-person spread and infection from BCG vaccination.  
 
Nosocomial transmission of BCG strains used in chemotherapy has, however, been mole-
cularly proven in two hospitals. Two cases initially attributed to a history of BCG expo-
sure from vaccination and endogenous BCG reactivation were later found to be from 
nosocomial exposure to another patient’s immunotherapy with BCG strain Tice.50,51 Simi-
larly, a second centre reported 3 serious nosocomial infections from exposure to a BCG 
immunotherapy strain that infected immunocompromised patients admitted on the same 
ward, leading to permanent changes in hospital biosafety practices.52 This highlighted the 
importance of careful diagnosis of M. bovis BCG strain before attributing the disease to 
latent BCG vaccine strain reactivation, as there can be more than one source of exposure 
to BCG, particularly on a cancer ward.  

 
It is crucial to obtain appropriate and adequate fluid and tissue specimens for testing. M. 
bovis BCG infection is under-diagnosed and under-reported for several reasons. At mini-
mum, specimens should be tested for acid fast bacilli, culture and sensitivity and if avail-
able, recommended biochemical markers to speciate any cultured isolates identified up to 
M. tuberculosis complex (mycobacteria pathogenic to humans that includes M. bovis).53 
Definitive confirmation of the Mycobacterium bovis BCG vaccine strain by molecular 
methods should be performed where available.54,55 The superiority of molecular testing 
has been shown by the test’s ability to correct misdiagnosed cases (eg. erroneously diag-
nosed as M. tuberculosis infection56 or M. bovis infection57), cases that otherwise would 
have remained undetected,4 or the cases noted above which depended upon PCR tests to 
confirm the source was a chemotherapeutic BCG strain.50-52  Furthermore, dual disease of 
M.bovis BCG and M. tuberculosis has been demonstrated.4 
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9.3.3.3  Anti-tubercular drug resistance 
Health care providers should be aware that all M. bovis BCG strains are inherently resis-
tant to pyrazinamide. Several BCG strains used in immunotherapy have been shown to 
have distinct antibiotic susceptibility profiles, and resistance to cycloserine.58  
 
There is evidence that BCG strains have a potential to acquire resistance to anti-tubercular 
drugs, particularly following monotherapy, and this has important implications for man-
agement. This potential was first recognised as early as the 1950’s, when BCG Göteburg 
strain acquired a degree of isoniazid resistance, likely from selection of resistant “mu-
tants” from serial cultures.59 
 
In 2004, a single case report in the UK and another in Brazil indicated possible reduced 
isoniazid sensitivity and reduced multi-drug sensitivity following monotherapy and mul-
tidrug therapy, respectively for BCG-related lymphadenopathy in children. Minimum in-
hibitory concentrations (MICs) were not provided.60,61 In 2005, the Netherlands notified 
WHO of mycobacterial isolates identified molecularly as BCG Danish 1331 having low or 
intermediate level isoniazid resistance (MIC = 0.5mcg/mL) following isoniazid monother-
apy for BCG-related lymphadenitis in 5 children (unpublished data). Also in 2005, a 
South African HIV-infected infant with disseminated BCG disease had a PCR-proven 
BCG Danish 1331 strain that acquired both isoniazid and rifampicin resistance (MIC ??????
mcg/mL and MIC ????????????? ??????????????????????????????????-tubercular drug ther-
apy.62 
 
Acquired resistance has also been reported following treatment of BCG immunotherapy-
related adverse events. In 2006, the BCG isolate acquired rifampicin resistance (MIC ?????
mcg/mL) after a course of isoniazid monotherapy followed by rifampicin monotherapy in 
an elderly Canadian woman with bladder cancer.63 
 
The Global Advisory Committee for Vaccine Safety, an independent scientific advisory 
for WHO, reviewed the reports of drug resistance in the Dutch cases, and concluded that 
the few cases of resistance did not warrant a change in vaccination policy.64  The informa-
tion does however, have implications for BCG-related AEFI management. If the decision 
is to provide anti-tubercular drugs, monotherapy should be avoided. Where available, sus-
ceptibility testing should be performed and repeated, for potential acquired resistance, and 
the appropriate authorities notified. 
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9.4  Discussion 
BCG is the only currently available vaccine against tuberculosis and part of childhood 
immunization programs worldwide because of reliable protection against pediatric tuber-
culosis. Although BCG vaccines are considered very safe in immunocompetent recipients, 
they are some of the most reactogenic vaccines in current use, with injection-site ulcers 
and scarring considered normal.11 This review was conducted because there was no 
previous review to guide management of BCG-related adverse events, and because widely 
different clinical practices are being followed. Our aim was to develop evidence-based, 
preliminary guidelines for further evaluation by clinicians and immunisation providers. 
Key general and specific considerations on the management of Local, Regional, Distant, 
IRIS, and Disseminated BCG adverse events have been summarised in Boxes 1-3. An 
early key point in management is determining the individual’s immune status. Clinical 
suspicion must remain high if the presentation is unusually severe, which may signal an 
underlying immunodeficiency. It is important to note our proposed guidelines are not in-
tended to replace local expertise and clinical judgement in individual cases. 
 
Despite longstanding use of BCG vaccines and the frequency of Regional disease out-
breaks, there were surprisingly few controlled studies on BCG-related AEFI. The con-
trolled studies available had inconsistent definitions and interventions which limited com-
parisons. We did not review non-English studies or the literature on the clinical and surgi-
cal management of dBCG disease in HIV-infected children, as large case series and dis-
cussion of management on this issue were recently published.4,5 BCG is also the only vac-
cine used as a chemotherapeutic agent.65 There is a body of literature on adverse events 
from BCG immunotherapy against certain cancers, as BCG has been given as an intrave-
sical instillation against superficial bladder cancers for decades. The spectrum of adverse 
events following chemotherapy includes disseminated infections and a definitive 
urological review on the management of BCG immunotherapy-related adverse events 
would be valuable.66 
 
Community health care providers usually encounter the most common BCG-related AEFI 
- Local or Regional BCG disease. The limited evidence indicates that neither anti-tuber-
cular drugs nor surgery have been effective in hastening resolution in immunocompetent 
individuals. Medical and surgical interventions also have additional risks and complica-
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tions. Furthermore, it is not known if anti-tubercular treatment reduces or negate any pro-
tection against M. tuberculosis disease induced by vaccination. From the available evi-
dence, we suggest that clinicians have a low threshold to perform needle aspiration of 
enlarged abscesses or suppurative, fluctuant lymph nodes, using sterile technique. This is 
a minimally invasive procedure and has the advantages of obtaining specimens to confirm 
the diagnosis, evacuate caseous inflammatory debris, and hasten resolution. Molecular 
techniques now provide a sensitive tool to detect BCG disease, however many settings 
may not have these resources. Importantly, anti-tubercular monotherapy is not recom-
mended as the potential for BCG acquired drug resistance has been demonstrated. 
 
There are other factors affecting the incidence of BCG-related AEFI. BCG vaccines are a 
group of different attenuated live strains. During the 1920s, samples of the original BCG 
strain were distributed to several laboratories worldwide where propagation continued by 
serial cultures for >30 years, before preservation by freeze-drying (lyophilization) became 
standard. Genetic drift before lyophilization resulted in several live attenuated BCG 
daughter strains (eg. Pasteur, Copenhagen, Tokyo, Moreau) now manufactured,67 each 
having a unique genotype.3 It is not fully clear whether certain BCG vaccines have better 
efficacy and safety profiles49 but there is evidence that certain strains such as BCG Pas-
teur and Danish 1331 are more reactogenic12,18 and Moreau, Tokyo and Glaxo are more 
attenuated strains.68 Milstein and Gibson reviewed countries’ reports of BCG lymphadeni-
tis outbreaks, finding that in addition to the type of BCG strain, the AEFI reports were af-
fected by manufacturing methods, bacillary dose, repeated dosing, route of administration, 
age at vaccination, administration technique, and artefactually from changes to adverse 
events reporting systems.1,18 
 
This review focussed on the management of BCG-related AEFI. It is important to remem-
ber that many adverse events are not related to the vaccine (i.e. unrelated to the intrinsic 
properties of the vaccine). One mandate of immunization programs is to provide effective 
surveillance, with investigation of serious or unusual cases and clusters of AEFI. Other 
causes of AEFI include programmatic errors such as improper administration, coinci-
dences, and reactions from an injection per se. AEFI management requires reporting to 
appropriate local health authorities. Full efforts should be made in identifying program-
matic issues that may reduce its incidence, such as improved screening for immunocom-
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promising conditions or refresher training on proper intradermal and sterile injection tech-
nique.  
 
We also encourage more information by publication of rare syndromes or serious diseases 
related to BCG vaccination. A clinical classification system of BCG-related adverse 
events is now available (Figure 2)4 as well as consensus AEFI definitions of induration, 
redness, swelling, abscess, nodule and cellulitis at the injection site, developed by the 
Brighton Collaboration.69 These standard systems should be used to improve the quality 
and comparability in newer studies.  
 
In conclusion, preventive vaccines provide enormous health benefits against death and 
disability from infectious diseases, and are given safely in the vast majority of the popu-
lation. Like any medical intervention, vaccines can unfortunately cause adverse events. 
One aspect of a responsible and responsive immunization program includes the availabil-
ity of evidence-based guidelines based on reviews such as this, to provide optimal clinical 
management of adverse events arising from recommended vaccinations. Our hope is that 
these management considerations will be useful for immunization providers and clinicians 
to improve patient outcomes and enhance investigation and reporting of BCG-related ad-
verse events. 
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10 Discussion and Conclusions 
The aim of this dissertation was to synthesise and contribute to knowledge and scien-
tific discussion on the clinical, epidemiological and public health issues surrounding 
influenza vaccination in pregnant women and BCG vaccination in HIV-infected 
infants. 
 
A narrative review of influenza vaccination in pregnancy was conducted, with 
consideration of theoretical risks of vaccination unique in pregnancy. The review was 
limited by the heterogeneity of retrospective cohort studies that measured different 
outcomes over different time periods (and influenza strains). A summary excess rate 
of influenza-related hospitalisation per trimester was inappropriate. The systematic re-
view of dBCG in HIV-infected infants is the first to gather all available international 
evidence and to calculate a pooled estimate of the incidence from hospital studies. The 
final review gathers and evaluates all available evidence on the management of BCG-
related adverse events, although the quality of studies was generally poor. 
 
Vaccines have been responsible for tremendous achievements in global public health. 
Each year immunisations prevent 3 million paediatric deaths and 750,000 disabilities 
(Ehreth 2003). However vaccines are still underused, inequitably distributed, poorly 
understood, and viewed with suspicion by some members of the public (Breiman 
2001). It is also recognised that the very act of enhancing safety surveillance and vac-
cine safety research can heighten public doubts about vaccines rather than offer 
reassurance of good monitoring (Francois et al. 2005).  
 
Safety concerns are heightened in particular with preventive medicines such as vac-
cines. It is important to recognise the high level of societal expectation. In general, if 
per dose comparisons were made, the safety profiles of vaccines are superior to com-
monly used chemical drugs. It is understandable, however, that the medical imperative 
of primum non nocere is set far higher for preventive drugs in healthy populations, as 
compared with those given to treat ill populations. Vaccines, as with other public 
health interventions, can expose millions of individuals, and often in combinations or 
series of doses. Several vaccines are targeted to vulnerable subpopulations such as in-
fants, for whom a serious AEFI could impact all potential years of life. As a vaccine 
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succeeds in disease prevention, the expectations and focus on the vaccine’s safety pro-
file increase.  
Vaccine risk communication and public perception are discussed below, but it is im-
portant to note there also remains substantial room to improve communication of 
safety reporting within the scientific community, and to raise adverse events analysis 
to the level of efficacy analysis in studies (O'Neill 2001). This is a particular opportu-
nity in large phase III trials which can provide rigorously controlled data on vaccine 
effectiveness and more common adverse events. Subgroup analyses can provide cau-
tious hypotheses on concerns or benefits in subpopulations that can lead to formal in-
vestigation. 
 
Statements such as “There were no serious adverse events.” or “The vaccine was 
found to be safe.” are often seen in published trials, and can lead to misinterpretation 
that may affect risk perception and management. It may be less well understood that 
vaccine safety itself cannot be “proven” and instead, is indirectly inferred by the 
absence of serious adverse events (Clements 2004).  
 
The Consolidated Standards of Reporting Trials (CONSORT, www.consort-statement. 
org) is the authoritative guide recommended by all major journals. The guide recom-
mends reporting of all important adverse events as well as reasons for subjects discon-
tinuing the trial. It provides an example that compares frequencies of adverse events 
between trial arms. CONSORT recommends a statement on how sample size was de-
termined, and the power to detect a certain effect size. However, there is no current 
recommendation or example of a prefacing statement that describes the limits of as-
sessing safety. This is an overlooked issue that could be addressed. 
 
It would be valuable if CONSORT recommended that a contextual, post hoc statement 
be consistently reported about zero-numerator serious adverse events in trials. As de-
scribed in the Introduction, Hanley’s Rule of Three approximates with 95% certainty 
the upper limit of a probability of an event, were it to exist, based on the number of 
independent observations (Hanley & Lippman-Hand 1983; Eypasch et al. 1995; 
Jacobson et al. 2001; Fritzell 2002). This approximation is not well-known or reported 
by trialists (Jovanovic & Levy 1997). There are other full statistical methods that can 
be used to estimate the probability from zero numerators (Chen & McGee 2008). This 
would provide a worst-case estimate of the incidence for a potential serious adverse 
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event within the trial period. An example of a more meaningful statement on safety 
reporting in a trial would be: “This trial found no serious adverse events in a sample 
size of N, followed for X days, with approximately 95% certainty that if any serious 
AEFI existed, the risk would be less than Y times per 100,000 doses”.  
 
Safety reporting that included the sample size or approximation of the non-incidence 
rate of a potential serious adverse event would serve as a reminder to the scientific 
community that all studies have limits in not detecting an event. Fuller contextual des-
criptions of adverse events should also be provided on the drug labelling and on-line 
websites of manufacturers.  
  
10.1 Influenza and inactivated influenza vaccines in pregnancy 
There are several considerations from the review in Chapter 7 (Mak et al. 2008a). 
What was highlighted is the substantial evidence indicating that pregnant women were 
disproportionately harmed during two of the past three pandemics in the last century. 
One historical review of the 1918/9 pandemic found estimates of fatal influenza in 
pregnancy from death certificates to be 530 to 570 per 100,000, compared with deaths 
in non-pregnant women of childbearing age of 490 per 100,000. Maternal deaths were 
likely underestimated as pregnancy status is not always known or recorded on the cer-
tificates (Reid 2005). During the pandemic, a report from one Parisian hospital de-
scribed 70% of pregnant women having pulmonary complications with early abortion 
in 6%, preterm delivery in 17%, and a case fatality of 60%. The common impression 
in 1918/9 was described in the journal, The Lancet: “’Woe unto them that are with 
child,’ might have been written of this influenza epidemic” (Anon 1919). There were 
similar case fatality rates during the 1957/8 pandemic. Possible factors that may have 
increased the vulnerability of pregnant women were underlying comorbidities and 
normal immunological or physiologic changes in pregnancy (Crapo 1996). 
  
Another influenza pandemic is expected. Considerable effort has been made to pre-
pare for what is expected to be a true global health emergency. Emergent influenza 
strains are being closely monitored for one that may produce the next pandemic. Since 
1997, several new subtypes have been documented (H5N1, H9N2, H1N2, H7N7) 
(Nicholson et al. 2003). Of particular concern was zoonotic outbreaks of H5N1 avian 
influenza causing fatalities in poultry handlers (Shu et al. 2006)). WHO pandemic 
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planning is based on the best-case scenario of a pandemic with 20% of the global 
population ill, 28 million hospitalised and 7 million dying (Stohr & Esveld 2004). In 
the worst-case scenario, based on an impact similar to the 1918/9 pandemic, the upper 
limit is as high as 81 million dying, with 96% of deaths occurring in the developing 
world (Murray et al. 2006). 
 
The next influenza pandemic will mobilise the first concerted public health effort to 
interrupt the impact and global spread through timely mass vaccination. Countries are 
urged to establish pandemic preparedness plans that include vaccine stockpiles and 
policies that outline the subpopulations given immunisation priority (WHO 2005). For 
these reasons, among others, an in-depth review of the risk-benefit surrounding mater-
nal influenza vaccination was timely. The evidence from past pandemics clearly indi-
cates pregnant women may need to be prioritised as one of the more vulnerable group 
for vaccination during a pandemic. Of course exact disease patterns of the pandemic 
influenza should be analysed in real time as data become available, to identify all sub-
populations excessively affected by that specific strain.  
 
For interpandemic influenza, there are several factors that add complexity to the risk-
benefit assessment for vaccination in pregnancy. It is important to note that in general, 
cumulative mortality from inter-pandemic years is still higher than in a pandemic 
(Simonsen et al. 1997). The review found the evidence of influenza-related burden in 
pregnancy was based mainly on retrospective electronic databases, the largest consis-
tently finding excess influenza-attributed hospital admissions in pregnant women in 
the second and third trimesters and in those having co-morbid conditions. However, 
there is concern with imprecision, biases and residual confounding even with carefully 
adjusted observational data (Jackson et al. 2006; Belongia & Shay 2008).  
 
There are several variables that limit conclusions on vaccine effectiveness and influ-
enza-attributed morbidity, based on the evidence summed across influenza seasons 
from retrospective database studies. Influenza morbidity varies year to year, 
depending on factors including virulence, strain geographic distribution, and level of 
cross-protection from past immunisation (from natural infection or vaccination). The 
composition of inactivated influenza vaccines is determined and manufactured each 
year, and the level that the vaccine strains correspond to circulating wildtype strains 
can be a determinant of that year’s vaccine effectiveness. 
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Currently a substantial amount of available safety data on influenza vaccination in 
pregnancy is based on a large US maternal cohort established in the 1950s. Although 
providing reassuring evidence, the data reflect the safety of 1950s inactivated influen-
za vaccines (arguably even higher reassurance, as these were less purified) in a study 
where enrolled pregnant women received combinations of other vaccines.  
 
Ethical reasons preclude the conduct of a vaccine trial with pregnant controls in sett-
ings that have already established policies to provide that vaccine in pregnancy. At 
present, there is only one RCT conducted in Bangladesh on maternal vaccination in 
the third trimester that measured influenza-confirmed illness in the infants, with 
encouraging vaccine effectiveness of 61% (95% CI: 9 to 84%) against febrile labor-
atory-confirmed influenza in infants and 28% (95% CI: 4 to 46%) against non-specific 
febrile respiratory illness in mothers (Zaman et al. 2008). The RCT was small, 
indicated by the wide confidence intervals surrounding the estimates. More data are 
needed as the current evidence base for the effectiveness of maternal influenza 
vaccination using laboratory-confirmed outcome measures is based on a few hundred 
subjects.  
 
For these above reasons, more vaccine safety data on modern influenza vaccines are 
needed. A carefully designed, large prospective cohort study would be highly valuable 
in addressing any remaining scepticism about the true burden of seasonal influenza 
and vaccine effectiveness in pregnant women and their young infants. Such a study 
should measure both effectiveness by laboratory-confirmed influenza and influenza-
like clinical illnesses in mothers and infants. Terminology should be clear in identify-
ing “laboratory-confirmed” illness as opposed to less specific measures of influenza-
associated (or -attributed or -related) illness or respiratory infections during the influ-
enza season, as previous terms were not always clear (Bhat N. et al. 2005). Virologic 
surveillance of circulating wildtype strains in the study setting should be actively un-
dertaken. Laboratory investigations would preferably include a combination of clinic 
rapid diagnostic tests for influenza and as well as laboratory confirmation (Effler et al. 
2002). It would be ideal if a study year included a severe influenza season. Although 
severity is not fully known prior to the onset of the season, a greater burden of disease 
is expected when a major drift is predicted in the circulating influenza viruses. 
 
10. Discussion and Conclusions 
 
 
 
144 
 
There is in general, a paucity of new vaccines and other drugs in the pipeline being 
developed specifically for maternal health. The fallout from teratogenic effects of tha-
lidomide in pregnancy in the 1960s has led to understandable caution with medicines 
given to pregnant women, particularly in the first trimester during organogenesis 
(White et al. 2008). Furthermore, there is minimal market or legal incentive for the 
pharmaceutical industry to conduct the necessary pre-licensing investigations to deter-
mine if use in pregnancy can be an additional on-label indication. The result is that re-
productive and developmental toxicology studies in animals are not performed during 
the pre-clinical stages of most drugs in development, and the pregnant subpopulation 
are actively excluded from pre-licensing trials. Most currently used vaccines were li-
censed without pre-licensing data on safety in pregnancy (Gruber 2003). 
 
Vaccination in pregnancy entails the highest level of societal and ethical expectations 
for safety, and especially for new medicines in pregnancy. For the first time, there are 
vaccine candidates in advancing stages of clinical trials that are against neglected 
tropical diseases. There are several tropical parasitic diseases causing enormous dis-
ease burdens and all currently lack vaccines. Some are known to have major adverse 
impacts on maternal and fetal health, such as malaria, hookworm, schistosomiasis, and 
Chagas disease (Hotez & Ferris 2006). When considering the consequences of malaria 
in pregnancy alone, the risks include maternal anaemia, intrauterine growth retarda-
tion, fetal infection and infant deaths related to increased prematurity and low birth 
weight. About 50 million pregnant women live in malaria-endemic regions, and each 
year 75,000 to 200,000 infant deaths are associated with maternal malaria (Steketee et 
al. 2001).  
 
It is important to consider the global perspective that 99% of all maternal deaths occur 
in low-income countries. There are many neglected areas of research on the pathoge-
nesis, immunology, epidemiology and public health consequences of several 
infectious diseases in pregnancy (Greenwood et al. 2007). If the hope for new 
poverty-related vaccines (and other medicines) is realised, it is expected that these 
vaccines will be used almost exclusively in poorly resourced countries, where infra-
structure to support pharmacovigilance is weak. (Travelers may also receive these 
vaccines, and travel medicine linked databases can be another potential source for 
safety surveillance of new vaccines in more resourced settings). This is particularly a 
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critical issue if new vaccines are given in pregnancy and rigorous, long-term follow 
up is essential. An existing collaboration like the INDEPTH network of 38 
demographic surveillance sites in 19 non-industrialised countries (http://indepth-
network.org) would be an ideal platform for long-term longitudinal studies on drug 
safety and effectiveness against poverty-related diseases. Building upon this esta-
blished research network would strongly address the recognised need to improve phar-
macovigilance in less resourced countries (Bentsi-Enchill 2007). There are several 
relevant areas for potential research in vaccine pharmacovigilance in low-resource 
countries. Despite decades of providing thiomersal-containing tetanus toxoid vaccine 
in pregnancy in many countries, there are only two published, reassuring case-control 
studies on tetanus toxoid exposure in pregnancy and congenital abnormalities 
(Silveira et al. 1995; Czeizel & Rockenbauer 1999). Another neglected area of 
research is specific vaccine effects in malnourished or preterm infant subpopulations.  
 
In countries where vaccination in pregnancy is routinely given, there are several rea-
sons why improved AEFI surveillance of vaccination in pregnancy should be augmen-
ted by establishing a long-term active registry (Gruber 2003). Pregnancy status is not 
consistently recorded, nor is additional important information usually captured in gen-
eral registries, such as timing of exposure(s) in gestational weeks (EMEA 2005). Al-
though epidemiological studies and passive surveillance systems have not indicated 
harm, lingering public concerns in industrialised countries over thiomersal in vaccines 
given in pregnancy and childhood have increased the market for thiomersal-free vac-
cines in single-dose vials (Mak et al. 2008b). This change was based on precautionary 
grounds and to maintain public confidence in immunisations in these countries. An ac-
tive registry in these better-resourced settings would be valuable for long-term evalua-
tion of thiomersal-free vaccinations in pregnancy and in childhood, to follow up preg-
nancy outcomes and the incidence of childhood development disorders.  
 
If only thiomersal-containing influenza vaccine is available, as in many countries, the 
benefit of vaccination is expected to greatly exceed any theoretical risks in pregnancy. 
In the event of a pandemic, large multi-dose vials may be used for maximally efficient 
vaccine production, and a preservative such as thiomersal will be required (Cox 1997; 
Celis 2005). Such a scenario also provides an important opportunity for AEFI surveil-
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lance during mass vaccination in a pandemic, particularly as the vaccine is being rap-
idly manufactured and given in mass campaigns. 
 
AEFI surveillance of pregnant women inadvertently vaccinated, especially during 
mass vaccination can provide important information that could not be collected in 
intervention studies. Health care workers and military workers are often targeted 
groups for vaccination, and many are women of child-bearing age. Even with history-
taking and screening, an estimated rate of unknown pregnancy up to 4 weeks gestation 
was 6 per 1000 women in the United States (CDC 2003). An example is from the 
United States, where smallpox vaccination has been reintroduced for mainly military 
personnel. As routine smallpox vaccination was discontinued a generation ago, famili-
arity with the vaccine had faded. However, fetal vaccinia is a known serious AEFI 
from vaccination in pregnancy. For these and other reasons, the United States en-
hanced passive surveillance as well as an active national smallpox vaccine registry for 
inadvertent vaccination in pregnancy (CDC 2003).  
 
10.2  Tuberculosis and BCG vaccines in HIV-infected children 
Early on in the HIV epidemic, there were concerns and calls for research on the safety 
of BCG vaccination in HIV-infected infants (Wright 1987; Reichman 1989; Athale et 
al. 1992; Weltman & Rose 1993). The review in Chapter 8a systematically gathered 
cohort studies in the HIV-infected infant subpopulation. Signals of an increased 
dBCG risk in HIV-infected children were reported as early as 1993 (Besnard et al. 
1993).  
 
A lack of studies still remains, however, on BCG effectiveness specifically in the 
HIV-positive infant subpopulation. A small case-control study of 116 pediatric tuber-
culosis cases in Zambia found that the presence of a BCG scar in HIV-infected chil-
dren did not provide lower odds of tuberculosis (OR 1.0, 95% CI: 0.2 to 4.6) while 
HIV-uninfected children had lower odds (OR 0.41, 95% CI: 0.18 to 0.92) (Bhat G. J. 
et al. 1993). A retrospective study in Argentina found that 12.5% (51/374) of 
hospitalised HIV-infected children had tuberculosis disease and there was no signifi-
cant difference between tuberculosis rates in BCG vaccinated (10.9%, 95% CI: 4.5% 
to 21.2%) and non-vaccinated children (14.2 %, 95% CI: 10.5% to 18.6%) (Fallo et 
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al. 2005). Prevention of childhood tuberculosis and vertical HIV transmission cur-
rently rests on non-vaccine strategies.  
 
There are many issues raised with WHO’s revised policy to contraindicate BCG in 
this subpopulation. One is the need to reexamine the recommended EPI immunisation 
schedule to provide BCG at birth or soon postnatally in countries having a substantial 
proportion of immunodeficient infants, as the current earliest determination of infant 
HIV status by PCR is 4-6 weeks of age. The standard EPI schedule with BCG at birth 
has not changed since the original outline for 6 vaccines established in the 1970s; 
diphtheria/pertussis/tetanus vaccines, however, first began at 3 months of age but EPI 
later recommended starting at 6 weeks of age (Halsey & Galazka 1985). It is 
important to note the EPI schedule was intended to serve as a general guide for 
countries to establish their own vaccine policies, and the schedule was not expected to 
be universally appropriate for all epidemiological and cultural settings (WHO 1980; 
Galazka et al. 1984). There are several variations in BCG vaccine policies among 
countries that do not conform with the suggested EPI schedule (Fine et al. 1999), 
(www.bcgatlas.org). Formal decision analyses and modeling of the different risk-
benefit parameters and BCG strategies in settings with high HIV and tuberculosis 
settings would be valuable. 
 
The risk of dBCG is estimated to be about 1% of vaccinated HIV-infected infants and 
efforts should be directed at addressing the root causes to decrease the subpopulation 
at risk (Mak et al. 2008d). Even in highly HIV-endemic settings, if maternal HIV pre-
valence can be reduced, or vertical transmission minimised by well functioning 
PMTCT programmes providing access to ART and safe breastfeeding, the absolute 
number of dBCG cases from inadvertent vaccination would be minimised even if 
BCG coverage continued routinely. For example, in one South African province, the 
estimated annual number of infants newly infected by HIV has decreased by nearly 
half in three years, from 1573 infants in 2004 to 806 infants in 2006. The 
improvement is mainly due to lower vertical transmission rather than change in the 
maternal HIV rate (Hesseling et al. 2008). In KwaZulu-Natal, vertical transmission 
rates as low as 2.9% have been reached  (Geddes et al. 2008). 
 
There is now strong evidence that ART initiated by 6-12 weeks of age will reduce 
early mortality (Violari et al. 2008) and may possibly reduce tuberculosis in HIV-in-
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fected infants (Kouakoussui et al. 2004). Timely ART requires timely HIV diagnosis, 
and one possibility is to integrate early infant HIV testing with the 6-week EPI visit 
(Mak et al. 2008c). Another question raised is the appropriate frequency of HIV tests 
and the trade-off of delaying BCG vaccination in HIV-exposed uninfected infants, as 
there is no information on BCG’s profile in this subpopulation. Assuming some pro-
tection would be afforded from BCG, postponing BCG vaccination in HIV-exposed 
uninfected infants could increase their risk of progressive tuberculosis disease in set-
tings highly endemic for tuberculosis.  
 
As access to ART expands, an important question is raised if there is now a safer time pe-
riod to give BCG vaccination in HIV-infected infants stabilised on ART. BCG would not 
be contraindicated if the vaccine’s long-term risk-benefit approached a similar ratio as 
immunocompetent children. There is sufficient clinical equipoise on the effect of delay-
ing BCG vaccination in HIV-infected infants on ART to warrant a controlled trial of 
BCG vaccine in this subpopulation. M. tuberculosis IRIS and ART-associated tuber-
culosis are serious diseases (Meintjes et al. 2008), particularly when compared with 
BCG IRIS. Furthermore, having to treat tuberculosis infection first can delay ART 
initiation. The lack of reliable correlates of immune protection against tuberculosis 
make study endpoints more challenging (Fine 1995). Such a trial would require long-
term follow up to examine all-cause mortality, culture-positive tuberculosis, and all 
BCG AEFI.  
 
There is an interesting corollary in BCG vaccine policy for HIV-infected infants and 
those with PIDs. Concern has centred around SCID, the most common congenital im-
mune deficiency disorder. Suggestions have been made in industrialised settings with 
low tuberculosis burdens to postpone BCG vaccination to avoid complicating the 
prognosis of infants later diagnosed with HIV or PIDs (Romanus et al. 1992; Dawar et 
al. 2004). Some policies in industrialised countries postpone BCG for 6 months or 
more (Infuso et al. 2006).  
 
As discussed in Chapter 8a, risk-benefits weights in industrialised settings with low 
tuberculosis and HIV burdens are different. Industrialised settings have more re-
sources, lower disease endemicity and hence higher risk intolerance. The incidence of 
SCID can be about 1-20 per 100,000 which can be a more common cause of 
immunodeficiency than HIV in infants in certain settings (Dawar et al. 2004). Some 
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subpopulations targeted for BCG vaccination may have a higher genetic 
predisposition for PIDs and potential BCG AEFI can interfere with life-saving 
treatment. SCID is not usually detected until 6 months of age and not regularly 
included in newborn screening, although routine screening is under consideration 
because a panel to test for SCID exists (Lindegren et al. 2004). If an infant with SCID 
is diagnosed early and receives prompt bone marrow transplantation (which has the 
potential of full, permanent immune restoration) survival is as high as 97%. Survival 
decreases to 69% if transplantation occurs after 3.5 months of age. The difference is 
mainly due to serious opportunistic infections developing after the first few months of 
life, including dBCG (Skinner et al. 1996; Buckley 2002; Ikinciogullari et al. 2002).  
 
As the current situation stands, there is no licensed vaccine against tuberculosis rec-
ommended in HIV-infected individuals, for whom tuberculosis is the leading cause of 
death. Non-vaccine strategies are the current mainstay; WHO recommends intensive 
early case detection and management by Directly Observed Therapy, Shortcourse 
(DOTS), which can have some effect in reducing disease transmission (Corbett et al. 
2007). However, diagnosis and management strategies are complicated, drug-resistant 
tuberculosis is an increasing concern, and global tuberculosis incidence continues to 
climb. There is an urgent need for highly effective new tools to reduce transmission 
by preventing primary latent tuberculosis and reactivated tuberculosis disease, both 
which are major stumbling blocks for control. 
 
As described earlier, BCG remains clinically relevant in immunocompetent recipients 
for reliable vaccine safety and effectiveness against childhood disseminated 
tuberculosis (Trunz et al. 2006) as well as against leprosy (Fine 1995). However with 
the contraindication in immunocompromised vaccinees and limited effects against 
adult pulmonary tuberculosis and disease transmission, some have called BCG an 
outdated vaccine (Gudmundsdotter & Hallengard 2008). There are several new 
tuberculosis vaccine candidates under clinical trials that either boost upon or replace 
current BCG vaccines (Kamath et al. 2005; Brennan et al. 2007). Potential new 
strategies are generating great interest, as these are the first tuberculosis vaccine 
candidates in 80 years (Hoag 2004). 
 
Two vaccine candidates based on boosting prior BCG vaccination are noted. There is 
considerable interest in maintaining BCG as an established EPI childhood vaccination 
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for its potential as a live vector for recombinant antigens of diseases (tuberculosis and 
potentially others). This strategy known as a heterologous prime-boost combination 
provides a prime vaccination such as BCG to increase Th-1 cellular immune 
responses, followed later by a booster using a different type of vaccine against the 
same antigen (McShane & Hill 2005). The advantage of maintaining BCG vaccination 
is that the majority of the world’s populations in current need of a new tuberculosis 
vaccine are already primed, having received childhood BCG vaccination. 
 
MVA85A is an example of a recombinant boost vaccine and a leading candidate under 
clinical trials, but is not yet tested in immunocompromised recipients (Ibanga et al. 
2006; Hawkridge et al. 2008). BCG-killed M. vaccae vaccine is a nonrecombinant 
boost candidate that was selected specifically for testing in HIV-infected recipients. 
After promising early trials (Waddell et al. 2000; Vuola et al. 2003), a placebo-con-
trolled phase III RCT (ClinicalTrials.gov NCT00052195) was conducted of a killed 
whole-cell M. vaccae tuberculosis vaccine as a five-dose series booster. Over 2300 
BCG-vaccinated, HIV-infected Tanzanian adults with childhood BCG vaccination 
scars and CD4 counts > 200 cells/mm3 were enrolled (Hoag 2004). The seven-year 
trial is completed and preliminary results confirms effectiveness against laboratory-
confirmed tuberculosis; full analyses are awaited (IUATLD 2008). The vaccine has 
not been tested in children. Safety concerns in immunodeficient recipients remain, 
however, if BCG is maintained as a potential antigen-delivery system and priming 
vaccine. 
 
There is encouraging animal research into a new recombinant BCG vaccine strain, 
rBCG30 which has shown greater protective immunity against tuberculosis in the 
guinea pig model, and could eventually replace current BCG strains (Horwitz et al. 
2000). The strain was further engineered to reduce the risk of overwhelming infection 
in the immunodeficient host. rBCG(mbtB)30 continues to overexpress the major sec-
retory protein of M. tuberculosis but also limits the number of replications of the BCG 
organism. When compared with BCG, this recombinant BCG strain was shown to be 
more attenuated in the SCID mouse model (Tullius et al. 2008). This is a promising 
step towards development of an improved BCG vaccine strain that is safe and 
effective in both immunocompetent and immunodeficient populations. 
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The safety and effectiveness of live, attenuated vaccines in immunocompromised sub-
populations is poorly studied in general. One corollary is the policy that live 
attenuated measles vaccination be given in HIV-infected children who are asymp-
tomatic or have early signs of immunosuppression, and to avoid vaccination only if 
there are signs of severe immunosuppression (WHO 2004). A study on active sur-
veillance for serious measles-related AEFI in children born to HIV-infected mothers 
with adequate laboratory investigations would be valuable. Results are awaited from a 
Cochrane systematic review on the current available evidence on this issue 
(Unnikrishnan et al. 2007).  
 
10.3 Management of BCG-related adverse events 
The review of management of BCG-related AEFI in Chapter 9 was part of a larger on-
going initiative by WHO to update a guide on the incidence and management of seri-
ous AEFI of vaccines. The original document provided only brief clinical 
management on serious adverse events related to EPI vaccines (WPRO 1999). 
 
Practical considerations on investigation and management of AEFI for each vaccine 
should be made readily available to EPI mangers and health care providers, as appro-
priate reporting mechanisms and a standard response are emphasised. This is especial-
ly relevant during National Immunisation Days (NID) where the absolute number of 
AEFI will increase as an expected proportion of doses administered in an intense and 
short campaign period when AEFI surveillance may also be heightened. Demonstra-
tion of timely AEFI investigation and guidance on the clinical management of con-
firmed vaccine-related AEFI also provides assurance to the public that the immunisa-
tion programme is actively managed and monitored. 
 
Management guidelines may also help reduce the unnecessary use of antitubercular 
drugs for BCG local or regional disease in immunocompetent individuals. The review 
identified the issue of the potential of acquired, anti-tubercular drug resistance in M. 
bovis BCG, but it appears that distant or disseminated BCG disease is not likely to 
lead to infectious pulmonary disease. This may be due to the ancestral species M. 
bovis having a predilection for extrapulmonary tuberculosis. Human-to-human 
transmission of BCG disease has not been demonstrated. 
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One of the main issues impeding adequate surveillance of BCG AEFI is the lack of 
adequate screening for serious BCG disease. BCG is closely related to M. 
tuberculosis, and as described in Chapter 9, misdiagnoses and non-specific diagnoses 
have occurred. Over the past 10 years, emerging availability of multiplex real-time 
PCR assays can now rapidly speciate MTBC members (Talbot et al. 1997; Pinsky & 
Banaei 2008). However, surveillance requires adequate laboratory facilities and 
resources. The majority of serious BCG-related AEFI is expected to occur undetected 
in poorly-resourced sub-Saharan African countries where the global HIV burden in 
children is concentrated. There is an approximate 1% risk of dBCG with resulting 
75% all-cause mortality from inadvertent vaccinations in the HIV-infected infant 
subpopulation without access to timely antiretroviral therapy. dBCG is iatrogenic and 
potentially avoidable, raising considerable ethical issues. 
 
10.4 Immunisation programmes  
Rychetnik noted that “public health interventions tend to be complex, programmatic, 
and context dependent” (Rychetnik et al. 2002). Decision-making in public health 
programmes balances the tensions among utilitarian, egalitarian and communitarian 
ethical principles (Roberts & Reich 2002). Immunisation policy is based on many 
considerations, but in general the ethical principle emphasised is utilitarian for maxi-
mising the overall population benefit and herd immunity against a disease. 
Furthermore, operational factors are taken into account, based on the feasibility, 
logistics and availability of resources to conduct and sustain the large-scale public 
effort. 
 
Issues facing immunisation programmes and decision making are substantially differ-
ent in industrialised and non-industrialised countries. Although immunisation pro-
grammes seek to reduce global health inequity by reducing vaccine-preventable dis-
eases, vaccines are unequally distributed within and among countries. This is especial-
ly reflected by newly licensed vaccines which are first introduced in industrialised 
countries, although poor countries have the populations that would benefit the most 
(Franco 2007). Organisations such as GAVI must play a role in providing leadership 
to develop new market strategies that sustain and expand access to vaccines in poorly 
resourced countries. 
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Clearly, screening for vaccine contraindications is more feasible in industrialised 
countries and there are classic policy criteria in determining whether to screen popula-
tions (Andermann et al. 2008). Beyond screening for subpopulations at increased risk 
from vaccination, the possibility of individualised genetic screening before vaccin-
ation has been put forward. “Vaccinomics”, is the area of pharmacogenomics that 
aims to investigate for underlying immunogenetic mechanisms of vaccine-related 
adverse events (Poland et al. 2008). For example, genetic differences were compared 
in the 94/428 (22%) individuals who developed fever after smallpox vaccination 
against afebrile vaccinees (Stanley et al. 2007; Reif et al. 2008). Vaccinomics is a 
potentially broad area of research, but highly at odds with feasibility of screening in 
large-scale programmes, especially when considering that currently available screen-
ing tests for known contraindications such as HIV and SCID are not optimally per-
formed.  
 
10.5  Public perception and risk communication 
Immunisation has been called a social contract and responsibility, as most current pre-
ventive vaccines are against human-to-human infections. There is an impressive num-
ber of potential vaccine candidates against infectious diseases, chronic diseases and 
cancer, but societal understanding and value of these developments have not kept pace 
(Breiman 2001). 
 
As the immunisation programme succeeds and cases of vaccine-preventable diseases 
sharply decline, so does the public consciousness of the disease and its consequences. 
In particular in industrialised countries, public focus has shifted towards issues of vac-
cine safety and the risk of rare but serious adverse events. Cases of AEFI temporally 
associated with vaccination can be compelling and emotive. Vaccine safety issues are 
raised more frequently when the vaccine-preventable disease has become less 
common or is less likely to be fatal or cause permanent damage (Neuzil & Griffin 
2005). An example is with influenza. For most cases, seasonal influenza is a self-
limited illness, and influenza is an example that may encourage complacency, partly 
due to familiarity with seasonal occurrence, the perception that influenza is a benign 
or inconsequential illness, and the misnomer of attributing any mild respiratory illness 
as the “flu”.  
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A secure climate to report safety is required to reduce repercussions and indemnity. 
This is needed in particular for vaccination in pregnancy where a societal, political, 
legal and financial framework must be established by government, academia and in-
dustry to address the barriers (Brent 2003). Some countries have already acted from 
earlier pressures. Vaccine safety issues were prominent in the 1970s, with legal dam-
ages awarded to injuries attributed to immunisation from diphtheria toxoid, whole-cell 
pertussis and tetanus toxoid vaccines. This led to the US National Childhood Vaccine 
Injury Act in 1986 which established a compensation program on a “no-fault” basis 
(CDC 2008). 
 
True “outbreaks” of BCG-related adverse events have led to public outcry and cessa-
tion of BCG immunisation programmes in Austria (Hengster et al. 1992) and Sweden 
(Romanus 1990). Some have estimated that an incidence of more than 1% in reported 
BCG-related lymphadenitis can lead to disruption of the immunisation programme 
(Milstien & Gibson 1990).  
 
More often, serious claims against vaccines are later shown to be unfounded, but the 
immediate effects can severely undermine vaccine uptake, from which the valid im-
munisation programme more slowly recovers. This has been seen in many settings 
worldwide, such as the concern of measles vaccine and autism in the United Kingdom 
(Burgess et al. 2006), of hepatitis B vaccine and multiple sclerosis in France 
(Ascherio et al. 2001), of polio vaccine and temporally related deaths during a severe 
malaria epidemic in Uganda (Nuwaha F et al. 2000), or of polio vaccine inducing 
infertility in northern Nigeria (Jegede 2007). Lessons learnt from past vaccine scares 
can be used as an opportunity to improve responses to future crises (Francois et al. 
2005). 
 
Uncertainty from incomplete scientific information pervades many levels of medical 
decision-making for interventions in general, not just for vaccine safety and effective-
ness (Politi et al. 2007). The challenge lies in providing precise scientific communica-
tion and imparting a balanced perspective to health care providers and to the public 
regarding risks, particularly of small-probability events and uncertainty. Presenting 
the risks and benefits of vaccines in a balanced manner is essential. Near zero risks, 
though small, should not be simply dismissed. 
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Research on methods to improve the precision of risk communication have taken into 
account the general public’s abilities with numeracy, charts and varying perceptions 
of terminology for frequency. Public risk perception has been shown to have a ratio 
bias, where a ratio using smaller numbers (i.e. 1 in 10) is perceived as being a lower 
risk than the equivalent mathematical ratio with bigger numbers (i.e. 10 in 100). 
Suggestions for communicating small probabilities include stating the absolute value 
of an increased risk above the baseline risk, and not just the relative magnitude. 
Perspective about a low risk event has been presented graphically by a sliver in a pie 
chart, or by the use of a magnifying glass over a low probability event along an 
arithmetic scale of frequencies (Lipkus 2007).  
 
The Erice Declaration of 1997 and the Manifesto in 2007 were two international 
statements developed by a group of pharmacovigilance experts (The Erice Declaration 
1997; Anon 2007). The declaration emphasised that effective communication on 
safety of medicines was needed, and that pharmacovigilance was a collective 
responsibility among society, health providers, researchers, media, and industry and 
government representatives. The manifesto called for global reform of the science of 
pharmacovigilance, toward proactively developing new methods to collect, monitor 
and study the risks and benefits of drugs, with core involvement of the public. These 
mandates apply to all medicines, but have particular relevance for vaccines. 
 
10.6 Conclusions 
The focus of this dissertation was on vaccine safety and effectiveness in subpopula-
tions. First, a narrative review examined the evidence for the risk from maternal 
influenza in pandemics and epidemics and the safety and effectiveness of maternal 
vaccination with inactivated influenza vaccines. Second, a systematic review was 
conducted on the risk of disseminated BCG disease in HIV-infected infants and the 
implications of revised BCG vaccine policy in low-income settings. A third review 
synthesised the evidence-based management of BCG-related adverse events. Based on 
these studies and the discussion, the following main conclusions were drawn: 
 
1. From historical reports and epidemiological studies, pregnant women were at in-
creased risk of death during influenza pandemics and of excess hospitalisations 
with increasing length of gestation in epidemic years, when compared with non-
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pregnant peers. Based on a limited number of vaccine safety studies conducted in 
pregnant women (largest being N=2291), serious adverse events have not been de-
tected. Several countries now formally recommend seasonal influenza vaccination 
in pregnancy. Enhanced safety surveillance and long-term follow up of vaccinated 
cohorts are recommended. 
 
2. HIV-infected children face a much higher risk of M. tuberculosis disease, however 
BCG effectiveness in preventing tuberculosis in this subpopulation has not been 
shown or adequately investigated. The summary risk of disseminated BCG disease 
in HIV-infected infants was 979 per 100,000 (95% CI: 564 to 1506) vaccinees, 
indicating a risk more than a thousandfold higher than in the baseline HIV-
negative population. Further research includes studying the impacts from delaying 
BCG, potential ameliorating effects of ART that may improve BCG’s risk-benefit 
profile, operational research for integration of early infant HIV testing with EPI, 
and new tuberculosis vaccine candidates that are safe and effective in the 
immunocompromised subpopulation. 
 
3. Guidelines on the management of BCG-related adverse events are an important 
component of a well prepared, actively managed and monitored immunisation pro-
gramme. The first point in management is determination of the affected individ-
ual’s immune status, as local and regional BCG disease in immunocompetent chil-
dren usually can be managed conservatively. If the decision is made to provide an-
titubercular drug therapy, monotherapy should be avoided because of the demon-
strated potential of BCG to acquire drug resistance.  
 
4. Vaccine pharmacovigilance is an increasingly important area of active research for 
various reasons in industrialised and non-industrialised countries. Several different 
database platforms are now available to evaluate safety. The collection, analysis 
and reporting of adverse events in trials need to be improved. Phase III and IV 
studies can provide valuable opportunities to investigate vaccine safety and effec-
tiveness in subpopulations. In poorly resourced countries, current and future vac-
cines, especially those targeting poverty-related diseases, would be ideally investi-
gated through large cohort studies within established surveillance networks. 
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Authors’ reply 
We thank David Ayoub and Edward Yazbak for their interest in our Review. We do 
not agree, however, with their view that we presented selective findings, or that evi-
dence supporting influenza immunisation in pregnancy is inconsistent with available 
vaccine safety data. 
 
We systematically searched the current available literature on the risk of influenza in-
fection and the risk-benefit of influenza vaccination in pregnancy.1  We considered the 
studies’ methodology, sample size, settings, influenza periods, outcome measures, 
whether adjustments were made for confounders, and the study years (since the type, 
spread, and virulence of influenza viruses vary across seasons2). The largest and long-
est historical cohort studies,3,4 which compared rates in defined influenza seasons with 
peri-influenza seasons stratified by trimester and adjusted for comorbidities, did find 
excess hospital admissions in pregnant women. Risk of hospital admission increased 
with length of gestation and with comorbidities. Another large cohort study published 
since our Review also supports these findings.5  
 
By contrast with hospital admission, we noted that maternal mortality from seasonal 
influenza is rarely reported (though well documented in past pandemics). Without rou-
tine laboratory testing, excess all-cause mortality is a longstanding epidemiological 
marker of the severity of seasonal influenza.2 Ashley and colleagues,6 from the UK’s 
Office for Population Censuses and Surveys (now the Office for National Statistics), 
published in a peer-reviewed journal. They listed the main causes of death from ran-
dom sampling one in 15 death certificates during the severe 1989-90 influenza epi-
demic. Eight deaths in pregnancy were found, compared with two in a similar 1985-86 
sample, suggesting an excess 90 maternal deaths (815-215). Ács and colleagues7 
used records and patient recall to classify maternal influenza-like illness. It is impor-
tant to note that this study, as well as others investigating prevalence of serological 
infection8 or hospital admission rates,3,4,9,10 were insufficiently powered to examine 
maternal mortality rates during seasonal influenza. Database cohorts are limited to 
easily measured outcomes usually without virological confirmation. We commented on 
two 5-6-year observational studies,9,10  one having low influenza-attributed admission 
rates,10 showing no benefit from maternal vaccination against medically attended in-
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fluenza-like illness in infants. The study authors noted limitations including insuffi-
cient power,9,10 residual confounding, non-specific outcomes, and study years includ-
ing mild influenza seasons.9 Randomised controlled trials (RCTs) provide evidence 
robust to both known and unknown confounders. Zaman and colleagues’11 RCT pub-
lished in The New England Journal of Medicine indicated a vaccine effectiveness in 
the third trimester of 63% (95% CI: 5-85%) against laboratory-confirmed febrile influ-
enza illness in infants, and 36% (95% CI: 4-57%) against maternal febrile respiratory 
illness. The control arm appropriately received polysaccharide pneumococcal vaccine, 
which might even have reduced their risk of pneumonia. Influenza-related morbidity 
rates in this trial are not unique to low-income settings.12  
 
Munoz and co-workers13 found no increased risk of hospital admission for respiratory 
illness in infants of vaccinated mothers. The higher antenatal proportions of transient 
hypertension (not pre-eclampsia), abnormal glucose tolerance tests, and infections 
(mostly streptococcal B) were not related to timing of maternal vaccination. Pregnancy 
outcomes did not differ between non-vaccinated and vaccinated women. From table 
5,13 based on one infant case in non-vaccinated, and two cases in vaccinated mothers, 
Ayoub and Yazbak calculated a 7.3-fold risk for pyloric stenosis, but without adjust-
ment for confounders or providing 95% CI (0.68-81.86) indicating compatibility with 
chance. 
 
From Heinonen and colleagues’ study,14 Ayoub and Yazbak cited relative risks of spe-
cific malformations standardised for hospital (ie, unadjusted for confounding), whereas 
Heinonen and colleagues provided adjusted relative risks (ARRs) for confounders indi-
cating no association between influenza vaccination in the first 4 months of pregnancy 
and any malformation (ARR 0.89, 95% CI: 0.61-1.32) or organ-system specific 
malformations.14 As multiple comparisons were made and based on few cases, chance 
findings can occur. Heinonen and co-workers considered statistical testing inappropri-
ate, noting “the positive associations, even when striking, are uninterpretable without 
independent confirmatory evidence”.14 Heinonen and co-workers examined topical 
thiomersal antimicrobial, not a vaccine preservative, based on 60 exposed pregnant 
women and found no association with malformations in any trimester when ARRs 
were adjusted for confounding (ARR 3.13, 0.87-7.60).14  
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Newer evidence included in three comprehensive reviews15-17 does not support a causal 
link between thiomersal in childhood vaccines and developmental toxicity. Furthermore, 
thiomersal-free inactivated influenza vaccines are now available in North America and 
Europe specifically for pregnant women and children, as a precautionary measure.18 Ay-
oub and Yazbak cited a literature review prepared to support nomination to the National 
Toxicology Program (NTP) of the US Department of Health and Human Services.19 The 
NTP made no classifications or conclusions regarding teratogenicity of thiomersal. Infor-
mation on denominators, confounders, and levels of ascertainment are needed to assess 
data from passive reporting systems such as the US Vaccine Adverse Event Reporting 
System.20  
 
The current evidence base does not indicate any serious risk from maternal influenza vac-
cination. We have recommended robust surveillance and research that includes virologi-
cally confirmed outcomes, to monitor safety and effectiveness where influenza immunisa-
tion is routinely recommended in pregnancy. 
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